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8Pancreatic ductal adenocarcinoma
Pathology
Several malignant and benign neoplasms can arise from the pancreas, stemming from ductal, acinar 
or islet cells. Since 85 percent of all pancreatic neoplasms are represented by pancreatic ductal 
adenocarcinoma (PDAC), the commonly used term ‘pancreatic cancer’ usually refers to this entity. The 
broader term ‘exocrine pancreatic neoplasms’ includes all tumors arising from ductal and acinar cells 
and their stem cells, making up 95 percent of all malignant neoplasms of the pancreas. Less than 5 
percent of pancreatic neoplasms are endocrine, arising from the islet cells [1]. Most PDACs (60-70%) 
are found in the head of the pancreas mainly in the upper half, which cause obstructive jaundice as 
the presenting symptom. The minority of PDACs is located in the uncinated process and body or tail 
of the pancreas.
Exocrine pancreatic neoplasms can be classified according to the WHO nomenclature, describing 
benign, premalignant and malignant lesions [2]. Premalignant lesions can be pancreatic intraepithelial 
neoplasias (PanIN), mucinous cystic neoplasms (MCN) or intraductal papillary mucinous neoplasms 
(IPMN) with varying grades of dysplasia, and are considered at risk for progression to invasive 
malignancy.
Malignant PDACs are mostly hard tumors with dense stromal fibrosis and moderate to poor 
differentiation. Local extension of tumors typically includes adjacent structures like duodenum, portal 
vein or superior mesenteric vessels, and a striking perineural invasion pattern is often observed [3].
Molecular etiology
Most commonly found genetic mutations in pancreatic adenocarcinoma can be divided into three 
broad categories: early activation of oncogenes such as K-ras [4-6]; subsequent inactivation of tumor 
suppressor genes such as TP53 [5,7], p16/CDKN2A [8-10], and SMAD4 [5,11]; and inactivation of genome 
maintenance / DNA damage repair genes such as hMLH1 and hMSH2 [5,12,13]. Careful genetic analysis 
of pancreatic tumors and its precursors have helped to develop a genetic progression model for PDAC 
[14]. PanIN lesions harbor many of the same mutations as PDAC, starting with K-ras gene mutation in 
PanIN-1 [15], p16/CDKN2A gene mutations in PanIN-2, and SMAD4 and TP53 inactivation in PanIN-3 
[14,16].
Incidence
An estimated 338.000 new cases of PDAC arise worldwide yearly, and 330.000 patients die of their 
disease, making PDAC the eight leading cause of death from cancer in men and women [17,18]. 
Incidence rates vary between 7-9 per 100.000 in men and 5-6.5 per 100.000 in women, resulting in a 
male-to-female ratio of 1.3:1. Around 80 percent of cases become clinically apparent in patients 60-80 
years (median age at diagnosis is 71 years); cases below the age of 40 years are rare.
Risk factors
The major risk factors for pancreatic cancer include hereditary factors like positive family history [19,20], 
hereditary pancreatitis [21,22], ataxia-telangiectasia [23], and germline mutations in oncogenes like 
BRCA1 [24,25], BRCA2 [25-27], STK11/PRSS1 (Peutz-Jeghers syndrome) [28] or CDKN2A (familial atypical 
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multiple-mole melanoma syndrome) [29,30]. Non-hereditary influenceable factors include cigarette 
smoking [31-33], high body mass index and lack of physical activity [34], diabetes mellitus [35], and 
non-hereditary chronic pancreatitis [36-39].
Symptoms
Early clinical signs of pancreatic cancer include abdominal pain, unexplained weight loss, jaundice 
and pruritus, but symptoms can vary with the location of the tumor [40,41]. 70 percent of patients 
suffer from diabetes mellitus, usually with an onset of less than 2 years [42]. Later occurring symptoms 
of progressive disease are related to liver metastasis and/or invasion of adjacent organs like stomach, 
colon and/or peritoneal cavity.
Diagnosis
Unfortunately, there is no screening tool to detect asymptomatic premalignant or early malignant 
pancreatic tumors. Although there is consensus that patients with a (inherited) predisposition for 
pancreatic cancer should be screened, there is no consensus on the most effective method or the 
optimal interval of screenings [43].
In general, the diagnostic evaluation of a patient with suspected pancreatic cancer includes serologic 
evaluation and abdominal imaging. Computed tomography (CT) of the abdomen with a specific 
pancreas protocol is preferred [44-46] since abdominal ultrasound is often an incomplete examination 
due to overlying bowel gas and low sensitivity for small (<3 cm) pancreatic lesions [47-49]. Additional 
testing (including biopsy) may be unnecessary before surgical intervention if the appearance of the 
pancreatic tumor on CT is typical, the CT scan provides enough information to assess resectability, 
and the patient is fit to undergo a major surgical resection. However, additional procedures may be 
indicated in cases where the diagnosis is doubtful with symptoms pointing to chronic or autoimmune 
pancreatitis, when resectability is uncertain, or when a therapeutic intervention is needed (like 
biliary tree decompression). Endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic 
ultrasound (EUS) can either confirm or dismiss the diagnosis of PDAC, with the opportunity to conduct 
brush cytology or preferably fine needle aspiration biopsies of the tumor [50-53].
The tumor-node-metastasis (TNM) system is used as oncologic staging system for PDAC. The goal of 
the staging work-up is to define the extent of disease to identify patients who are eligible for curative 
resection. Pancreatic tumors are categorized on a continuum from resectable, borderline resectable 
to unresectable according to either the involvement of adjacent structures and/or the presence of 
distant metastases. Locally advanced, unresectable tumors usually invade the celiac artery, superior 
mesenteric artery and vein, portal vein, and/or hepatic artery. Tumors that are not definite resectable or 
unresectable are called ‘borderline resectable’. After careful assessment, only 15-20 percent of patients 
who present with a pancreatic tumor are considered candidates for resection.
Treatment
Radical (R0) surgery by means of pancreaticoduodenectomy (Whipple procedure) for tumors in the 
head or neck of the pancreas, or (laparoscopic) distal pancreatectomy for tumors in the body or tail 
of the pancreas is the only potential curative treatment option to date for stage I/II PDAC. Variations 
in technique or more extensive surgery have not lead to improvement in outcomes [54], and irradical 
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resections (R1) are still common [55]. Adjuvant chemotherapy (gemcitabine or fluorouracil) has been 
shown to improve overall survival slightly [56-58], while the efficacy of adjuvant radiation therapy is 
still under debate [59-61].
Patients with locally advanced and thus unresectable stage III or metastatic stage IV PDAC have shown 
to receive little survival benefit from palliative chemotherapy [62-65]. Also, radiation therapy for stage 
III PDAC was shown not to improve survival [66,67].
Prognosis
The prognosis after treatment is dependent mostly on TNM stage and histologic grade of the primary 
tumor. However, even for the 10–15 percent of patients with resectable disease, the prognosis is poor: 
median survival after resection of pancreatic tumors and adjuvant chemotherapy has been around 
24 months and 5-year survival 20 percent [57], although numbers for true PDAC (excluding the 15% 
other types of pancreatic malignancies) are probably worse [68]. For patients with locally advanced 
or metastatic pancreatic cancer, the outlook is even grimmer: with palliative chemotherapy, median 
survival has been only 6 months [62]. Patients with an irradical resection have shown a slightly longer 
survival rate than patients with stage III PDAC not undergoing resection [55].
Oncolytic viruses
Oncolytic viruses (OVs) are viruses that selectively infect and damage malignant tumors without 
damaging normal tissues, and are employed in what is called oncolytic virotherapy [69]. Most malignant 
tumors have evolved to escape immune surveillance, and resist apoptosis and growth inhibition, 
which are not only hallmarks of cancer, but also play an important role in antiviral responses [70-73]. As 
such, cancer cells are more susceptible to (oncolytic) virus infection and virus induced killing. OVs use 
infected cancer cells’ cellular resources to produce progeny virus, while infection results in a variety 
of cell death types, ranging from apoptosis, necrosis and autophagy, to immunogenic cell death and 
necroptosis. In addition, virus induced local and systemic responses to OVs including destruction of 
tumor vascularity, triggering anticancer immune responses, and therapeutic activity of OV expressed 
transgene-encoded proteins can enhance the oncolytic efficacy of the therapy.
Cancer selectivity of OVs can be either naturally occurring as with Newcastle disease virus, reovirus, 
mumps virus and Moloney leukemia virus. Other viruses, such as measles virus, adenovirus, vesicular 
stomatitis virus, vaccinia virus and herpes simplex virus have been genetically engineered to make 
them cancer specific. With the advent of reverse engineering techniques, modifications attributing 
to efficacy and safety of OVs have marked the introduction of new generations of recombinant OVs. 
Most recent developments have focused on conditional replication in tumor cells, expression of 
(therapeutic) transgenes as well as targeting and/or enhanced delivery of OVs [74-77].
Over 60 years ago, cancer patients were treated with (impure) naturally occurring OV preparations in 
clinical trials that would not pass the critical evaluations of today’s standards [78-80]. Some successes 
were reported, but patients also frequently became ill or died when infection spread to normal 
tissues. Today, the newer generations of oncolytic viruses have been evaluated extensively for their 
efficacy in preclinical trials, and have shown to be more effective than first generation vectors on 
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many occasions [81-85]. Talimogene laherparepvec (an oncolytic herpes simplex virus) has recently 
undergone evaluation in a phase III clinical trial in patients with advanced or metastatic melanoma. 
This will probably be the first oncolytic virus to obtain FDA approval, while a marketing authorization 
application for the European Union has also been submitted to the EMA [86]. For most of the used OVs, 
safety in terms of toxicity has been studied in laboratory animals and humans [82]. However, studies 
focusing on environmental shedding and possible recombination of OVs with wildtype viruses are 
relatively scarce [87].
Newcastle disease virus (NDV)
NDV as an oncolytic virus
NDV has been described as a naturally occurring oncolytic virus as early as 1952 [88-90]. Since then, 
numerous clinical trials have employed wildtype NDV strains (MTH-68, 73-T, PV701, HUJ) either as a direct 
oncolytic agent, or as an oncolysate vaccine for treatment of patients with various types of advanced 
stage cancer [91-101]. Results of these early trials have been relatively disappointing, illustrated by the 
lack of further development of these treatment strategies.
NDV selectively replicates in and destroys tumor cells while sparing normal cells, presumably because 
of defective interferon (IFN) signaling pathways in tumor cells [102-106], although discrepancies 
for this theory have also been reported [107-109]. The tumor-specific replication and subsequent 
induced cytolysis, and the inability of the virus to spread among healthy cells, make NDV a safe cancer 
therapeutic agent. The IFN produced by normal cells surrounding the tumor cells upon NDV infection, 
besides having antiviral effects, might exert an antiproliferative effect against cancer cells, like human 
pancreatic adenocarcinoma cell lines (HPACs) [110,111].
In more recent years, the interest in oncolytic NDV has revived with the advent of recombinant 
viruses [112,113]. Several approaches have been used to improve oncolytic efficacy of recombinant 
NDV (rNDV), including increasing virulence by increasing the cleavability of the F protein [114-119], 
transfer of therapeutic or immunomodulating transgenes [114,115,120-122], targeting of tumor cells 
with modified attachment proteins [123,124], and combination therapy targeting immune checkpoints 
[125]. Increasing virulence of rNDV improved the direct oncolytic efficacy most, and most preclinical 
studies have employed mesogenic virulent rNDVs for expressing transgenes [113]. NDV has been 
shown to be very safe in tumor models using mice or rats, even when used in high dose and injected 
intravenously [116,118,119,126].
Safety of oncolytic NDV
Surprisingly, detailed information on (pre)clinical safety testing of oncolytic NDVs is scarce, and a 
comparison of different (non-)virulent strains in non-human primate models has never been described. 
Preclinical studies employing NDV as a vaccine vector using subcutaneous, intranasal and/or 
intratracheal administration has shown that NDV as vaccine vector is highly attenuated in non-human 
primates [127-132]. However, virulent NDV strains pose an environmental risk, as birds (specifically 
poultry) are very susceptible to infection with mesogenic or velogenic strains. Relevant shedding of 
live virus was observed after infection in early clinical trials [93,99]. Although NDV is an RNA virus with 
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an inherent high viral polymerase error rate due to the lack of proofreading, (recombinant) viruses with 
or without transgene(s) have shown to be genetically very stable upon passaging [120,122,133].
 
Clinical virology of NDV
NDV belongs to the genus Avulavirus within the family of Paramyxoviridae and has a natural avian host 
range comprising over 240 species of bird [134]. Newcastle disease, and consequently NDV, has been 
named after an described outbreak in Newcastle-upon-Tyne, although the disease entity has been 
reported earlier in the Dutch East Indies [135,136]. NDV was previously also known as avian paramyxovirus 
type 1 (APMV-1). NDV infections cause high mortality and economic losses in the poultry industry. 
NDV strains vary widely in pathogenicity and have been classified accordingly into three pathotypes: 
lentogenic (low virulent, no mortality in susceptible hosts), mesogenic (intermediate virulent, < 10 
percent mortality) or velogenic (highly virulent viscerotropic or neurotropic, 10-100 percent mortality) 
[112,137]. NDV spreads primarily through direct contact between infected and healthy birds and via 
oral, nasal and ocular secretions and droppings. Infection occurs by virus inhalation, ingestion or 
conjunctival contact. Symptoms of NDV infection in poultry include respiratory (sneezing, coughing, 
gasping and nasal discharge), gastrointestinal (green waterish diarrhea), neurological (paralysis, 
twisting of head and neck, ataxia and clonic spasms) and general symptoms (loss of appetite, drop of 
egg production and peri-ocular tissue swelling). Prophylactic vaccination of (commercial) poultry for 
NDV is currently applied on a large scale and (suspected) outbreaks have been rigorously acted upon 
to prevent further spread [138], although outbreaks still occur regularly and the virus is considered 
endemic in some countries lacking resources for adequate disease prevention and control [139].
Zoonotic NDV
Although NDV can cause severe and lethal disease in poultry, infection is relatively asymptomatic 
in humans. Human infections with NDV have been observed after exposure to virus while handling 
infected birds or cadavers and lyophilized or aerosolized NDV vaccines. The associated symptoms have 
been described as mild: acute conjunctivitis and laryngitis, occasionally accompanied by low-grade 
fever and chills, with a rapid and spontaneous resolution [140-146]. Human-to-human transmission has 
never been reported.
Pigeon paramyxovirustype 1 (PPMV-1)
In the early 1970s, cases of NDV infection in racing pigeons were reported, and the antigenically distinct 
NDV variant that could be isolated is now best known as PPMV-1 [147,148]. Based on their difference 
in reactivity in hemagglutination assays, and their host specificity for columbiform species, all PPMV-1 
strains cluster in lineage VIb/I of genotype VI chicken NDV strains [149-152]. Since the first outbreaks, 
the disease has been spread to all parts of the world as a result of contact between birds at races 
and exhibitions. PPMV-1 is now endemic in both domestic and wild pigeons and other columbiform 
species in Europe and North America, from where it regularly spreads to poultry, causing substantial 
outbreaks [149,153-160]. Although all PPMV-1 strains analyzed to date contain a multibasic amino acid 
motif at the F protein cleavage site, not all PPMV-1 strains are virulent in chickens (see also the next 
paragraph on molecular virology of NDV). However, serial passaging can result in virulent variants 
[161-166]. PPMV-1 disease signs in pigeons generally include a series of nervous disorders: bilateral or 
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unilateral locomotor disturbances of wings or legs, torticollis, and watery green diarrhea. Respiratory 
signs are not often seen [167]. Two cases of human infection with PPMV-1 associated with fatal disease 
have been reported: one in the USA [168] and one in the Netherlands (unpublished data). Both cases 
involved severe pneumonia and an immunosuppressive condition as an underlying comorbidity.
Molecular virology of NDV
NDV is an enveloped, non-segmented negative-sense RNA virus harboring a 15.186, 15.192 or 15.198 
nucleotides long genome which contains six open reading frames (ORFs) [169-171]. These ORFs encode 
the nucleoprotein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-
neuraminidase (HN) and the RNA dependent RNA polymerase (L). Conserved sequences called 
‘gene-start’ and ‘gene-end’ flank all six genes and serve as a transcriptional promoter and terminator, 
respectively. In addition, intergenic non-coding nucleotide stretches lie between the genes varying in 
length from 1 to 47 nucleotides [172]. The 3’ and 5’ ends of the genome make up the leader and trailer 
regions of 55 and 114 nucleotides long, respectively [172]. RNA editing during P gene transcription 
results in two additional structural proteins, V and W [173].
An NDV virion consists of genomic viral RNA encapsidated within the ribonucleoprotein (RNP) 
complex, which on itself consists of the NP, P and L proteins. The M protein surrounds this complex 
and a lipid bilayer completes the envelope, from which glycoproteins HN and F protrude. NDV’s HN 
glycoprotein can bind to sialic acids on the host cell membrane, triggering F protein-mediated fusion 
of the viral envelope with the cellular membrane. After entry, the RNP complex dissociates from the M 
protein and is released into the cytoplasm, where NDV undergoes its complete replication cycle. The 
viral polymerase complex first transcribes viral genomic RNA into mRNAs that code for viral proteins 
until sufficient amounts have accumulated. It then switches to synthesize full-length plus-strand anti-
genomic RNA, which serves as template for the production of minus-strand genomic RNA. Under 
direction of the M protein new RNP complexes are transported back to the cell membrane, where they 
are assembled into new virions, which are then released from the host cell by budding. HN activity is 
necessary for virus detachment and also prevents self-aggregation of viral particles.
Virulence of NDV can be attributed mostly to the (multi)basic cleavage site of the fusion protein [174,175]. 
Cleavage of the precursor protein F0 into active F1 and F2 by host cell proteases is needed for progeny 
viruses to become infective [176]. Lentogenic NDV strains possess a monobasic amino acid motif at 
the F protein cleavage site, which makes them only infective when cleaved by trypsin-like proteases 
found only extracellular in the respiratory and intestinal tract. In contrast, mesogenic and velogenic 
NDV strains possess a multibasic amino acid motif at the F protein cleavage site, which can be cleaved 
intracellular by ubiquitous furin-like proteases. As a result, these strains can cause systemic disease, 
which may be fatal. In cell culture conditions, these virulent strains also cause F protein mediated 
cell-to-cell fusion, leading to the formation of so-called syncytia: giant multi-nucleated cells that serve 
as virus production factories. Besides the F protein cleavage site, other viral factors also contribute to 
NDV virulence, including HN, which also determines viral tropism, and the viral polymerase complex 
[175]. The V protein is also important for virulence, as it is a potent IFN antagonist in susceptible hosts 
[177-180].
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Innate immunity in oncolytic virotherapy
During optimizing of the effect of oncolytic viruses for use in cancer therapy, most efforts have focused 
on increasing virulence, expressing transgenes and targeting tumor cells. Less is known about the 
potential role of the innate immune system in oncolytic virotherapy. The innate immune system is 
capable of sensing intracellular pathogen-associated molecular patterns occurring when a normal 
cell becomes infected with a (viral) pathogen like NDV [71]. This will lead to the production of type I 
interferons (IFNs), which act as an autocrine and paracrine signal to upregulate IFN-stimulated genes 
(ISGs). Besides having antiviral effects, type I IFNs, in particular IFNβ, also exert anti-proliferative, pro-
apoptotic and pro-inflammatory effects in tumor cells, which could attribute to oncolytic virus efficacy 
[110,111,125,181,182]. On the other hand, viruses use different strategies to counteract the innate immune 
system to increase infectivity and replication efficiency, which could potentiate oncolytic efficacy [120], 
but might also have an impact on perceived safety of oncolytic NDV. The non-structural NS1 protein 
of influenza A virus is one of the most potent antagonists of innate immunity characterized to date 
[183,184]. NDV’s V protein is also a potent IFN antagonist in susceptible hosts, but not in human cells 
[177-180].
Outline of this thesis
Pancreatic ductal adenocarcinoma (PDAC) still remains a difficult to treat disease. The work presented in 
this thesis was undertaken to develop a new treatment modality for PDAC, virotherapy using oncolytic 
Newcastle disease virus (NDV).
To obtain ‘proof of principle’ for oncolytic efficacy of NDV for PDAC we investigated the responses of 
several human pancreatic adenocarcinoma cell lines (HPACs) to inoculation with NDV in chapter 2. We 
focused on the oncolytic potential of a wildtype strain NDV, and assessed the innate immune response 
of the different cell lines to evaluate the basis of oncoselectivity of NDV in PDAC.
Subsequent improvement of the oncolytic efficacy of NDV was evaluated in chapter 3, describing 
experiments undertaken using recombinant viruses with immunomodulating capacity, as well as 
more virulent recombinant NDVs both in vitro and in a nude mouse model for PDAC. We focused on 
the innate immune responses and oncolytic efficacy in HPACs, in addition to efficacy of intratumoral 
injection of different rNDVs in a nude mouse model for PDAC.
Chapter 4 focuses on the safety of oncolytic NDVs. Although much is known on the oncolytic potential 
of NDV, studies on safety are relatively scarce. We therefore evaluated the toxicity and shedding of 
lentogenic and mesogenic (recombinant) NDV strains when injected intravenously in high doses in 
non-human primates.
In chapter 5, we present a study with a PPMV-1 strain isolated from a fatal human case. The virus was 
investigated for the zoonotic potential, e.g. causing disease in a non-human primate model, when 
inoculated via the natural route.
In chapter 6, the findings presented in this thesis, and the progress in the field of OVs is discussed.
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Abstract
Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy 
against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought 
to occur because of differences in innate immune responses between normal and tumor cells. In our 
effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the 
responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic 
adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, 
this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication 
resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and 
NDV replication or NDV induced cytotoxicity. IFN production by HPACs after NDV infection differed 
substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased 
the cytotoxic effects in most HPACs. These findings suggest that not all HPACs have functional defects 
in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These 
data support the rationale for designing recombinant oncolytic NDVs with optimized virulence, which 
should likely contain an antagonist of the IFN pathways.
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Introduction
An estimated 277.000 new cases of pancreatic adenocarcinoma arise worldwide yearly, and 266.000 
patients die of this disease [185]. Radical surgery is the only potential curative treatment option to 
date. However, even for the 10-15% of patients with resectable disease, the prognosis is poor: median 
survival after resection is 24 months and 5-year survival 20% [57]. For patients with locally advanced 
or metastatic pancreatic cancer, the outlook is even grimmer: with palliative chemotherapy median 
survival is just 6 months [62]. Development of novel treatment options for pancreatic cancer is of 
crucial importance.
The local or systemic administration of oncolytic viruses such as Newcastle disease virus (NDV) to 
cancer patients is a promising treatment strategy with encouraging results in a variety of tumor types 
[83,96,113,186]. NDV is a replication competent oncolytic virus belonging to the family Paramyxoviridae 
with a natural avian host range. The virus has a replication cycle confined to the cell cytoplasm without 
integration or recombination. NDV strains are categorized in three different groups based on the 
severity of disease they cause in birds: lentogenic (avirulent), mesogenic (intermediate virulent) and 
velogenic (virulent). While NDV can cause severe and lethal disease in poultry, infection is relatively 
asymptomatic in humans [101].
NDV selectively replicates in and destroys tumor cells while sparing normal cells, presumably due to 
defective interferon (IFN) signaling pathways in tumor cells [102-106]. Infection of normal cells leads 
to IFN production which inhibits viral replication. The tumor-specific replication and subsequent 
induced cytolysis, and the inability of the virus to spread among healthy cells, make NDV a safe cancer 
therapeutic agent. The IFN produced by normal cells surrounding the tumor cells upon NDV infection, 
besides having anti-viral effects, might exert an anti-proliferative effect against human pancreatic 
adenocarcinoma cell lines (HPACs) [110].
Several naturally occurring NDV strains have shown anti-tumor activity without major side effects 
in phase I-II clinical trials [92,95,96,101]. However, the success of these therapies was only marginal, 
likely due to the IFN sensitivity or over-attenuation of the virus. In addition, some tumor cells are still 
capable of mounting effective antiviral responses, which may at least partially explain the observed 
resistance of some tumors to oncolytic NDV therapy [114,120]. The generation of recombinant viruses 
has provided opportunities to improve the efficacy of oncolytic NDV virotherapy [114,115,120,121,187-
189].
Pancreatic tumors are heterogeneous in cell composition, and information is lacking on defects in IFN 
pathways in these cells. Our ultimate goal is to generate an optimized recombinant NDV (rNDV) with 
destroying capacity of all different cell types of pancreatic tumors. For a rational design, we evaluated 
the susceptibility of 11 HPACs for NDV, response to this infection with regard to IFN production and 
cytotoxicity, and response to IFN treatment.
20
Material and Methods
Cell lines and culture conditions
The human pancreatic adenocarcinoma cell lines were obtained from the American Type Culture Collection 
(Wesel, Germany) and authentication was performed using Short Tandem Repeat profiling [190]. Cells were 
used not more than 25 passages after thawing. PANC-1, MIA PaCa-2, BxPC-3, Hs 700T, Hs 766T, CFPAC, SU.86.86, 
AsPC-1, Capan-1, Capan-2 and HPAF-II were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-
1640) supplemented with 100 U ml-1 penicillin, 100 U ml-1 streptomycin, 2 mM L-glutamine (PSG) and 5% or 
10% HyClone Characterized Fetal Bovine Serum (FBS HC; Thermo Fischer Scientific, Breda, the Netherlands). 
The non-neoplastic human lung fibroblast cell line MRC-5 was cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with PSG and 10% FBS HC. 293T cells were cultured in DMEM supplemented 
with PSG, 0.5 mg ml-1 geneticin, 1 mM sodium pyruvate, 1% non-essential amino acids and 10% FBS HC. Vero 
clone 118 cells [191] were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with PSG 
and 10% FBS HC. All cells were kept at 37 °C with 5% CO
2
 in a humidified incubator. Periodically, cells were 
tested and confirmed to be mycoplasma-free. All media and supplements were purchased from GIBCO (Life 
Technologies, Bleiswijk, the Netherlands).
Newcastle disease virus
All infection experiments were performed with lentogenic wild-type NDV isolated from a cloacal swab of a 
wild female mallard taken on 17th of October 2002 in Lekkerkerk, the Netherlands. The virus was cultured in 
embryonated chicken eggs using standard techniques. The F cleavage site was sequenced and the deduced 
amino acid sequence was found to be 112GRQGRL117, confirming this to be a lentogenic NDV. All infection 
experiments were performed in the presence of reduced concentration FBS HC (3%), without the addition of 
trypsin. Virus stocks were titrated by end point dilution assay in Vero clone 118 cells. To read out infection, cells 
were stained with chicken polyclonal anti-NDV antibody and rabbit-FITC labeled anti-chicken IgG antibody 
(1:2000 & 1:1000 dilution respectively; both from Abcam, Cambridge, UK) 72 hours after inoculation. Viral 
titers were calculated using the method of Reed & Muench [192]. In infection experiments, the term m.o.i. 
refers to multiplicity of infection. An m.o.i. of 1 equals one 50% tissue infective dose (TCID
50
) per cell. Low, 
medium and high m.o.i. are defined in this manuscript as an m.o.i. of 0.01, 0.1 and 1 respectively.
Replication curves
1.5 x 10^6 cells in T25 flasks (Corning, Amsterdam, the Netherlands) were inoculated with NDV at low m.o.i. 
After 1 hour incubation, cells were washed three times with PBS, and fresh infection medium was added. At 
time points 0, 6, 12, 24, 48 and 72 hours after washing, duplicates of 100 μl supernatant were collected, mixed 
with 100 μl 50% (w/v) sucrose, and frozen at -80 °C. Samples were titrated in quadruplicate as described 
before.
Cytotoxicity assay
Quadruplicates of 2 x 10^4 cells per well in 96-well plates (Corning) were either mock inoculated or 
inoculated with NDV at different m.o.i. (low – medium - high). After 48 hours, 100 μl fresh medium was 
added. At time points 0, 24, 48, 72, 96 and 120 hours post inoculation, cells were washed once with PBS 
and lysed by incubation with 100 μl 0.9% Triton X for 45 minutes at 37 °C. Lactate dehydrogenase (LDH) 
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in 50 μl of lysate sample was assayed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
Leiden, the Netherlands) following the manufacturer’s instructions. Cell viability is presented as percentage 
absorption (450 nm, Tecan Infinite F200, Giessen, the Netherlands) of inoculated versus mock inoculated cells, 
which were considered to be 100% viable. Although measurements were performed at multiple time points, 
we only show data from time point 5 days post inoculation, since this represented differences between 
observed cytotoxicity best.
IFN measurement with luciferase bioassay
To determine the presence of type I IFN in the supernatants of infected cells, a bioassay using a plasmid 
with the interferon stimulated response element (ISRE) fused to the firefly luciferase gene (pISRE-Luc; Agilent 
Technologies, Amstelveen, the Netherlands) as reporter was used. 24 hours post inoculation, supernatants of 
(mock-)infected cells were collected and stored at -20 °C. This time point was chosen to be able to measure IFN 
production without possible interference from decreasing cell viability and/or secondary IFN signaling loops. 
293T cells were transfected using the calcium phosphate method [193] with pISRE-Luc as reporter plasmid 
and Simian virus 40-Renilla-luciferase (pRL-SV40; Promega) as internal control. The next day, the collected 
supernatants were treated with UV to inactivate virus present in the supernatant and 300 μl was placed 
on the transfected 293T cells, together with 200 μl fresh 293T medium. After 24 hours, luminescent signals 
were generated using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer’s 
instructions and detected with a Tecan Infinite F200 microplate reader. Renilla luciferase signals were used to 
normalize firefly luciferase signals to correct for 293T cell number and transfection efficiency. IFN produced 
by NDV-infected cells is presented as fold change as compared to mock infected cells. Recombinant human 
IFN-β-1a (Merck Calbiochem, Darmstadt, Germany) was used as a positive control.
NDV staining and Fluorescence-activated cell sorting (FACS) analysis
Cells were harvested by trypsinization and subsequently fixed and permeabilized using Cytofix/Cytoperm 
following the manufacturer’s instructions (BD, Breda, the Netherlands). Next, cells were incubated on ice for 1 
hour with chicken polyclonal anti-NDV antibody (1:800 dilution), washed and subsequently incubated on ice 
for another hour with rabbit-FITC labeled anti-chicken IgG antibody (1:400 dilution). Cells were washed and 
fixed in 2% paraformaldehyde. FITC signals were detected using a BD FACS Calibur cytometer and FACS data 
was analyzed using BD CellQuest Pro software.
RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)
RNA was isolated using the High Pure RNA Isolation kit (Roche, Woerden, the Netherlands) following the 
manufacturer’s instructions. RNA was reverse transcribed using a two-step protocol. First, 22 μl (of a total 
of 50 μl) of eluted RNA was mixed with 2 μl random primers (500 μg ml-1; Promega), 2 μl dNTP’s (10 mM) 
and 1 μl RNAse inhibitor (40 U μl-1; Promega). This mix was heated for 5 minutes at 65 °C and immediately 
put on ice. Next, 8 μl FS buffer (5x), 2 μl DTT (0.1 M), 2 μl Superscript III RT (200 U μl-1; Life Technologies) and 
1 μl RNAse inhibitor (40 U μl-1) was added. This mix was incubated for 5 minutes at 25 °C and for 1 hour 
at 60 °C to synthesize cDNA. qRT-PCR was performed using 4 μl of cDNA in an ABI PRISM 7000 Sequence 
Detection System (Life Technologies), using TaqMan gene expression assays for ISG56, OAS1 and Mx1 
(Hs00356631, Hs00973637 and Hs00895608; all from Life Technologies). β-actin was used as household 
gene (forward primer 3’-ggcatccacgaaactacctt-5’, reverse primer 3’-agcactgtgttggcgtacag-5’, probe 
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3’-atcatgaagtgtgacgtggacatccg-5’). Results are presented as fold change of treated samples versus control 
samples (triplicates), calculated using the 2−ΔΔC
T
 method [194].
Statistical analysis
Continuous data were compared between the groups using the Mann-Whitney U test. Correlation between 
continuous data was calculated using Spearman’s rank correlation coefficient (rho). P values of <0.05 were 
considered statistically significant.
Results
For a rational design of recombinant NDVs with improved oncolytic efficiency acting against all different 
sorts of pancreatic tumor cells, we evaluated the responses to NDV for 11 different HPACs with regards 
to cytotoxic effects and innate immune responses: PANC-1, MIA PaCa-2, BxPC-3, Hs 700T, Hs 766T, CFPAC, 
SU.86.86, AsPC-1, Capan-1, Capan-2 and HPAF-II.
HPACs differ in susceptibility to NDV replication and subsequent cytotoxic effects
To assess the susceptibility of the 11 HPACs to NDV replication and NDV induced cytolysis, multicycle 
replication kinetic studies with wild-type lentogenic NDV were conducted. Cells were inoculated at low m.o.i. 
and virus titers in the culture supernatant were determined at different time points post inoculation. MRC-5, a 
normal human fibroblast cell line known to be susceptible to NDV infection, was taken as control.
Based on NDV replication capacity in the different HPACs, the cells were categorized into 3 groups (table 
1; figure 1): supporting high replication (peak titer > 1,0 x 105: Capan-1, HPAF-II and SU.86.86), supporting 
low to medium replication (peak titer 1,0 x 104 to 1,0 x 105: Capan-2, BxPC-3, AsPC-1, PANC-1 and CFPAC) and 
supporting minimal replication (peak titer < 1,0 x 104: Hs 766T, Hs 700T and MIA PaCa-2).
Table 1: NDV replication. Virus yield obtained after inoculation of MRC-5 (normal fibroblast) and 11 different human 
pancreatic adenocarcinoma cell lines (HPACs) with NDV.
Cell line Peak titer(TCID
50
/ml)
MRC-5 1,0 x 104
Capan-1 3,4 x 106
HPAF-II 1,6 x 106
SU.86.86 1,7 x 105
Capan-2 6,6 x 104
BxPC-3 5,5 x 104
AsPC-1 3,1 x 104
PANC-1 1,3 x 104
CFPAC 1,2 x 104
Hs 766T 4,6 x 103
Hs 700T 2,8 x 103
MIA PaCa-2 2,7 x 103
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Figure 1: Replication kinetics of NDV in HPACs and MRC-5 fibroblasts. Representative HPACs for each category are 
shown (A = high replication: peak titer > 1,0 x 105; B = medium replication: peak titer 1,0 x 104 to 1,0 x 105; C = no replication: 
peak titer < 1,0 x 104). Samples were taken at indicated time points and titrated by end-point dilution assay in Vero clone 
118 cells. Means and standard deviations of duplicate titrations are plotted.
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The differences observed in NDV replication were reflected in the induced cytotoxicity (figure 2). In 
general, cells with high virus replication showed cytotoxicity already at low m.o.i. (SU.86.86, Capan-1, 
HPAF-II) while cells displaying low to medium virus replication required inoculation at medium m.o.i. to 
kill most cells. Inverse correlation was observed between peak viral titers and percentage cell survival 
at low and medium m.o.i. (Spearman’s rho -0,77 and -0,74 respectively). MIA PaCa-2 and Hs 700T did 
not support virus replication and displayed cytotoxic effects only at high m.o.i. These findings indicate 
that NDV replication is an important factor to cause cytotoxicity in HPACs.
Figure 2: Cytotoxicity induced by NDV infection on all HPACs and MRC-5. Cells were either mock inoculated (not 
shown) or inoculated with NDV at low (white bars), medium (grey bars) or high m.o.i. (black bars). Cytotoxicity was 
measured daily for 5 days by LDH assay, with day 5 post inoculation being depicted. Results are presented as percentage 
of surviving cells as compared to mock inoculated cells, which were considered to be 100% viable. Means and standard 
deviations of quadruplicate experiments are plotted. * = p < 0,05 as compared to MRC-5 cells.
HPACs differ in IFN production and signaling pathways
For most HPACs, variation of NDV replication corresponded with differences in cytotoxic effects 
induced by the NDV infection. The observed variation in replication might result from differences in 
innate immune responses between the HPACs, as was described in earlier studies in other cell lines 
[103-106].
To investigate differences in the IFN production pathway, cells were inoculated with NDV at high m.o.i. 
to obtain high percentages of infected cells and 24 hours later IFN content in the supernatant was 
determined (figure 3A). Six out of 11 HPACS (SU.86.86, Capan-1, Capan-2, BxPC-3, AsPC-1, MIA PaCa-2) 
failed to induce substantial IFN production upon NDV infection. This lack of IFN production was not 
due to low percentage of infected cells, as all HPACs displayed more than 68% infected cells by FACS 
analysis upon inoculation with this high m.o.i. The insensitivity of MIA PaCa-2 cells to NDV infection and 
induced cytotoxic effects could not be explained by IFN production as these cells did not produce IFN 
upon NDV infection. Interestingly, five HPACs (HPAF-II, CFPAC, PANC-1, Hs 766T and Hs 700T) did induce 
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IFN production upon NDV infection, as did control MRC-5 fibroblasts. This is not an unusual finding as 
IFN production by tumor cells has been demonstrated before [104,106,187]. No correlation was found 
between virus replication or cytotoxic effects of NDV and IFN production in these cells (Spearman’s 
rho -0,27; -0,08; -0,13 and -0,32 for replication; cytotoxicity at low, medium and high m.o.i. respectively). 
This is best demonstrated by the HPAF-II cell line, which produces relatively large amounts of IFN, yet 
is highly susceptible to NDV.
The tumor selectivity of NDV has also been shown to be due to defects in the IFN signaling pathway 
[104]. To test for defects in the JAK-STAT signaling pathway, cells were either mock treated or treated 
with 1000 IU ml-1 of recombinant human interferon beta (IFN-β). After 24 hours, expression of 
mRNA of three important interferon-stimulated genes (ISGs: interferon-stimulated gene 56 (ISG56), 
2’-5’-oligoadenylate synthetase 1 (OAS1) and myxovirus resistance 1 (Mx1) was determined (figure 3B).
As expected, all three tested ISGs in normal human lung fibroblast MRC-5 cells were upregulated upon 
IFN treatment, while these cells also produced IFN upon NDV infection. Of the 5 IFN producing HPACs 
(HPAF-II, CFPAC, PANC-1, Hs 766T and Hs 700T), 4 displayed a diminished upregulation as compared 
to MRC-5 fibroblasts for at least one of the mRNAs. Although lower than MRC-5 control, they still 
displayed at least a tenfold upregulation of at least one of the assayed ISG-mRNAs, which might still be 
biologically significant. For Hs 700T cells, which demonstrated production of IFN upon NDV infection, 
2 out of 3 tested ISGs were highly upregulated upon IFN treatment. Thus, Hs 700T cells produce IFN 
upon NDV infection, and a mostly intact IFN signaling pathway in these cells results in expression of 
antiviral genes. Failure to upregulate OAS1 mRNA suggests that Hs 700T cells have a mutation in or 
deletion of this antiviral gene, but nevertheless they were still protected from infection. In summary, 
most of the tested HPACs showed a retained ability to respond to type I IFN, and the significance of the 
lower magnitude of response in some HPACs is unclear. Furthermore, no statistical correlation (tested 
with Spearman’s rank) was found between virus replication or cytotoxic effects of NDV and ISG-mRNA 
upregulation.
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Figure 3
(A) IFN production 24 hours after NDV infection. Cells were either mock inoculated or inoculated with NDV at high 
m.o.i. After 24 hours, supernatants were tested for IFN content. Results are presented as fold change in IFN content in 
supernatants of NDV inoculated versus mock inoculated cells. Means and standard deviations of duplicate measurements 
are plotted. Indicated underneath the cell line names are infection percentages determined by FACS analysis.
(B) Expression levels of anti-viral ISGs upon IFN-β treatment. Cells were either mock treated or treated with 1000 IU of 
recombinant human IFN-β. After 24 hours, RNA was isolated and real time RT-PCR was performed for ISG56-mRNA (white 
bars), OAS1-mRNA (grey bars) and Mx1-mRNA (black bars). Results are presented as fold change gene induction of treated 
versus mock treated cells calculated using the 2−ΔΔCT method. Means and ranges of triplicate experiments are plotted.
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IFN-β pre-treatment can hamper NDV replication and protect from NDV induced cytotoxicity in 
most HPACs
To study whether the observed differences in IFN signaling also reflected a functional effect on 
replication of NDV in these cells, multicycle replication curves for NDV were generated in HPACs pre-
treated with IFN-β. As shown in figure 4A, pre-treatment of the HPACs with IFN-β decreased virus 
replication in most cells to levels comparable to resistant HPACs, and replication was delayed in 
Capan-1 and SU.86.86 cells by 24 hours (figure 4B).
Figure 4 
(A) Peak virus titers obtained after infection at low m.o.i. of cells either mock treated (white bars) or IFN-β 
treated (1000 IU ml-1; black bars) for 24 hours. Samples were taken at different time points and titrated by end-point 
dilution assay in Vero clone 118 cells. Peak titers are depicted with corresponding standard deviation of two independent 
titrations.
(B) Growth kinetics of NDV infection in selected HPACs after IFN-β pre-treatment of cells. Cells were mock-treated 
(straight lines, filled symbols) or treated with 1000 IU ml-1 IFN-β (dashed lines, open symbols) for 24 hours. After pre-
treatment, multicycle replication kinetics were performed, starting with low m.o.i. infection.
IFN-β pre-treatment also decreased NDV induced cytotoxic effects in most cells (figure 5), while IFN-β 
did not induce measurable cytotoxicity by itself after 24 hours (data not shown). HPACs like HPAF-
II, Capan-2, CFPAC, PANC-1 and Hs 766T showed almost complete survival of cells after IFN-β pre-
treatment and subsequent NDV infection. Interestingly, HPAF-II was one of the HPACs that showed 
complete protection for NDV induced cytotoxicity after exogenous IFN pretreatment, while these cells 
are capable of producing IFN upon NDV infection without being protected. It is important to note 
that cells were pretreated with a relatively high amount of exogenous IFN-β (1000 IU) for 24 hours. This 
in contrast to lower amounts of endogenous IFN without a pretreatment period in cells infected at 
lower m.o.i. This could explain the seemingly contradictory results in infection experiments with and 
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without IFN pretreatment. Capan-1 cells, in which IFN-β pre-treatment did not completely block viral 
replication, still displayed NDV induced cytotoxicity, but at lower levels as compared with cells not pre-
treated with IFN-β, while IFN-β pre-treatment displayed no relevant protective effect on SU.86.86 cells. 
This again indicated that virus replication was important for the cytotoxic effects.
Figure 5: Induced cytotoxicity upon NDV inoculation after IFN-β pre-treatment of HPACs and MRC-5 cells. Cells 
were either mock inoculated (not shown) or inoculated with NDV at medium m.o.i. after mock treatment (white bars) or 
IFN treatment for 24 hours (black bars). Cytotoxicity induced by NDV infection was measured daily for 5 days by LDH assay 
(only day 5 is depicted). Results are presented as percentage of surviving cells as compared to mock inoculated cells, 
which were considered to be 100% viable. Means and standard deviations of quadruplicate experiments are plotted. * = 
p < 0,05.
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Discussion
In our search for new therapies for pancreatic adenocarcinoma, we have focused our attention on the use 
of NDV as an oncolytic agent. Several wild-type NDV strains (MTH-68, 73-T, Ulster, PV701, HUJ) have been 
described as being effective oncolytic viruses, killing tumor cells originating from various cancer types in 
vitro as well as in vivo [96,113]. However, the success of these viruses in treatment of cancer patients was 
only marginal [93,101]. The development of reverse genetic techniques has revived the use of oncolytic 
viruses, and the oncolytic efficiency of NDV has been improved in vitro and in vivo by either generating 
viruses with higher virulence [126,195] or generating viruses that express immune modulatory genes 
[114,115,120,121,188,189].
For a rational design of a recombinant oncolytic NDV to treat patients with pancreatic tumors, we here 
evaluated the effect of wild-type NDV infection on human pancreatic adenocarcinoma cell lines (HPACs) 
in vitro. A broad panel of 11 different HPACs was chosen in order to study a heterogeneous population of 
pancreatic tumor cells, which resembles the heterogeneity of these tumors in patients.
Our results demonstrate that variations in NDV replication in the different HPACs generally coincided 
with differences in induced cytotoxic effects, with cell lines displaying more cytotoxic effects upon better 
NDV replication. This suggests that virus replication itself is a critical factor for NDV induced cytotoxicity, 
as was described in earlier studies in other cells [102-107,187,196-198]. This would argue for increasing 
the fusogenicity of an optimized recombinant NDV for treatment of pancreatic tumors. We observed 
multicycle replication of a lentogenic strain of NDV in some HPACs without addition of exogenous trypsin. 
Pancreatic tumor cells have been shown to produce trypsinogen [199,200], and this endogenous present 
trypsin could explain this observation and possibly differences between HPACs in supporting multicycle 
NDV replication.
It is thought that replication of oncolytic NDV is tumor specific because tumor cells have defects in 
the innate immune responses; however, discrepancies for this theory have also been reported [107-
109]. Numerous studies have focused on defective IFN production as a reason for tumor-specific NDV 
susceptibility, however only limited sets of tumor cell lines were used, which could have resulted in 
non-representative findings [105,106]. By studying a more elaborate panel of HPACs, we convincingly 
demonstrate that IFN production by the HPACs does not correlate with NDV susceptibility. This is in 
accordance with findings reported by some other groups [107-109]. Interestingly, a recent study focusing 
on oncolytic Vesicular stomatitis virus (VSV) infection of a similar panel of HPACs reported mostly the same 
HPACs to be capable of producing IFN upon viral infection [201]. However, where we could not detect 
a correlation between IFN production and resistance against NDV infection, this was detected for VSV 
infection of HPACs.
Besides lack of IFN production, defective IFN signaling through the JAK-STAT pathway has been indicated 
to be responsible for tumor specific replication of NDV [103-105]. Although our results with 11 different 
HPACs show a highly variable and generally low anti-viral gene expression pattern after IFN stimulation, we 
also show that most HPACs can still use IFN to signal to an antiviral state. IFN pretreatment protected the 
cell lines from NDV replication and induced cytotoxicity. These results indicate that IFN signaling pathways 
are still functional in most HPACs, and it is possible that while we measured 3 important and well-known 
ISG-mRNA expressions, we missed others that play a role in anti-viral defense. A gene expression profiling 
approach could provide more detailed information on the regulation of different ISGs in these HPACs.
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IFN induced by other tumor cells or bystander cells could be able to protect tumor cells from viral 
replication and NDV induced cytotoxic effects. Indeed, earlier reports also showed that IFN pretreatment 
could hamper NDV replication, although with a slightly lower effectiveness when compared to normal 
cells [104,105]. We argue that IFN production within a tumor environment could prevent oncolytic NDV 
from replicating in most tumor cells, thus preventing eradication of heterogeneous tumors.
Few other groups have demonstrated that IFN production and signaling are not the only factors to 
consider. Cells over expressing anti-apoptotic proteins like Rac1 [108], Livin [109], and Bcl-xL [107] also 
showed markedly increased susceptibility to NDV replication and virus mediated killing, irrespective of 
IFN production and signaling. It is possible that differences in apoptotic, necrotic or autophagy pathways 
account for the differences observed between HPACs. Further research is needed to elaborate on this 
theory.
IFN not only hampers viral replication, it also has direct anti-proliferative effects on pancreatic cancer 
cells [110,181,202,203] and it initiates signaling towards a potentially very effective antiviral and antitumor 
adaptive immune response [182]. It is under debate whether an improved oncolytic NDV should stimulate 
the IFN pathway [114,115] or suppress the immune system [120]; both approaches have shown to be 
feasible and effective. As a consequence, tuning of the balance between virulence and interaction with 
the IFN pathways of oncolytic viruses may be needed depending on the ultimate application.
This study was conducted to obtain more information for a rational design of an improved recombinant 
oncolytic NDV. On the one hand we studied the heterogeneity of HPACs in response to NDV infection. This 
allowed us to categorize the cells in three groups, based on susceptibility to NDV infection and induced 
cytotoxicity. These differences provide a rationale for improving the virulence of NDV, and subsequently 
test various recombinant NDVs against prototype HPACs of these three groups. In addition, this study, 
as shown by others, demonstrated that NDV infection and replication is hampered by IFN treatment of 
tumor cells. This underlines the need to also improve the IFN antagonistic properties of oncolytic NDV. 
The best recombinant oncolytic NDV in vitro could be one that encodes an IFN antagonistic protein and 
has higher fusogenicity due to inclusion of a different fusion protein. In conclusion, NDV is a promising 
candidate oncolytic virus for further preclinical testing on pancreatic cancer models, and reverse genetic 
techniques will enable us to generate NDV with improved oncolytic effect.
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Abstract
Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment 
of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F
0
) 
or an IFN antagonistic protein (rNDV-NS1-F
0
), as well as an rNDV with increased virulence (rNDV-F
3aa
) for 
oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did 
not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not 
NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F
3aa
) resulted 
in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells 
inoculated with rNDV-hIFNβ-F
0
, while inoculation with rNDV-NS1-F
0
 resulted in a complete block of 
interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-
F
3aa
 caused markedly more cytotoxicity compared to rNDV-F
0
, while inoculation with rNDV-hIFNβ-F
0 
and rNDV-NS1-F
0
 induced cytotoxic effects comparable to those induced by the parental rNDV-F
0
. 
Evaluation in vivo using mice bearing subcutaneous pancreatic cancer xenografts revealed that only 
intratumoral injection with rNDV-F
3aa
 resulted in regression of tumors. We conclude that although 
lentogenic rNDVs harboring proteins that modulate the type I interferon pathway do have an oncolytic 
effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy.  
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Introduction
Patients with pancreatic adenocarcinoma still have very poor survival rates, and current therapies are 
of limited effect [57,62]. Oncolytic Newcastle disease virus (NDV) could be a promising new therapeutic 
agent for the treatment of pancreatic cancer. NDV has been described as a naturally occurring oncolytic 
virus as early as 1952 [88-90]. Since then, numerous clinical trials have employed wild type NDV strains 
either as a direct oncolytic agent, or as an oncolysate vaccine for treatment of patients with various 
types of advanced stage cancer [91-96]. Results of these early trials have been relatively disappointing, 
illustrated by the lack of further development of these treatment strategies. With the advent of 
recombinant DNA techniques it has become possible to genetically engineer NDV [112], and interest in 
the use of recombinant NDV (rNDV) as an oncolytic virus has revived over the last decade [113].
NDV selectively replicates in and destroys tumor cells while sparing normal cells, presumably because 
of defective interferon (IFN) signaling pathways of the innate immune system in tumor cells. Previously, 
we reported that a lentogenic wild type NDV strain replicated in and was cytotoxic for 11 human 
pancreatic adenocarcinoma cell lines (HPACs) with high variability. These differences in the response of 
HPACs were not due to defects in innate immunity pathways as a number of these cell lines produced 
type I IFN upon NDV infection [204]. We, and others, have also shown that IFN produced by tumor 
cells and the normal cells surrounding the tumor cells exerts anti-proliferative, pro-apoptotic and 
pro-inflammatory effects in tumor cells, possibly attributing to oncolytic efficacy [110,111,125,181,182]. 
Therefore, rNDVs armed with the IFN gene might result in a virus with higher oncolytic efficacy. 
However, the antiviral activity of IFN hampers NDV replication in tumor cells [204]. Viruses use different 
strategies to counteract the IFN pathway to increase infectivity and replication efficiency. The non-
structural NS1 protein of influenza A virus is one of the most potent antagonists of the IFN response 
of the innate immunity characterized to date [183,184]. Oncolysis of tumor cells depends on efficient 
virus infection and replication, therefore, incorporation of an IFN antagonist, such as the NS1 protein of 
Influenza A, in the genome of rNDV could be a way to improve the oncolytic efficacy of rNDV.
NDV strains are categorized in three different groups based on the severity of the disease they cause 
in birds: lentogenic, mesogenic, and velogenic and this classification correlates with their oncolytic 
properties in cancer cells. Increasing the virulence of rNDV has been shown to improve direct oncolytic 
efficacy most, resulting in preclinical studies using mesogenic virulent rNDVs expressing transgenes, 
such as IFN and the NS1 protein of influenza virus [113]. However, virulent NDV strains pose an 
environmental risk, as birds (specifically poultry) are very susceptible to infection with mesogenic or 
velogenic strains.
We hypothesize that arming lentogenic rNDV with IFN-modulating genes, either accelerating or 
blocking the IFN response, would improve the oncolytic effect of NDV sufficiently to circumvent 
using virulent rNDV with the associated potential biosafety risks. In the present study we compared 
lentogenic rNDVs expressing either hIFNβ or the IFN antagonistic protein (NS1) of the Influenza virus 
with those of a virulent rNDV (rNDV-F
3aa
) for direct oncolytic efficacy.
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Material and Methods
pNDV cloning 
A full length cDNA clone of lentogenic NDV strain La Sota (pNDV-F
0
) and expression plasmids pCIneo-
NP, pCIneo-P and pCIneo-L, as well as cloning plasmid pGEM-T-PM-cassette were kindly provided 
by Ben Peeters from the Central Veterinary Institute of Wageningen UR, the Netherlands [112,205]. 
To create a full length rNDV-F
0
 expressing either GFP, hIFN-β or NS1 protein of influenza strain A/
PuertoRico/8/1934, a DNA fragment containing the open reading frame (ORF) encoding these proteins 
was inserted into the intergenic region between the P and M genes of pNDV-F
0
 flanked by appropriate 
NDV-specific transcriptional gene-start and gene-end signals. Cloning strategies resulted in full length 
NDV genomes that complied with the rule-of-six [206]. To create a full length NDV cDNA clone with a 
multibasic cleavage site in the fusion protein, the amino acid sequence of the protease cleavage site 
was changed from 112GRQGR↓L117 (lentogenic) to 112RRQRR↓F117 (mesogenic; pNDV-F
3aa
) by means of 
site-directed mutagenesis as described earlier [114]. Full length NDV plasmids were sequenced using a 
3130xL Genetic Analyzer (Life Technologies, Bleiswijk, the Netherlands) to exclude incidental mutations 
that could arise during the cloning process.
Recombinant virus rescue
Recombinant NDVs were rescued using a method adapted from the original method described 
previously [112]. Briefly, BSR-T7 cells were transfected with 5 µg full length pNDV, 2.5 µg pCIneo-NP, 1.25 
µg pCIneo-P and 1.25 µg pCIneo-L using 10 µl lipofectamine (Life Technologies). Three days later, 200 
µl BSR-T7 supernatant was injected into the allantoic cavity of 10 day old specified pathogen free (SPF) 
embryonated chicken eggs. After incubation in a humidified egg incubator at 37°C for two or three 
days (mesogenic or lentogenic rNDVs, respectively), allantoic fluid was harvested and presence of virus 
demonstrated by hemagglutination assay [207]. Samples displaying hemagglutination were passaged 
once more in eggs to increase virus titer, and allantoic fluid was harvested after 2 or 3 days. Pooled fresh 
allantoic fluid was purified and concentrated by ultracentrifugation at 27.000 rpm for two hours at 4°C 
using a 30%/60% sucrose gradient. rNDV stocks were stored at -80°C.
Recombinant influenza virus A/PuertoRico/8/34 was rescued and titrated as described before [208].
Titration of rNDV
Virus stocks were titrated by end point dilution assay in Vero-118 cells, as described before [204]. All 
infection experiments were performed in the presence of reduced concentration FBS HyClone (3%; 
Thermo Fischer Scientific, Breda, The Netherlands), without the addition of exogenous trypsin.
Characterization of rNDV
RNA from virus stocks was isolated using the High Pure RNA Isolation kit (Roche, Woerden, the 
Netherlands) following the manufacturer’s instructions and reverse transcribed into cDNA using a 
two-step protocol, as described before [204]. Amplicons generated with RT-PCR using primers flanking 
the P-M intergenic or F protein cleavage site region were sequenced to confirm the sequence of the 
inserted gene between the P and M genes and the protease cleavage site of the fusion protein (F
0
/F
3aa
).
Expression of NS1 protein was assayed in Vero-118 cells (mock-)inoculated at m.o.i. 3 with either rNDV-F
0
, 
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rNDV-NS1-F
0
 or positive control influenza A/PuertoRico/8/34. Whole cell-lysates taken 18 hours post-
inoculation were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a Hybond-C Extra nitrocellulose membrane (GE Healthcare Life Sciences, 
Diegem, Belgium). Membranes were stained for NS1 using primary monoclonal mouse anti-influenza 
A NS1 antibody (AB_2011757 / sc-130568; 1:1000 dilution; Santa Cruz Biotechnology, Heidelberg, 
Germany) and secondary peroxidase-conjugated polyclonal goat anti-mouse antibody (P0447; 1:2000 
dilution; Dako, Heverlee, Belgium) or for β-tubulin using peroxidase-conjugated monoclonal rabbit 
anti-β-tubulin antibody (9099; 1:1000 dilution; Cell Signaling Technology, Leiden, the Netherlands). 
Chemiluminescent signals were generated using Amersham ECL Prime Western Blotting Detection 
Reagent (GE Healthcare Life Sciences) following manufacturer’s instructions and detected using a 
ChemiDoc MP system (Bio-Rad, Veenendaal, the Netherlands).
Cell lines and culture conditions
The HPACs SU.86.86, HPAF-II, BxPC-3, PANC-1, MIA PaCa-2, Hs 700T, CFPAC, Hs 766T, AsPC-1, and 
Capan-2 were obtained from the American Type Culture Collection and authenticated using Short 
Tandem Repeat profiling [190]. Cells were used not more than 25 passages after thawing. HPACs, non-
neoplastic human lung fibroblasts MRC-5, Vero-118, BSR-T7 and 293T cells were cultured as described 
before [204,209].
Replication curves
For MIA PaCa-2 cells 3.0 × 106 and for SU.86.86, HPAF-II, BxPC-3, PANC-1 and Hs 700T 1.5 × 106 cells in 
T25 flasks (Corning, Amsterdam, The Netherlands) were inoculated at m.o.i. 0.1, in triplicate. After a 1 
h incubation, cells were washed three times with PBS and fresh medium was added. At time points 
0, 2 12, 24, 48, and 96 h after washing, duplicates of 100 μL supernatant were collected, mixed with 
100 μL 50% (w/v) sucrose, and frozen at −80 °C. Samples were titrated by end point dilution assay in 
quadruplicate as described before [204].
RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) for hIFNβ mRNA
Twenty-four hours after inoculation with rNDV at m.o.i. 3, cells were lysed with 300 µL lysis buffer of the 
Total Nucleic Acid Isolation kit (Roche) and RNA was isolated using a MagNA Pure LC machine (Roche) 
following the manufacturer’s instructions. qRT-PCR (30 cycles) was performed with 20 μL RNA in an 
ABI PRISM 7000 Sequence Detection System (Life Technologies), using TaqMan gene expression assay 
for human IFNβ1 (Hs00277188_s1, Life Technologies). The primers in this assay map to the extreme 3’ 
end of the hIFNβ gene (Hs00277188_s1, www.lifetechnologies.com), with the reverse primer annealing 
downstream of the stop codon of the hIFNβ coding sequence. This region is not present in the rNDV-
hIFNβ-F
0
 virus. Therefore, the qRT-PCR assay is not able to detect IFN-mRNA transcribed from the virus, 
and the assay will only detect endogenous transcribed IFN-mRNA. To detect both endogenous and 
exogenous expressed IFN, primers and probes mapping in the IFN coding region were used with an 
in-house developed assay and β-actin was used as household gene. The sequences of the primers and 
probes for the IFN-coding region and β-actin have been described before [210]. Results are presented 
as fold change of inoculated samples versus mock-inoculated samples (duplicates), calculated using 
the 2−ΔΔC
T
 method [194].
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IFN measurement with luciferase bioassay
Cells were inoculated in triplicate at m.o.i. 3 and 24 hours post inoculation, supernatants were collected 
and assayed for IFN contents using a bioassay as described before [204]. IFN produced by NDV-
inoculated cells is presented as fold change in luminescence compared to mock inoculated cells.
Cytotoxicity assay
Quadruplicates of 2 x 104 cells per well in 96-well plates (Corning) were either mock inoculated or 
inoculated with rNDV at different m.o.i. (range 0.0001 - 100). After 48 hours, 100 μl fresh medium was 
added. At time point 120 hours post inoculation, cell viability was determined using the CytoTox 96 
Non-Radioactive Cytotoxicity Assay (Promega, Leiden, the Netherlands) as described before [204]. 
Prism for Windows version 5.03 (GraphPad software, La Jolla, CA) was used to analyze data using the 
log(inhibitor) vs. normalized response (variable slope) function to obtain LD
50
 values. The extra sum-
of-squares F test was used to compare LD
50
 values. P-values of <0.05 were considered statistically 
significant.
Ethics statement
All experiments involving animals were conducted strictly according to European guidelines (EU 
directive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997). 
The experimental protocol was reviewed and approved by an independent animal experimentation 
ethical review committee, not affiliated with Erasmus MC (DEC consult number EMC2921).
Animals and experimental design
Groups of 30 athymic nude mice (strain NMRI-Foxn1nu; Charles River, Sulzfeld, Germany) were injected 
subcutaneously in their flank with 3 x 106 SU.86.86, BxPC-3 or MIA PaCa-2 cells. Tumor width (w) and 
length (l) were measured using a digital caliper (VWR International, Amsterdam, the Netherlands) and 
tumor volume was calculated using the modified ellipsoid formula w2 x l / 2 [211,212]. Tumors were 
allowed to grow until the average tumor volume per group reached 50 mm3 (3-5 weeks) and animals 
were appointed randomly stratified for tumor size to one of five treatment groups: PBS, rNDV-F
0
, rNDV-
hIFNβ-F
0
, rNDV-NS1-F
0
 or rNDV-F
3aa
. Animals were injected intratumorally every other day for a total 
of 4 injections with 5 x 107 TCID
50
 rNDV in a total volume of 50 µl or an equivalent volume PBS. After 
injection, tumor sizes were recorded two times weekly. Animals were euthanized if tumor volume 
exceeded 2000 mm3, non-healing tumor ulcerations or excessive weight loss occurred, and ultimately 
40 days after first injection with rNDV or PBS. Last observed tumor volumes were carried forward to 
calculate median volumes per group. Continuous data were compared between the groups using the 
Mann–Whitney U-test. One-sided P-values of <0.05 were considered statistically significant.
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Results
Cloning, rescue and characterization of recombinant NDVs
Five different rNDVs were generated which were used throughout this study: rNDV-F
0
, rNDV-GFP-F
0
, 
rNDV-hIFNβ-F
0
, rNDV-NS1-F
0
 and rNDV-F
3aa
 (Figure 1a). Amplicons of the P-M intergenic (Figure 1b) 
and F protein cleavage site were sequenced to confirm identity of the rNDV stocks. Upon titration 
of virus stocks, only infection with rNDV-F
3aa
 lead to syncytia formation in cell cultures, characteristic 
for infection with mesogenic NDV (data not shown). In addition, western blot assay confirmed the 
expression of NS1 by rNDV-NS1-F
0
 (Figure 1c).
Figure 1. Generation and characterization of rNDVs. (a) Cloning strategy to obtain full length NDV plasmids. The 
nucleotide length of the NDV genome is noted below the plasmid names and all full length plasmids and pGEM-T-PM-
cassette are drawn to scale. The 3’-terminal leader, intergenic regions and 5’-terminal trailer are shown as horizontal lines. 
Gene-end and gene-start sequences in the PM intergenic region are depicted as vertical black and white rectangles, 
respectively. fwd: forward; rev: reverse; nt: nucleotides; pGEM-T: plasmid backbone of pGEM-T-PM-cassette; NP: 
nucleoprotein gene; P: phosphoprotein gene; V: accessory V gene; M: matrix gene; F: fusion gene; HN: hemagglutinin-
neuraminidase gene; L: large protein gene. (b) PCR product of PM intergenic region. RNA of indicated rNDV stocks was 
reverse transcribed into cDNA and the PM intergenic region was amplified with RT-PCR using flanking primers. (c) Western 
blot for expression of NS1 protein. Whole cell lysates of Vero-118 cells (mock-) inoculated with indicated viruses were 
assayed for expression of the NS1 protein or tubulin protein.
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Replication kinetics of rNDVs
To test whether the expression of additional transgenes or a change in cleavability of the F protein had 
an effect on replication kinetics of rNDVs, replication curves were generated for the different viruses 
on six different HPACs. HPACs were selected based on replication efficiency of the wild type virus as 
reported in our previous study [204].
Upon inoculation, no significant differences were observed for replication of the lentogenic viruses 
rNDV-F
0
, rNDV-GFP-F
0
, and rNDV-NS1-F
0
 on all cells. SU.86.86 and HPAF-II cells supported replication 
of these viruses to high titers, while replication was less efficient in the other four cell lines (Figure 2).
Inoculation with rNDV-hIFNβ-F
0
 resulted in attenuated replication in all cells, with significant lower 
titers in SU.86.86, HPAF-II and BxPC-3 cells compared to inoculation with rNDV-F
0
. 
In contrast, inoculation with the mesogenic virus rNDV-F
3aa
 resulted in efficient multicycle replication 
in most cell lines. Inoculation of SU.86.86 with rNDV-F
3aa
 resulted in significant higher titers at t = 24 
compared to those of rNDV-F
0
 and after this time point titers of rNDV-F
3aa
 declined, due to the loss of 
cells as an effect of the efficient replication. Inoculation with rNDV-F
3aa
 of BxPC-3, PANC-1, MIA PaCa-2, 
and Hs 700T cells resulted in significant higher titers at t = 24, 48 and 96 compared to those of rNDV-F
0
. 
Although the titers for rNDV-F
3aa
 in HPAF-II cells were higher than those of the other viruses in HPAF-II 
cells these differences were not significant (Figure 2).
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Figure 2. Replication kinetics of rNDVs in 6 different human pancreatic adenocarcinoma cell lines (HPACs). Cells 
were inoculated in triplo with m.o.i. 0.1 and samples were taken at indicated time points and titrated by end-point dilution 
assay in Vero-118 cells. Means and standard deviations of triplicate titrations are plotted. H.p.i.: hours post inoculation. * = 
p < 0.05 vs. rNDV-F
0
 (one-way ANOVA + Bonferroni post-test), tested for time points 24, 48 and 96 h.p.i.
Modulation of IFN response by rNDVs
As IFN has a direct effect on oncolysis, the capacity of the viruses to induce, enhance or block IFN 
production was evaluated. Ten HPACs, as well as Vero cells (lacking the endogenous IFN genes) and 
MRC-5 cells (fully IFN competent), were inoculated with the five different rNDVs and at 24 hours after 
inoculation both hIFNβ protein production as well as gene expression levels were measured. The gene 
expression assay for endogenously expressed IFN maps to the extreme 3” end of the hIFNβ gene, 
with the reverse primer annealing downstream of the stop codon of the hIFNβ coding sequence. This 
region is not present in the rNDV-hIFNβ-F
0
 virus, thus only the endogenous transcribed IFN-mRNA is 
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detected and not IFN-mRNA transcribed from the rNDV-hIFNβ-F
0
 virus.
Inoculation with rNDV-F
0
 or rNDV-GFP-F
0
 resulted in upregulation of endogenous hIFNβ gene 
expression in MRC-5 cells and in eight of the HPACs. No upregulation was observed in SU.86.86, 
MIA PaCa-2 and, as expected, Vero cells. These findings were mostly in agreement with our findings 
using wild type NDV, except for BxPC-3 cells [204]. Inoculation with rNDV-hIFNβ-F
0
 did not change 
this pattern of endogenous hIFNβ gene expression. An in-house assay detecting expression of 
both endogenous and exogenous IFN genes revealed similar expression levels as detected with the 
validated endogenous assay for cells inoculated with rNDV-F
0
 or rNDV-GFP-F
0
, but, as expected, higher 
expression levels for rNDV-hIFNβ-F
0
 inoculated cells (data not shown). With this assay, expression of 
exogenous expressed hIFNβ mRNA was also detected in rNDV-GFP-F
0
 inoculated SU.86.86, MIA PaCa-2 
and Vero cells, in which endogenous IFN genes are absent or not upregulated (Figure 3a). Inoculation 
with rNDV-NS1-F
0
 resulted in a marked decrease in endogenous hIFNβ gene expression levels in HPAF-
II, BxPC-3, CFPAC, AsPC-1, Capan-2 cells, and MRC-5 fibroblasts, while no differences were observed in 
PANC-1 and Hs 766T cells, compared to expression levels in these cells inoculated with rNDV-F
0
. 
To test whether the differences in expression of the hIFNβ genes also resulted in differences in protein 
production, functional IFN protein content was determined in the supernatants of inoculated cells. 
Due to biosafety issues, we could not measure IFN in supernatants of cells inoculated with rNDV-F
3aa
. 
Upon inoculation with rNDV-F
0
, cells demonstrated variation in the extent of IFN production. Six of the 
10 HPACs produced significant less IFN compared to IFN-competent MRC-5 cells, while HPAF-II, CFPAC, 
and Hs 766T had a similar range of IFN production. Incorporation of GFP in the genome of rNDV-F
0
 did 
not change this pattern in most HPACs. Only HPAF-II and Hs 766T cells produced significant less IFN 
upon inoculation with rNDV-GFP-F
0
 compared to inoculation with rNDV-F
0
, while the opposite was 
observed for CFPAC cells. 
Upon inoculation with rNDV-hIFNβ-F
0
, all cells produced significant higher amounts of IFN compared 
to inoculation with rNDV-F
0
, due to viral expression of the exogenous hIFNβ gene (Figure 3b). This 
exogenously expressed IFN did not induce upregulation of endogenous hIFNβ gene expression in 
SU.86.86, MIA PaCa-2 and, of course, Vero-118 cells (as seen in Figure 3a). Inoculation of HPACs and 
MRC-5 cells with rNDV-NS1-F
0
 resulted in a significant decrease of IFN production in all these cells as 
compared to cells inoculated with rNDV-F
0
 (Figure 3b).
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Figure 3. IFN responses upon inoculation with rNDVs. Cells were either mock inoculated or inoculated with the 
indicated rNDV at m.o.i. 3. After 24 hours: (a) RNA was isolated and quantitative real-time polymerase chain reaction 
(qRT-PCR) was performed for hIFNβ mRNA. Results are presented as fold change gene induction of treated versus 
mock treated cells calculated using the 2−ΔΔC
T
 method [194]. Means and ranges of triplicate experiments are plotted. (b) 
Supernatants were tested for functional IFN content using an ISRE-luc bioassay [204]. Results are presented as fold change 
in luminescence compared to mock inoculated cells. Means and standard deviations of triplicate experiments are plotted. 
x = p < 0.05 vs. MRC-5 (one-way ANOVA + Bonferroni post-test), * = p < 0.05 vs. rNDV-F
0
 (one-way ANOVA + Bonferroni 
post-test).
a
b
A
N
R
m egnahc dloF
NFI egnahc dloF
rNDV-F0
rNDV-GFP-F0
rNDV-hIFNβ-F0
rNDV-NS1-F0
rNDV-F3aa
rNDV-F0
rNDV-GFP-F0
rNDV-hIFNβ-F0
rNDV-NS1-F0
SU
.8
6.
86
H
PA
F-
II
B
xP
C
-3
PA
N
C
-1
M
IA
 P
aC
a-
2
H
s 
70
0T
C
FP
A
C
H
s 
76
6T
A
sP
C
-1
C
ap
an
-2
Ve
ro
-1
18
M
R
C
-5
SU
.8
6.
86
H
PA
F-
II
B
xP
C
-3
PA
N
C
-1
M
IA
 P
aC
a-
2
H
s 
70
0T
C
FP
A
C
H
s 
76
6T
A
sP
C
-1
C
ap
an
-2
Ve
ro
-1
18
M
R
C
-5
0
20
40
60
80
100
120
140
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
x
x
x
x
x
x
x x
x
100
101
102
103
104
105
x
x
x
x
x
x
x
x
x
44
In vitro cytotoxicity
To evaluate the effect of increasing the virulence or incorporation of hIFNβ or NS1 in the genome of 
rNDV on direct oncolysis, HPACs and MRC-5 fibroblasts were inoculated with serial dilutions of the 
viruses and the median lethal dose (LD
50
) was determined for each rNDV-cell line combination. Mean 
LD
50
 levels for rNDV-F
0
 and rNDV-GFP-F
0
 were generally comparable between cell lines, although 
SU.86.86, Hs 700T, Capan-2 and MRC-5 demonstrated significant lower cytotoxicity upon inoculation 
with rNDV-GFP-F
0
 compared to rNDV-F
0
, while CFPAC cells demonstrated higher cytotoxicity for rNDV-
GFP-F
0
 compared to rNDV-F
0
 (* above green bars in Figure 4). This indicates that incorporation of 
inert transgenes might have some effect on oncolytic efficacy, but with similar variation in reaction 
between the different cell lines.
Compared to rNDV-F
0
, expression of NS1 from rNDV-NS1-F
0
 did not improve the oncolytic effect for 
most cells. Equal LD
50
 values were detected for rNDV-F
0
 and rNDV-NS1-F
0
 in HPAF-II, Hs 700T, Hs 766T, 
and Capan-2 cells, with even higher LD
50
 values in the other cells. Compared to rNDV-F
0
, expression of 
exogenous IFN from rNDV-hIFNβ-F
0
 decreased the oncolytic effect significantly in SU.86.86 cells and 
Hs 766T cells, but increased oncolysis significantly in MIA PaCa-2, Capan-2 and MRC-5 cells. Although 
statistical analyses revealed differences in the oncolytic effect between rNDV-GFP-F
0
, rNDV-NS1-F
0 
and rNDV-hIFNβ-F
0
, with variation in the response of the different cells, the results shown in Figure 4 
demonstrate that inoculation with the more virulent rNDV-F
3aa
 results in a clear improvement of the 
oncolytic effect.
Inoculation with rNDV-F
3aa
 resulted in a significant increase in oncolysis in all HPACs when compared to 
inoculation with rNDV-F
0
 (* above purple bars) for 7 out of 10 HPACs (SU.86.86, PANC-1, Hs 700T, CFPAC, 
Hs 766T, AsPC-1, Capan-2) when compared to rNDV-NS1-F
0
 (^  above red bars), and for 7 out of 10 HPACs 
(SU.86.86, HPAF, BxPC-3, PANC-1, Hs 766T, AsPC-1 and Capan-2) when compared to rNDV-hIFNβ-F
0
 (# 
above blue bars). Compared to rNDV-hIFNβ-F
0
, which revealed improved oncolysis in MIA PaCa-2 and 
Capan-2 cells, rNDV-F
3aa
 had significantly increased oncolytic effect on Capan-2 cells but an equal effect 
on MIA PaCa-2 cells. In general, HPAF-II, MIA PaCa-2 and Hs 700T were most resistant to the oncolytic 
effects induced by the five viruses, including the virulent rNDV-F
3aa
.
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Figure 4. Median LD
50
 upon inoculation with rNDVs. Cells were either mock inoculated (not shown; set as 100% viable) 
or inoculated with rNDV at different m.o.i. (range 0.0001-100). Cytotoxicity was measured after 5 days by LDH assay and 
LD
50
 values were calculated. Means and ranges of LD
50
 calculations are plotted. * = p < 0.05 rNDV-GFP-F
0
, rNDV-hIFNβ-F
0
, 
rNDV-NS1-F
0
 and rNDV-F
3aa
 as compared to rNDV-F
0
. # = p < 0.05, rNDV-F
3aa
 compared to rNDV-hIFNβ-F
0
. ^ = p < 0.05 rNDV-
F
3aa
 compared to rNDV-NS1-F
0.
In vivo efficacy: rNDV-F3aa effective in multiple models
After having shown oncolytic and immunomodulating efficacy in vitro, we extended our evaluation 
of rNDVs to in vivo experiments in immune-deficient subcutaneous xenograft mouse models for 
pancreatic adenocarcinoma. Before starting treatment experiments, toxicity of all viruses was tested 
in small groups of mice (n=3), using per group escalating doses starting from 1 x 106 TCID
50
 up to 
four times 5 x 107 TCID
50
 injected intravenously or subcutaneously. None of the injected mice showed 
adverse effects or excessive weight loss during these experiments, and we concluded it was safe to 
inject mice with the highest dose. Also, based on a separate pilot experiment, we decided to inject 
mice intratumorally with rNDV since this gave better treatment responses compared to intravenous 
injection.
SU.86.86 tumor xenografts were resistant to all rNDV treatments, even to multiple injections with 
mesogenic rNDV-F
3aa
 (Figure 5). While BxPC-3 and MIA PaCa-2 tumor xenografts were resistant to 
injection with rNDV-F
0
, rNDV-hIFNβ-F
0
 and rNDV-NS1-F
0
, they did respond to injection with rNDV-F
3aa
. 
Treatment with rNDV-F
3aa
 resulted in tumor regression in 5 out of 6 animals and median tumor sizes 
were significantly smaller starting at day 13 and 10 after the first injection for BxPC-3 and MIA PaCa-2 
tumor xenografts respectively (P < 0.05). Upon necropsy of these animals, only very small residual 
tumors were found, as opposed to the mostly large tumors in animals treated with either PBS or 
lentogenic rNDV injections.
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Figure 5. Efficacy of rNDV treatment in a mouse model using SU.86.86, BxPC-3 or MIA PaCa-2 subcutaneous 
tumor xenografts. Animals were treated and evaluated as described in the material and methods section. Graphs 
with specific xenograft-treatment combinations depict individual mouse tumor volumes with black lines and dots. Last 
observed tumor volumes were carried forward to calculate median volumes per group in the lowest plots. *: P < 0.05 as 
compared to PBS group. D.p.i.: days post first injection.
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Discussion
In our efforts to further develop oncolytic virotherapy for pancreatic cancer, we focused our attention on 
the use of recombinant NDVs. In our previous study, we evaluated the efficacy of a wild type lentogenic 
oncolytic NDV strain in a panel of 11 HPACs. This demonstrated a high degree of variation between 
the cells in their response to inoculation with NDV, not only in oncolysis but also in activation of the 
IFN response [204]. We hypothesized that increasing the oncolytic effects of NDV would overcome this 
variability. Various strategies have been reported to improve the efficacy of oncolytic rNDVs: transfer of 
therapeutic or immunomodulating transgenes [114,115,120-122], targeting of tumor cells with modified 
attachment proteins [123,124], and increasing virulence by increasing the cleavability of the F protein 
[114-119]. As increased virulence can raise biosafety issues, we aimed to improve the direct oncolytic 
effect of non-virulent (lentogenic) rNDVs by expressing IFN modulating genes and we compared their 
efficacy with a more virulent (mesogenic) rNDV.
Expression of a non-modulating transgene (GFP) or the NS1 protein of the Influenza A virus from a 
lentogenic rNDV did not change the replication kinetics of rNDV-F
0
 in a set of six HPACs, but expression 
of high levels of exogenous hIFNβ from rNDV-hIFNβ-F
0
 hampered virus replication in susceptible HPACs. 
This was not surprising, since we showed earlier that HPACs have mostly intact IFN signaling pathways 
and replication of NDV is sensitive to IFN treatment [204]. In contrast to the lentogenic viruses, the 
mesogenic rNDV-F
3aa
 was capable of multicycle replication in all HPACs tested. This higher efficiency 
in replication correlated with higher cytotoxic effects for NDV-F
3aa
 in most HPACs, indicating this to be 
the oncolytic rNDV with the highest oncolytic efficacy. This is in agreement with other studies that 
reported on the oncolytic efficacy of mesogenic rNDVs [114-119]. However, three HPACs (HPAF-II, MIA 
PaCa-2, and Hs 700T) remained somewhat resistant to rNDV-F
3aa
-induced cytotoxicity, and it remains 
to be determined why some cells are more resistant than others. Future experiments should elaborate 
more on the etiology of differences in susceptibility of HPACs for the oncolytic effects of NDV. These 
experiments should not only focus on innate immunity, but also on differences in apoptotic, necrotic, 
autophagy and/or immunogenic cell death pathways. Elucidating knowledge on the traits defining 
susceptibility to NDV induced oncolytic effects would allow improvement of oncolytic NDV to also 
attack relatively resistant tumor cells.
As previously reported for wild type NDV, inoculation with rNDV-F
0
 resulted in IFN production by a 
number of HPACs, but this did not always correlate with virus replication kinetics or oncolytic effects 
induced by rNDV-F
0
 [204]. Inoculation with rNDV-NS1-F
0
 resulted in markedly reduced hIFNβ gene 
expression levels in most HPACs capable of expressing endogenous hIFNβ and, more interestingly, 
in almost complete absence of IFN production in almost all HPACs. Indeed, it is known that NS1 of 
influenza A is a potent blocker of IFN induction by, among other mechanisms, suppressing RIG-I 
receptor signaling, IRF3 dimerization and subsequent IFNβ promoter activation [183,184]. Expression of 
exogenous hIFNβ from rNDV-hIFNβ-F
0
 did not lead to increased expression levels of the endogenous 
hIFNβ gene, but did result in production of high amounts of hIFNβ protein. This illustrates that 
lentogenic rNDV-F
0
 is very suitable as a (transient) gene therapy vector, as the (additional) production 
of IFN can only be attributed to viral hIFNβ gene expression. Interestingly, the lower replication of 
rNDV-hIFNβ-F
0
 did not always result in significant lower cytotoxicity in most HPACs (such as MIA Paca-2 
cells), indicating that hIFNβ might have a cytotoxic effect by itself. A recent publication demonstrated 
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that most HPACs are susceptible to exogenous hIFNβ treatment, but SU.86.86 cells were found to be 
relatively resistant [111]. In line with these findings, inoculation of SU.86.86 cells with rNDV-hIFNβ-F
0
 lead 
to lower cytotoxicity as compared to inoculation with rNDV-F
0
. Apparently, rNDV-hIFNβ-F
0
 replication 
and resulting cytotoxicity is hampered by the exogenous hIFNβ produced by inoculated SU.86.86 cells, 
while SU.86.86 cells are insensitive to the cytotoxic effects of hIFNβ. These findings are also in line with 
studies showing that incorporation of IFNβ genes into oncolytic viruses such as vesicular stomatitis 
virus or vaccinia virus leads to lower virus replication in cell lines with intact IFN signaling pathways 
[213-216], and, previously, we showed that most HPACs do have intact and functional innate immune 
pathways [204].
We observed up regulation of hIFNβ mRNA and functional IFN protein production in BxPC-3 cells, 
which was in conflict with the results of our previous study [204]. Other groups have also noted an 
unstable phenotype of BxPC-3 [217] and the difference between our findings in this study and the 
previously published one may be attributed to higher passage numbers of BxPC-3 cells used earlier.
Exogenous expression of influenza NS1 protein from rNDV-NS1-F
0
 did not change replication kinetics 
in the inoculated HPACs. However, it did lead to less cytotoxicity in most HPACs, indicating again 
that IFN has a cytotoxic effect on these cells. This is in contrast with results reported for a mesogenic 
rNDV expressing NS1 (rNDV-NS1-F
3aa
), which induced enhanced tumor cell killing due to inhibition of 
apoptosis, leading to increased syncytia formation [120]. 
In vivo experiments using a subcutaneous xenograft tumor model using BxPC-3 or MIA Paca-2 cells in 
immune-deficient mice demonstrated that intratumoral treatment with mesogenic rNDV-F
3aa 
induced 
tumor regression or stabilization. In contrast, SU.86.86 tumors, which are highly susceptible for oncolytic 
rNDV-F
3aa
 treatment in vitro, did not respond to injection with rNDV-F
3aa
 in vivo. SU.86.86 tumors showed 
a relatively aggressive growth rate in this mouse model when compared to the other tumor bearing 
groups, which might explain why rNDV-F
3aa
 treatment was not successful in achieving tumor regression 
or stabilization. These results illustrate again that variation in response and heterogeneity of tumors 
contributes to the efficacy of oncolytic virotherapy. Intratumoral treatment with the lentogenic viruses 
did not lead to direct oncolytic effects in this model, indicating that, for direct oncolytic effects, the 
mesogenic rNDV-F
3aa
 is most effective.
The immune system is thought to contribute to the efficacy of oncolytic viruses and to efficient 
clearance of the virus from healthy cells [125]. In this study we have focused on the direct oncolytic 
effects of the virus and the contribution of IFN to this, in absence of the immune system. It might well 
be possible that the transgenes expressed by the lentogenic viruses would increase the efficacy in an 
immune competent model, however based on our results we expect a higher efficacy of rNDV-F
3aa 
in 
these models. Evaluation of the beneficial effects of the immune system to the oncolytic effects of 
rNDV-F
3aa
 needs to be performed in an immune-competent model for pancreatic adenocarcinoma. 
Although transgenic animal models that mimic the natural development of pancreatic tumors have 
been created, at the moment these are limited and difficult to employ for evaluation of the efficacy of 
oncolytic viruses. 
In conclusion, expression of exogenous IFN modulating genes from lentogenic rNDVs does not 
significantly enhance direct oncolysis induced by these viruses compared to those induced by a more 
virulent virus. However, increasing the virulence of rNDV by increasing cleavability of the F protein lead 
to a significant improvement of oncolytic activity of recombinant NDV. For further development of 
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virulent rNDV for oncolytic virotherapy, the biosafety risks of the virus for birds and poultry should be 
addressed. In addition, knowledge should be elucidated on the heterogeneity of pancreatic tumors 
and on the traits defining susceptibility to NDV induced oncolytic effects.
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Abstract
Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic potential. Detailed preclinical 
information regarding the safety of oncolytic NDV is scarce. In this study we evaluated the toxicity, 
biodistribution and shedding of intravenously injected oncolytic NDVs in non-human primates (Macaca 
fascicularis). Two animals were injected with escalating doses of either a non-recombinant vaccine 
strain, a recombinant lentogenic strain or a recombinant mesogenic strain. To study transmission, 
naive animals were co-housed with the injected animals. Injection with NDV did not lead to severe 
illness in the animals or abnormalities in hematologic or biochemistry measurements. Injected animals 
shed low amounts of virus, but this did not lead to seroconversion of the contact animals. Postmortem 
evaluation demonstrated no pathological changes or evidence of virus replication. This study 
demonstrates that NDV generated in embryonated chicken eggs is safe for intravenous administration 
to non-human primates. In addition, our study confirmed results from a previous report that naïve 
primate and human sera are able to neutralize egg-generated NDV. We discuss the implications of 
these results for our study and the use of NDV for virotherapy.
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Introduction
Newcastle disease virus (NDV) is a single stranded negative-sense RNA virus belonging to the genus 
Avulavirus within the family of Paramyxoviridae [134]. NDV infections were first recognized early in the 
20th century as a cause of high mortality and economic loss in the poultry industry [135]. Consequently, 
prophylactic vaccination of poultry is currently applied on a large scale, and (suspected) outbreaks 
are rigorously acted upon [138]. NDV strains vary widely in pathogenicity, which can be attributed 
mostly to the (multi)basic cleavage site of the fusion (F) protein [174,175]. Strains can be classified into 
three pathotypes: lentogenic (low virulent, no mortality in susceptible hosts), mesogenic (intermediate 
virulent, < 10% mortality) or velogenic (highly virulent viscerotropic or neurotropic, 10-100% mortality) 
[112,137].
Human infections with NDV have been observed after exposure to virus while handling infected 
birds or cadavers and lyophilized or aerosolized NDV vaccine. The associated symptoms have been 
described as mild: acute conjunctivitis and laryngitis, occasionally accompanied by low-grade fever 
and chills, with a rapid and spontaneous resolution [140-146]. Human-to-human transmission has 
never been reported.
During the last decade, NDV has become a renewed focus of research in the field of oncolytic viruses 
[83,113]. The tumor-specific replication and ability to induce a robust antiviral and antitumor immune 
response make the virus a good candidate for further development for virotherapy in cancer patients. 
Early clinical trials employing wildtype NDV strains for (intravenous) oncolytic therapy have shown NDV 
to be generally safe [91-93,97-101]. Several studies have demonstrated that increasing the virulence of 
recombinant NDV (rNDV) by editing the F protein cleavage site results in better oncolytic activity, but 
also in higher pathogenicity in chickens [114,116,195]. Surprisingly, detailed information on preclinical 
safety testing of oncolytic NDVs is scarce, and a comparison of different (non-)virulent strains in non-
human primate models has never been described.
In our efforts to further translate oncolytic NDV to the clinic, we evaluated the toxicity, biodistribution 
and shedding of oncolytic NDV after injection of non-human primates with three different strains. Two 
recombinant strains (rNDV), one lentogenic and one mesogenic, were compared with a commercially 
available clonal vaccine strain, because this vaccine strain has a long history of safe usage in the poultry 
industry. Similar to clinical trials that employed wild-type NDV strains for intravenous oncolytic therapy, 
we generated the viruses in embryonated chicken eggs [91-93,97-101]. In the midst of our experiments 
it was reported that naive human serum is able to neutralize NDV generated in embryonated chicken 
eggs, in contrast to virus generated in human cells [218]. This was explained by the fact that egg-
generated viruses do not express human regulators of complement activity (RCA; CD46 and CD55) on 
their viral envelope and are therefore susceptible to neutralization by complement when incubated 
with non-homologous (e.g. human or primate) serum. In the current study we confirm that non-heat 
inactivated (non-HI) primate and human sera neutralized NDVs generated in embryonated eggs in 
vitro and we discuss the implications of these results for our study and the use of NDV for virotherapy.
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Material and Methods
Cell lines and culture conditions
BSR-T7, Vero clone 118 (Vero-118) and MRC-5 cells were cultured as described before [204,209]. All media 
and supplements were purchased from GIBCO (Life Technologies, Bleiswijk, the Netherlands).
Virus preparation
A full-length cDNA clone of lentogenic NDV strain La Sota (pNDV-F
0
) and expression plasmids pCIneo-
NP, pCIneo-P and pCIneo-L were kindly provided by Ben Peeters from the Central Veterinary Institute of 
Wageningen UR, the Netherlands [112]. To create a full length NDV with multibasic cleavage site in the 
fusion protein, the amino acid sequence of the protease cleavage site was changed from 112GRQGR↓L117 
(lentogenic) to 112RRQRR↓F117 (mesogenic; pNDV-F3aa) by means of site-directed mutagenesis as 
described earlier [114]. Recombinant viruses (rNDV-F
0
 and rNDV-F
3aa
) were rescued using a method 
adapted from the original method described previously [112]. Briefly, BSR-T7 cells were transfected 
with 5 µg pNDV-F
0
 or pNDV-F
3aa
, 2.5 µg pCIneo-NP, 1.25 µg pCIneo-P and 1.25 µg pCIneo-L using 10 
µl lipofectamine (Life Technologies). Three days later, 200 µl BSR-T7 supernatant was injected into the 
allantoic cavity of 10 day old specified pathogen free (SPF) embryonated chicken eggs. After incubation 
in a humidified egg incubator at 37°C for two or three days (rNDV-F
3aa
 or rNDV-F
0
, respectively), allantoic 
fluid was harvested and presence of virus demonstrated by hemagglutination assay, as described 
before [207]. Samples displaying hemagglutination were passaged once more in eggs to increase 
virus titer, and allantoic fluid was harvested after 2 or 3 days. Fresh allantoic fluid was purified and 
concentrated by ultracentrifugation at 27.000 rpm for two hours at 4°C using a 30%/60% sucrose 
gradient. Aliquots of purified rNDV were stored at -80°C. Recombinant virus stocks were sequenced to 
confirm the sequence of the protease cleavage site of the fusion protein (F
0
/F
3aa
). Stocks were titrated 
by end point dilution assay in Vero-118 cells, as described before [204].
Additional rNDV-F
0
 and rNDV-F
3aa
 stocks were grown in Vero-118 and MRC-5 cells. To this end, cells were 
infected with MOI 0.1 in the presence of 20 µg ml-1 trypsin (Lonza, Breda, the Netherlands) and virus 
was harvested after 3 days.
Non-recombinant plaque purified (egg-generated) clonal vaccine strain AviPro ND C131 was obtained 
from Lohmann Animal Health (Cuxhaven, Germany). Vials containing 1 x 109 EID
50
 were reconstituted 
and diluted (if needed) in cold phosphate buffered saline (PBS) immediately before use, and vials were 
used only once.
Ethics statement
All experiments involving animals were conducted strictly according to European guidelines (EU 
directive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997). 
The experimental protocol was reviewed and approved by an independent animal experimentation 
ethical review committee, not affiliated with Erasmus MC (DEC consult number EMC2921).
Animals and experimental design
Nine juvenile (average age 5 years), male NDV-seronegative cynomolgus macaques (Macaca fascicularis) 
were used. All animal handling was performed under light ketamine/medetomidine anesthesia, and 
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atipamezole was administered after handling to reverse the effect of medetomidine. Three weeks 
before the start of the experiment a Data Storage Tag centi-Temperature probe (Star-Oddi, Brussels, 
Belgium) was implanted intraperitoneally, set to register temperature every 10 minutes. Figure 1 
displays a detailed experimental timeline. Animals were housed in groups of three per isolator (A: 
AviPro ND C131; B: rNDV-F
0
; C: rNDV-F
3aa
). Two animals (inject 1 & 2) per group were injected i.v. into the 
posterior tibial vein with escalating viral doses (day 0: 1 x 107; day 1: 1 x 108; day 2: 1 x 109 EID
50 
or TCID
50
), 
the third animal (control) served as contact animal. Animal wellbeing was observed daily throughout 
the experiment, and the animals were weighed on day 0-4, 7, 14 and 21. Samples (see below) were 
collected just before and 2 hours after injection on day 0, 1 and 2, and also once on day 3, 4, 7, 14 and 
21. The two injected animals per group were sacrificed on day 4, the contact animal on day 21, and all 
animals underwent full necropsy.
Samples
Eye, nose, throat and rectum swabs were collected in virus transport medium [219]. After vortexing, 
200 µl medium was used for RNA isolation and residual medium was stored at -80°C for virus isolation 
later on.
Small volume blood samples were taken from an inguinal vein and collected into Vacuette Z Serum 
Sep Clot Activator and K
3
EDTA tubes (both from Greiner Bio One, Alphen aan de Rijn, the Netherlands). 
Clotted blood samples were centrifuged and 100 µl separated serum was assayed with Piccolo 
BioChemistry Panel Plus Reagent Discs (Abaxis, Darmstadt, Germany), which were processed using a 
Piccolo Xpress chemistry analyzer (Abaxis) following the manufacturer’s instructions. Measurements 
were obtained for glucose, BUN, creatinine, calcium, albumin, total protein, ALAT, ASAT, alkaline 
phosphatase, GGT, amylase and CRP. Reference values (if indicated) were obtained from the 
supplemental data of a publication by Xie et al [220].
100 µl EDTA blood (AviPro ND C131 and rNDV-F
0
 groups only) was tested using a pocH-100iV 
automated counter (Sysmex, Etten-Leur, the Netherlands). Due to biosafety issues, these data could 
not be obtained for animals in the rNDV-F
3aa
 group. 500 µl EDTA blood was incubated with 10 ml Red 
Blood Cell Lysis Buffer (Roche, Woerden, the Netherlands) for 10 minutes, centrifuged, washed with 
PBS and centrifuged again. The cellular pellet, representing mostly WBCs, was resuspended in TRIzol 
(Life Technologies) and stored at -80°C. Remaining EDTA blood was centrifuged to separate plasma, of 
which 200 µl was used for RNA isolation.
Necropsy
Animals were sacrificed by exsanguination under deep anesthesia. All collected organ samples were 
transferred to tubes containing either 10% neutral-buffered formalin or RNAlater (Life Technologies), or 
were frozen without additives at -80°C. Broncho-alveolar lavage (BAL) was performed by direct infusion 
of PBS into the right main bronchus. Recovered BAL fluid was centrifuged and the cellular pellet 
resuspended in TRIzol. Organ samples in RNAlater were stored at -80°C, thawed later and transferred 
to tubes containing a quarter inch ceramic sphere in virus transport medium. After homogenization 
using a FastPrep 24 tissue homogenizer (MP Biomedicals, Eindhoven, the Netherlands), samples were 
centrifuged and cleared supernatant was used for RNA isolation.
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RNA isolation and qRT-PCR
Samples stored in TRIzol were processed according to the manufacturer’s instructions to isolate RNA. 
200 µl of other samples (swabs, plasma and organ homogenates) was combined with 300 µl lysis buffer 
of the Total Nucleic Acid Isolation kit (Roche) and RNA was isolated in a volume of 50 µl using a MagNA 
Pure LC machine (Roche) following the manufacturer’s instructions.
NDV specific qRT-PCR was performed using 5 µl (TRIzol samples) or 19,5 µl (MagNA Pure samples) RNA 
in an ABI PRISM 7000 Sequence Detection System using TaqMan Fast Virus 1-Step Master Mix (both from 
Life Technologies) in a total volume of 30 µl. The NDV specific primers used were described by Wise et al 
[221]. The RT step was 5 minutes at 50°C, followed by 95°C for 20 seconds. Cycling consisted of 45 cycles 
of 3 seconds denaturation at 95°C, 5 seconds annealing at 54°C and 31 seconds extension at 60°C.
Virus isolation
200 µl medium from collected swabs or 200 µl supernatant of homogenized dry frozen organs 
was injected in duplicate into 10 day old SPF embryonated chicken eggs. After 2 or 3 days (samples 
containing rNDV-F
3aa
 or Avipro ND C131 and rNDV-F
0
, respectively), allantoic fluid was harvested and 
tested for presence of virus by hemagglutination assay.
NDV serology
Sera were tested for NDV specific antibodies by hemagglutination inhibition assay (HI) using SPF turkey 
erythrocytes [207]. To neutralize neuraminidase activity, serum samples were pretreated with cholera 
filtrate for 16 hours at 37°C, followed by inactivation for 1 hour at 56°C. Diluted chicken polyclonal anti-
NDV antibody was used as positive control.
Histopathology
Samples for histologic examination were stored in 10% neutral-buffered formalin (lungs after inflation 
with formalin), embedded in paraffin, sectioned at 4 mm, and stained with hematoxylin and eosin for 
examination by light microscopy. The following tissues were examined by light microscopy for the 
presence of histopathological changes: lungs, primary bronchus, trachea, liver, spleen, kidney, nasal 
septum, nasal concha, eye and conjunctiva.
Additionally, separate sections were stained for NDV using an immunoperoxidase method. Tissue 
sections were mounted on coated slides (KliniPath, Duiven, the Netherlands), deparaffinised, 
rehydrated and endogenous peroxidase was blocked by incubating slides in 3% H
2
O
2
 in bidest for 10 
minutes. Antigen was retrieved by boiling slides in Tris buffer (pH 9) for 15 minutes and sections were 
subsequently washed in PBS containing 0.05% Tween 20. Slides were incubated in PBS with 0.1% BSA 
(Aurion, Wageningen, the Netherlands) for 10 minutes at room temperature. After this, slides were 
incubated with monoclonal mouse anti-NDV antibody (HyTest Ltd, Turku, Finland) in PBS with 0.1% BSA 
for 1 hour at room temperature. Mouse IgG2a (R&D Systems, Abingdon, UK) was used as isotype control. 
After washing, slides were incubated with goat anti-mouse antibody (Southern Biotech, Birmingham, 
AL) labeled with horseradish peroxidase (HRP) for 30 minutes at room temperature. HRP activity was 
revealed by incubating slides in 3-amino-9-ethylcarbazole in N,N- dimethylformamide for 10 minutes. 
Slides were imbedded in Imsolmount and overlayed with Pertex (both from KliniPath). Brain tissue from 
a cormorant (Phalacrorax auritus) known to be infected with virulent NDV was used as positive control.
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Virus neutralization assay
VN assays were performed as described previously [222]. Briefly, 3 human sera and 3 naive primate sera 
were left untreated (non-HI) or heat inactivated (HI) for 30 minutes at 56°C. Twofold serial dilutions of 
the sera starting at a 1:10 dilution were mixed 1:1 with 100 TCID
50
 of rNDV. After incubation at 37°C for 1 
hour, the serum–rNDV mixture was transferred to 96-wells plates containing Vero-118 cells. Plates were 
incubated for 1h at 37°C, and inoculum was replaced by 200 μL fresh medium. After six days, end-point 
dilutions were read by scoring cytopathic effect.
Results
To compare the safety of three different oncolytic NDVs, two macaques per group were injected i.v. 
with either lentogenic Avipro ND C131, lentogenic rNDV-F
0
 or mesogenic rNDV-F
3aa
 (Figure 1). A dose 
escalation design was chosen to observe potential toxicity at different doses. To study transmission, 
naive animals were co-housed with the injected animals.
Figure 1: Timeline of experimental set up. Time is depicted in days (d) and hours (h). inject 1 & 2: inoculated animals 1 
& 2; control: contact animal; S: sample time point; A: Avipro ND C131; B: rNDV-F0; C: rNDV-F3aa; †: euthanasia.
Clinical and vital signs
During the experiments, none of the injected animals displayed behavioral changes or overt signs of 
illness. Specifically, no conjunctivitis or ocular, oral or nasal discharge was observed. Animals were lively 
and displayed normal appetite similar to the period before the start of the experiment. No change in 
stool consistency or color was observed. All injected animals maintained their body weight (Figure 2a).
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Figure 2: Clinical parameters recorded throughout the experiment. (a) Animals were weighed at indicated time points. 
(b) Body temperature was recorded using an intraperitoneally implanted probe (Star-Oddi). (c) Detailed view of body 
temperature just after third NDV injection. Blue circles & green squares: inoculated animals 1 & 2; red triangles: contact 
animal; d.p.i.: days post first inoculation; h.p.i.: hours post first inoculation; black box in (b): area of detailed view in (c).
Animals injected with Avipro ND C131 had a short-term fever peak higher than 40°C after injection with 
the highest dose (1 x 109 50% egg infectious dose (EID
50
) on day 2, which decreased rapidly the same 
day (Figures 2b,c). Animals injected with the medium (1 x 108 50% tissue culture infectious dose (TCID
50
) 
and highest dose (1 x 109 TCID
50
) of rNDV-F
3aa
 also had a short term fever peak after injection on day 1 
and 2 with a maximum around 39.5°C, which also decreased rapidly (Figures 2b,c). Sharp decreases in 
registered temperature during the first five days can be attributed to the general anesthesia animals 
underwent for sampling and injection.
Similar to the injected animals, none of the contact animals displayed signs of illness. All contact 
animals maintained their body weight up to 3 weeks after the start of the experiment (Figure 2a). 
In contrast to the injected animals, none of the contact animals had an abnormal increase of body 
temperature during the experiment (Fig. 2b,c; data after day 4 not shown).
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Hematology and serum chemistry
Hemoglobin (Hb) concentration in all injected animals dropped from an average of 10.0 mmol l-1 at the 
start of the experiment, to an average of 7.1 mmol l-1 at day 4, which was still within normal limits (Figure 
3a; reference value 6.7-9.7 mmol l-1)[220]. This decrease was probably due to the blood sampling during 
the first few days. Leukocyte counts were on the low side of normal and slightly lower than normal 
in one of the animals injected with rNDV-F
0
, however no overt leukocytopenia or leukocytosis was 
observed (Figure 3b). Platelet counts did not show any abnormalities (Figure 3c).
Figure 3: Hematological parameters for animals injected with lentogenic viruses and their co-housed contact animals. 
Due to biosafety issues, these parameters could not be obtained for animals injected with rNDV-F
3aa
. EDTA blood samples 
were analyzed using an automated counter (Sysmex pocH-100iV) to obtain a basic blood profile. Blue circles & green 
squares: inoculated animals 1 & 2; red triangles: contact animal; d.p.i.: days post first inoculation. Reference values [220] are 
indicated by the grey area between the dotted lines.
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In all injected animals kidney function, as measured by blood urea nitrogen (BUN) and creatinine 
concentration, did not deteriorate during the experiment (Figures 4a,b). Animals injected with Avipro 
ND C131 had slight increases of liver enzyme concentrations, with a maximum alanine aminotransferase 
(ALAT) of 94 U l-1 (reference value: 11-78 U l-1 [220]) and aspartate aminotransferase (ASAT) of 184 U l-1 
(reference value: 23-71 U l-1 [220]), which seemed to decrease spontaneously on day 4 (Figures 4c,d). 
Animals injected with rNDV-F
0
 or rNDV-F
3aa
 also had slight increases in liver enzyme concentrations, 
but much less than animals injected with Avipro ND C131. Gamma glutamyltransferase (GGT) values 
did not increase during the experiment, although they were generally higher than the reference values 
(Figure 4e; reference value: 18-65 U l-1 [220]). A peak in serum amylase concentration was detected in 
one animal injected with Avipro ND C131, while other injected animals had no abnormalities in their 
serum amylase concentrations (Figure 4f). C-reactive protein (CRP) was detected (detection limit >5 mg 
l-1) in multiple serum samples of injected animals, but no peaks in concentration were observed (Figure 
4g). Since there are no reference values for amylase or CRP measurements in cynomolgus macaques, it 
is difficult to evaluate the measurements obtained. Other serum chemistry markers (glucose, calcium, 
albumin, total protein and alkaline phosphatase) were not found to be abnormal during the course of 
the experiment (data not shown).
Hematologic parameters obtained for contact animals showed the same pattern as obtained from 
the injected animals: slight decreases in Hb concentration over time and normal leukocyte and 
platelet counts (Figure 3). Biochemistry values obtained for the contact animals revealed that BUN and 
creatinine, did not increase during the experiment (Figures 4a,b). In contrast with animals injected with 
Avipro ND C131, the contact animal did not show elevated liver enzymes (Figures 4c,d). The contact 
animal in the rNDV-F
3aa
 group showed slightly elevated liver enzymes, whereas injected animals did 
not (Figures 4c,d). GGT and amylase measurements did not show abnormalities (Figures 4e,f). Finally, 
there was a peak observed in CRP concentration in the contact animal in the rNDV-F
3aa
 group of 86 mg 
l-1 (Figure 4g).
Figure 4: Serum chemistry parameters in samples taken just before injection. Samples taken at indicated time points 
were assayed using an automated serum chemistry analyzer (Piccolo Xpress) to obtain a basic serum chemistry profile. 
Blue circles & green squares: inoculated animals 1 & 2; red triangles: contact animal; d.p.i.: days post first inoculation; BUN: 
blood urea nitrogen; ALAT: alanine aminotransferase; ASAT aspartate aminotransferase; GGT: gamma glutamyltransferase; 
CRP: c-reactive protein. Reference values [220] are indicated by the grey area between the dotted lines.
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Virological data
All injected animals had detectable NDV-RNA in their plasma and WBCs immediately after injection 
of the lowest dose until euthanasia on day 4 (Figure 5a). Animals injected with either virus showed 
shedding of viral RNA from eyes, nose and throat, but not from their rectum, starting around the time 
of injection of the medium dose, with a peak after injection of the highest dose (Figure 5b). A low 
number of qRT-PCR positive swab samples (almost exclusively those taken on day 2) were also found 
positive in virus culture, without a correlation between Ct value and culture results.
A few samples collected from the eyes, nose and throat of the contact animals were found to be 
positive for NDV-RNA (Figure 5b). However, viable virus was isolated only once from a throat swab 
(rNDV-F
0
, day 2+2h). Sporadically, the contact animals also had detectable NDV-RNA in plasma or WBC 
samples (Figure 5a).
Hemagglutination inhibition assay conducted on sera collected from the contact animals 21 days after 
exposure revealed that contact animals had not seroconverted (data not shown).
Figure 5: Virological parameters from samples taken from animals just before and 2 hours after injection. Blood (a) 
and swab (b) samples were collected at indicated time points. Total RNA was isolated and NDV specific qRT-PCR was 
performed on all samples (positive = +, negative = -). qRT-PCR positive swab samples were cultured in SPF embryonated 
chicken eggs (positive = green, negative = red, not cultured = blank). WBC: white blood cells; i1 & i2: inoculated animals; c: 
contact animal; A: Avipro ND C131; B: rNDV-F
0
; C: rNDV-F
3aa
; d: days post first inoculation; h: hours.
Necropsy & histopathology
Samples of organs collected upon necropsy were tested for the presence of NDV-RNA with qRT-PCR. 
I.v. injection with all three strains of NDV resulted in a systemic distribution of viral RNA mainly to the 
(upper and lower) respiratory tract, spleen, liver and kidney (Figure 6). No differences in distribution 
were observed between the three groups (Avipro ND C131 vs. rNDV-F
0
 vs. rNDV-F
3aa
). Virus was not 
isolated from the RNA positive samples.
A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C
i1 - + - + - + - + - + + + + + + + + + + + + + + +
i2 - - - + + + - - + + + + + + + + + + + + + + + +
c - - - - - - - - + - - - - - - + - - - - - + - - - - - - - - - - -
i1 - - - + + + + - + + + + + + + + + + + + + + + +
i2 - - - - + + + + + + + + + + + + + + + + + + + +
c - - - - - + - - - - - - - + - - - - - - - + - - - - - - - - + - -
i1 - - - - - - - - + - - + - - - + - + + + - + + +
i2 - - + - - - - - - + - - - - + + - + + + + - - +
c - - + - - - - - + - - - - - + - + + - + - + - - - - - - - + - - -
i1 - - - - - - - - + + - + - - - + + + - - + - - +
i2 - - - - - - - - + - - + - - + + + + - - - - - +
c - - - - - - - - + - - - - - - - - + - - - - - - - - - - - - - - -
i1 - - - - - - - - - - - - + - - + + + + - + - - +
i2 - - - - - - - - - - - - - + - + + + + + + - - +
c - - - - - - - - - - - - - - - + + - + - + - - + - - - - - - - - -
i1 - - - - - - - - - - - - - - - - - - - - - - - -
i2 - - - - - - - - - - - - - - - - - - - - - - - -
c - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
d14 d21d4
a
b
d7
Throat
Rectum
d0 d0+2h d1
Plasma
WBC
Eye
Nose
d1+2h d2 d2+2h d3
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Figure 6: Virological parameters at necropsy. Organs were collected on day 4 (inoculated animals) or day 21 (contact 
animal) post first inoculation. Tissue samples were homogenized and supernatant was used to isolate total RNA. NDV 
specific qRT-PCR was performed on all samples (positive = +, negative = -). qRT-PCR positive swab samples were cultured 
in SPF embryonated chicken eggs (negative = red, not cultured = blank). A: Avipro ND C131; B: rNDV-F
0
; C: rNDV-F
3aa
; i1 
& i2: inoculated animals; c: contact animal; BAL: bronchi-alveolar lavage; RUL: right upper lobe; RLL: right lower lobe; TB: 
tracheo-bronchiolar; LN: lymph node.
No gross pathological changes were observed at necropsy of injected animals. The following incidental 
lesions were detected upon light microscopy: mild acute focal suppurative bronchoadenitis in one 
animal injected with Avipro ND C131 and mild acute focal suppurative rhinitis with hemorrhage in 
one animal injected with rNDV-F
3aa
. Otherwise, no microscopic lesions were detected in any of the 
evaluated tissues of any of the injected macaques. Immunohistochemic staining for NDV revealed no 
infected cells in tissues that were positive for NDV-RNA. None of the rare incidental lesions detected 
were considered to be related to the treatment.
One incidental lesion was detected in a contact animal by light microscopy: mild acute focal alveolar 
hemorrhage in the animal in the rNDV-F
0
 group, considered not to be related to exposure to virus. 
Immunohistochemical staining for NDV again revealed no infected cells in evaluated tissues. None of 
the organs collected from contact animals on day 21 tested positive for NDV-RNA (Figure 6).
i1 i2 c i1 i2 c i1 i2 c
BAL + - + + + + + + +
Lung RUL + + - + - - - + -
Lung RLL + + - + + - - + -
Trachea - - - - - - - + -
Bronchus + + - - - - - - -
TB LN - - - + + - - - -
Mesenterial  LN - - - + + - - - -
Colon - - - - - - - - -
Ileum - - - - - - - - -
Heart - - - - - - - + -
Liver + - - - + - - + -
Spleen + + - + + - + + -
Kidney + + - + + - + + -
Adrenal - - - - + - - + -
Pancreas - - - - - - - - -
Brain - - - - - - - - -
Liquor - - - - - - - + -
Nasal septum - + - - - - - + -
Nasal concha + + - - - - - - -
- - - - - - - - -
B CA
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Virus neutralization (VN)
VN assays were conducted with virus stocks generated in embryonated chicken eggs and in human 
or primate cells. These viruses were tested against a panel of human and primate sera (Table 1). This 
experiment revealed that indeed non-HI naive human and primate sera, but not HI sera, neutralized 
rNDVs generated in embryonated chicken eggs. This was in contrast with rNDVs generated in primate 
(Vero-118) or human (MRC-5) cells, which managed to escape neutralization by non-HI naive human 
and primate sera.
Table 1: Virus neutralization assay using rNDVs generated in eggs, MRC-5 or Vero-118 cells. rNDVs were incubated with 
serum and titrated on Vero-118 cells. Values indicate VN-titers. V-118: Vero-118; HI: heat-inactivated.
rNDV-F0 rNDV-F3aa
Egg MRC-5 V-118 Egg MRC-5 V-118
Primate
Non-HI
1 40 0 0 45 0 0
2 20 0 5 20 0 0
3 40 5 0 25 0 0
HI 
1 10 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
Human
Non-HI
1 40 15 15 60 10 0
2 40 0 0 40 0 0
3 30 0 0 60 0 0
HI
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 10 0 0
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Discussion
Limited information is available on preclinical biosafety regarding administration of oncolytic NDV 
in a human-like animal model. Therefore, we carried out a safety study comparing the toxicity, 
biodistribution and shedding of NDV strains differing in virulence in non-human primates.
A non-recombinant, commercially available vaccine strain was included, since this virus has a long 
history of safe usage in vaccinating poultry. Two other (recombinant) strains were tested as they are 
candidates for future virotherapy with oncolytic NDV, and are suitable for further development using 
reverse genetics. These two rNDVs differed in virulence as defined by their F protein cleavage site. 
Considering virulent NDV strains as potential oncolytic viruses, it is also important to know whether the 
virus is capable of spreading to the environment, as this could lead to accidental infection of susceptible 
hosts, and could thus also pose a serious threat to the poultry industry or domestic bird species.
We found that i.v. injection of a high dose of all three strains was safe for the animals. No clinical 
signs of illness were observed in the vaccine or recombinant virus injected animals, except short term 
fever in animal injected with the highest dose Avipro ND C131 and rNDV-F
3aa
. Hematologic and serum 
chemistry parameters were mostly within normal range, with the exception of slightly elevated liver 
enzymes upon Avipro ND C131 injection. This could be related to the presence of preservatives and 
lyophilization products in vials of this vaccine strain, specifically peptone, magnesium sulphate, sucrose 
or gelatin. We hypothesize that other incidental findings of abnormalities in measured biochemistry 
parameters are most likely unrelated to the experiment. Due to biosafety issues, we were not able to 
measure hematologic parameters for animals injected with rNDV-F
3aa
. However, it is unlikely that these 
parameters would differ much from the measurements obtained from animals injected with non-
virulent strains, since there was no indication for increased pathogenicity (see below) of the virulent 
strain in this non-human primate model.
Analysis of the distribution of NDV showed that i.v. injection resulted in systemic spread, with most of 
the viral RNA ending up in the respiratory tract, spleen and liver. Histological examination however, did 
not reveal infected cells in any of the examined organs, indicating that substantial virus replication in 
these organs did not occur.
We observed shedding of virus from injected animals, irrespective of the strain used and we cannot 
exclude transmission of virus. However, productive infection of the contact animals did not occur, 
since no seroconversion was detected. Earlier studies of human infection with NDV reported mostly 
on workers in the poultry industry having contact with live virus either when handling infected or dead 
poultry or lyophilized or aerosolized vaccine strains [140-146]. The exposure of these human cases 
was probably to a higher dose than the contact animals in the present study, since they developed 
symptoms within a couple of days and seroconverted 1-2 weeks after exposure. We therefore argue 
that contact animals in the present study were not exposed to high concentrations of shed NDV, 
since they did not develop any symptoms nor did they seroconvert after 3 weeks of observation. 
Nonetheless, appropriate biosafety measures preventing environmental spread have to be considered 
when administrating high dose oncolytic NDV.
Preclinical studies employing NDV as a vaccine vector using subcutaneous, intranasal and/or 
intratracheal administration showed that NDV as vaccine vector is highly attenuated in non-human 
primates [127-132]. However, it is difficult to compare these studies with the one we present here, as 
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these animals were not i.v. inoculated and the viral doses administered in these vaccine studies were 
relatively low.
Several clinical phase I/II trials have been described previously in which high dose wild-type oncolytic 
NDV was injected i.v. into patients with advanced and/or metastatic solid cancer [91-93,97-101]. These 
trials employed naturally occurring, in vitro selected egg-grown oncolytic strains of NDV. Viral doses 
used in these clinical studies were comparable to the dose administered in the present study: up to 34-
120 x 109 EID
50
 m-2 (body surface) as compared to an equivalent dose of 4 x 109 TCID
50
 m-2 recombinant 
virus in our study, noting that egg titration is generally about tenfold more sensitive than tissue culture 
titration [92,99,223]. A study recruiting 14 patients suffering from glioblastoma multiforme showed that 
i.v. injection of a high dose of the lentogenic oncolytic strain NDV-HUJ was safe, with grade I-II fever as 
only adverse event [92]. Infectious virus was recovered from blood, saliva and urine samples up to 96 
hours after injection. Two other phase I/II studies with a total of 95 patients showed that i.v. injection 
of a virulent NDV strain (PV701) was safe in patients with advanced or metastatic solid tumors [93,99]. 
Common side effects included fever, diarrhea and slight transient elevation of liver transaminases (but 
only in patients with hepatic metastases). Shedding of injected virus was also observed up to three 
weeks after injection. Measures to prevent environmental spread of this virulent NDV strain were not 
described [93,99]. Overall, the results of our present preclinical safety study with (recombinant) NDV 
strains corresponds well with the results previously reported on phase I/II clinical trials.
During the execution of our animal experiments it was reported that NDV generated in embryonated 
chicken eggs or non-human cells is susceptible to neutralization by human serum through complement 
binding and activation [218]. This was clearly an important finding related to our experiment. Upon 
testing, we confirmed that non-HI primate and human sera neutralized egg-generated NDV, in contrast 
to NDV generated in primate or human cells. All clinical trials thus far have used egg-generated virus 
stocks and still reported positive effects for NDV virotherapy as well as shedding of infectious virus, 
indicating that egg-generated NDV is still capable of replication [91-93,97-101]. The efficacy of NDV 
virotherapy might increase when using virus stocks generated in human or primate cells. However, 
neutralization by complement might also be important for safe administration of high doses of NDV, 
and abolishing this could result in more toxicity and a higher risk of shedding to the environment. More 
information should therefore be obtained on the safety and oncolytic efficacy of virotherapy with NDV 
stocks generated in human or primate cells.
Our data in a non-human primate model using recombinant avirulent and virulent NDV strains 
corroborates with the data from clinical trials with wild-type strains. Based on the lack of virus 
replication in organs, absence of NDV-related lesions and hematologic or biochemistry abnormalities, 
we conclude that the i.v. administration of oncolytic NDV generated in eggs is safe, even when using 
high doses of a virulent strain, when taking appropriate biosafety measures to prevent environmental 
spread. Future research has to elucidate whether NDV generated in human or primate cells has a similar 
safety profile and oncolytic efficacy.
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Abstract
Although Newcastle disease virus is known to cause mild transient conjunctivitis in humans, there 
are two recent reports of fatal respiratory disease in immunocompromised human patients infected 
with the pigeon lineage of the virus, pigeon paramyxovirus type 1 (PPMV-1). In order to evaluate the 
potential of PPMV-1 to cause respiratory tract disease in a non-human primate as a model for human 
disease, we inoculated 1.0 x 108 median tissue culture infectious dose of PPMV-1 into the trachea and 
nares and onto the conjunctiva of three cynomolgus macaques (Macaca fascicularis) and examined 
them by clinical, virological, and pathological assays. In all three macaques, PPMV-1 replication was 
restricted to the respiratory tract and caused pulmonary consolidation affecting up to 30% of the lung 
surface by 3 days post inoculation. Both alveolar and bronchiolar epithelial cells expressed viral antigen, 
which co-localized with areas of diffuse alveolar damage. The results of this study demonstrate that 
PPMV-1 is a primary respiratory pathogen in cynomolgus macaques, and support the conclusion that 
PPMV-1 may cause fatal respiratory disease in immunocompromised human patients.
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Introduction
Newcastle disease virus (NDV), or avian paramyxovirus type 1 (APMV-1), is classified in the genus 
Avulavirus, subfamily Paramyxovirinae, family Paramyxoviridae [224]. Genetic and antigenic analysis have 
demonstrated that NDV strains cluster in 10 different genotypes, with different sublineages [149]. Based 
on their difference in reactivity in hemagglutination assays, and their host specifity for columbiform 
species, all pigeon paramyxoviruses (PPMV-1) cluster in lineage VIb/I of genotype VI chicken NDV 
strains [149-152]. 
NDV infection is known to cause mild disease in humans. Most commonly, human infection is associated 
with conjunctivitis, which resolves within one week. Less often, it is associated with transient fever 
or chills [225-228]. So far, only two cases of human infection with NDV associated with fatal disease 
have been reported, one in the USA [168] and one in the Netherlands (unpublished data). Both cases 
involved severe pneumonia and an immunosuppressive condition as an underlying comorbidity, and 
both virus isolates from the patients were typed as PPMV-1.
PPMV-1 was first detected in Southeastern Europe in the 1980s and became established in pigeon 
populations across Europe. From there, PPMV-1 has spread and continues to spread world-wide, 
including multiple invasion events into North America. PPMV-1 is now established in both domestic 
and wild pigeons and other columbiform species in Europe and North America, from where it regularly 
spreads to poultry, causing substantial outbreaks [149,153].
Strains of NDV and PPMV-1 can be categorized into three different groups based on the severity of 
disease they cause in birds: lentogenic (avirulent), mesogenic (intermediate virulent) and velogenic 
(virulent). These differences in virulence can be explained mostly by differences in the cleavage site 
in the fusion (F) protein, which is synthesized in an inactive form (F0) and needs to be proteolytically 
cleaved by host cellular proteases into active F1 and F2 forms in order to become functional. Activation 
of the F0 protein will result in fusogenic activity promoting virus-to-cell fusion and cell-to-cell fusion. 
Lentogenic viruses have a monobasic cleavage site, which can only be cleaved by trypsin-like proteases 
found in the respiratory and digestive tracts of birds. More virulent strains have a multibasic cleavage 
site, which can also be cleaved by furin-like proteases, found more abundantly in most organs and 
explaining why virulent strains can replicate systemically in birds [112]. Of note, virulent PPMV-1 strains 
possess a multibasic cleavage site and cause disease in columbiform species. However, some strains 
need further adaptation to become virulent in other bird species like poultry [164,165,229].
NDV strains have been tested in different animal models to evaluate their virulence for mammals. 
Inoculation of lentogenic, mesogenic, and velogenic strains of NDV induced conjunctivitis in rhesus 
macaques and rabbits, but only after mild mechanical abrasion of the conjunctival epithelium [230]. 
Intranasal combined with intratracheal inoculation of a mesogenic strain of NDV (Beaudette C) into 
African green monkeys resulted in a low level of replication at scattered locations in the lung, without 
overt disease signs: pathologic changes were not evaluated [127]. Intranasal inoculation of a lentogenic 
strain of NDV (La Sota) into BALB/c mice [231] or Syrian golden hamsters [232] resulted in body weight 
loss and, at 3 days post inoculation (dpi), necrotizing broncho-interstitial pneumonia associated with 
virus antigen expression in bronchial epithelium. Recently, evaluation of lentogenic and mesogenic 
recombinant NDV strains as oncolytic agents injected intravenously in high dose into non-human 
primates demonstrated no apparent toxicity [233]. However, the virulence of PPMV-1 in laboratory 
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mammals, as a model for human disease via a natural inoculation route has not been evaluated.
We used the PPMV-1 isolate from a fatal human case to investigate the potential of this isolate to cause 
respiratory tract disease in a non-human primate model. To this end, three cynomolgus macaques 
were inoculated and pathological, immunohistochemical and virological analyses were performed 
at 3 dpi. We demonstrate that PPMV-1 can cause severe virus-associated pneumonia in a non-human 
primate model.
Material and methods
Virus preparation 
The PPMV-1 isolate was obtained from an adult female patient from the Netherlands with multiple 
myeloma, who died from respiratory failure after receiving allogenic bone marrow transplantation and 
immunosuppressive treatment (unpublished data). The virus isolate was passaged twice on human 
rhabdomyosarcoma cells and once on Vero cells. Prior to inoculation, the virus isolate was cultured 
in 10-day-old embryonated chicken eggs using standard techniques, and harvested after two days. 
Pooled fresh allantoic fluid was purified and concentrated by ultracentrifugation at 27.000 rpm for two 
hours at 4°C using a 30%/60% sucrose gradient. The virus stock was titrated by end point dilution assay 
in Vero clone 118 cells, as described before [204]. The infectious virus titer of this stock was 5 x 108 median 
tissue culture infective dose (TCID
50
) per ml.
Experimental protocol
Three cynomolgus macaques, 3.5 yrs old, were colony-bred and had been maintained in group housing, 
where they were screened annually—and tested negative—for the following infections: simian virus 40, 
polyomavirus, tuberculosis, measles virus, mumps, simian immunodeficiency virus, simian retrovirus type 
D, and simian T-cell leukemia virus. Prior to inoculation, they were examined clinically and determined as 
healthy by a registered veterinarian. One month before the start of the experiment a Data Storage Tag 
centi-Temperature probe (Star-Oddi, Brussels, Belgium) was implanted intraperitoneally, set to register 
temperature every 10 minutes. One week before inoculation, the macaques were placed together in a 
negatively pressurized, HEPA-filtered isolator cage. They were provided with commercial food pellets 
and water ad libitum, and fruit samples twice daily. The macaques were inoculated with 1.0 x 108 TCID
50
 
of PPMV-1, which was suspended in 4.5 ml of phosphate-buffered saline (PBS). Approximately 3 ml was 
applied intratracheally by use of a catheter, 0.5 ml in each nare, and 0.25 ml on each of the conjunctivae. 
The macaques were observed daily for the occurrence of malaise, coughing, exudate from the eyes 
or nose, forced respiration, and any other signs of illness. The macaques were euthanized at 3 dpi by 
exsanguination under ketamine and medetomidine hydrochloride anesthesia. Just before inoculation 
and daily until euthanasia, the macaques were anesthetized with ketamine and medetomidine 
hydrochloride and pharyngeal, nasal, ocular, and rectal swabs were collected in 1 ml transport medium 
[219] and stored at –70 °C until RT-PCR and/or virus isolation. In addition, 4 ml blood was collected from 
an inguinal vein at each of these time points and collected in Vacuette Z Serum Sep Clot Activator tubes 
(Greiner Bio One, Alphen aan de Rijn, The Netherlands).
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Ethics statement
All experiments involving animals were conducted strictly according to European guidelines (EU 
directive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997). The 
experimental protocol was reviewed and approved by an independent animal experimentation ethical 
review committee, not affiliated with Erasmus MC (DEC consult number EMC2796).
 
Clinical biochemistry
Clotted blood samples were centrifuged and 100 µl separated serum was assayed with Piccolo 
BioChemistry Panel Plus Reagent Discs (Abaxis, Darmstadt, Germany), which were processed using a 
Piccolo Xpress chemistry analyzer (Abaxis) following the manufacturer’s instructions. Measurements 
were obtained for glucose, blood urea nitrogen (BUN), creatinine, calcium, albumin, total protein, alanine 
aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), γ-glutamyl 
transpeptidase (GGT), amylase and C-reactive protein (CRP). Reference values (if indicated) were obtained 
from the supplemental data of a publication by Xie   [220].
Autopsy and tissue sampling
Autopsies were carried out according to a standard protocol. Organs were examined for lesions and 
sampled for laboratory analyses. For histopathology and immunohistochemistry, samples of adrenal 
gland, brain stem, cerebellum, cerebrum, conjunctiva, ethmoid bone, eye, eyelid, heart (left and right 
ventricle), kidney, large intestine, lung (left and right; cranial, medial and caudal lobes), liver, mesenteric 
lymph node, nasal conchae, pancreas, small intestine, spleen, tonsil, and tracheo-bronchial lymph were 
collected in 10% neutral-buffered formalin (lungs after inflation with formalin). For RT-PCR, broncho-
alveolar lavage (BAL) was performed by direct infusion of PBS into the right main bronchus. Recovered 
BAL fluid was centrifuged and the cellular pellet resuspended in TRIzol and stored at -80 °C until further 
analysis. In addition, samples of adrenal gland, brain, cerebrospinal fluid, conjunctiva, heart, kidney, 
mesenteric lymph node, lung (right cranial and caudal lobes), large intestine, liver, nasal concha, nasal 
septum, pancreas, primary bronchus, small intestine, spleen, trachea, and tracheo-bronchial lymph node 
were collected in RNAlater (Life Technologies, Bleiswijk, The Netherlands) and stored at -80°C until further 
analysis. For virus isolation, samples from the same tissues as for RT-PCR were stored without additives at 
-80°C until further analysis.
Histopathology
Samples for histopathological analysis were embedded in paraffin, sectioned at 3 µm, and stained with 
hematoxylin and eosin (H & E) for examination by light microscopy. Tissue sections of a clinically healthy 
juvenile cynomolgus macaque that had not been infected with PPMV-1 were used as a negative control.
Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 3 µm-thick sections of the same tissues examined histopathologically 
were stained using an immunoperoxidase method. Tissue sections were mounted on coated slides 
(Klinipath, Duiven, The Netherlands), deparaffinized and rehydrated. Endogenous peroxidase was 
blocked by incubating sections in 3% H
2
O
2
 in PBS for 10 min at room temperature (RT). Antigen was 
retrieved by boiling buffer (pH 9) for 15 min. Sections were subsequently washed with PBS containing 
74
0.05% Tween 20 (Fluka, Chemie AG, Buchs, Switzerland) and incubated in PBS with 0.1% BSA (Aurion, 
Wageningen, The Netherlands) for 10 min at RT. After this, sections were incubated in PBS with 0.1% BSA 
with a monoclonal mouse antibody IgG2a to NDV (dilution 1:100, MAb 6H12; La Sota strain, Hytest Ltd, 
Turku, Finland) or with a negative control isotype mouse monoclonal antibody (dilution 1:100, MAb 003, 
R&D System, Minneapolis, USA) for 1 hr at RT. After washing, sections were incubated with goat anti-
mouse antibody (dilution 1:400, Southern Biotech, Birmingham, AL) labeled with horseradish peroxidase 
(HRP) for 1hr at RT. HRP activity was revealed by incubating the sections in 3-amino-9-ethylcarbazole 
(Sigma Chemical Co., St. Louis, USA) in N,N-dimethylformamide (Sigma Chemical Co.) solution for 10 min 
at RT, resulting in a red precipitate. Sections were counterstained with hematoxylin. Brain tissue sections 
from a cormorant (Phalacrorax auritus) known to be infected with NDV were used as positive control. 
Tissue sections of a clinically healthy juvenile cynomolgus macaque that had not been infected with NDV 
were used as a negative control.
RNA isolation and qRT-PCR assay 
BAL samples stored in TRIzol were processed according to the manufacturer’s instructions to isolate RNA. 
Tissue samples stored in RNAlater were weighed, thawed, transferred to tubes containing a quarter-
inch-diameter ceramic sphere in virus transport medium, and homogenized using a FastPrep 24 tissue 
homogenizer (MP Biomedicals, Eindhoven, The Netherlands). The homogenates were centrifuged, and 
the cleared supernatants were used for RNA isolation. 200 µl of the cleared supernatant of tissue samples, 
as well as 200 µl of other samples (transport medium of swabs, plasma) were combined with 300 µl lysis 
buffer of the Total Nucleic Acid Isolation kit (Roche, Woerden, The Netherlands) and RNA was isolated in 
a volume of 50 µl using a MagNA Pure LC machine (Roche) following the manufacturer’s instructions.
NDV-specific qRT-PCR was performed on 5 µl (TRIzol samples) or 19.5 µl (MagNA Pure samples) RNA in an 
ABI PRISM 7000 Sequence Detection System using TaqMan Fast Virus 1-Step Master Mix (both from Life 
Technologies) in a total volume of 30 µl, as described earlier [233].
Virus isolation 
200 µl transport medium from collected swabs or 200 µl supernatant from homogenized tissue samples 
was injected in duplicate into 10-day-old specific-pathogen-free embryonated chicken eggs. After 2 days 
allantoic fluid was harvested and tested for presence of virus by hemagglutination assay.
Results
Clinical findings of experimentally inoculated macaques
The body temperature of macaque #2 increased to 39.5 °C at 0.5 dpi, compared to 38.5 °C for macaque 
#1 and 38.0 °C for macaque #3 at that time point. Otherwise, no clinical signs were seen. Clinical 
chemical changes in the plasma were limited to creatinine and C-reactive protein (CRP) (Table 1). 
The creatinine concentration of Macaque #2 was slightly elevated at 1 dpi, but returned to normal 
concentrations at 2 and 3 dpi. The creatinine concentration of the other macaques remained within 
the normal range. The CRP concentration in all macaques was increased at 1 dpi, and returned below 
the level of detection at 2 and 3 dpi.
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Gross pathology
All three macaques had locally extensive or multifocal pulmonary lesions, which were red-purple, 
slightly raised, and firmer than normal (Figure 1). The estimated volume of affected lung tissue differed 
per macaque: 30% (macaque #1), 25% (macaque #2), and 1% (macaque #3). The only gross lesions 
outside the respiratory tract were in lymphoid organs. All three macaques had enlarged tracheo-
bronchial lymph nodes and prominent white pulp of the spleen, while macaque #1 also had enlarged 
tonsils and mandibular lymph nodes, and multiple red areas in mesenteric and pancreatic lymph 
nodes.
Figure 1. Gross pathology of experimental PPMV-1 inoculation in cynomolgus macaques. A-C: Overview of the ventral 
aspect of the lungs. D-E: Close-up of the right lower lung lobe. F: Close-up of the right upper and middle lung lobes. There 
is a locally extensive area of consolidation in the right lower lung lobe of macaques #1 (A,D) and #2 (B,E). There are multiple 
areas of consolidation (arrows)in the right upper and middle lung lobes of macaque #3 (C,F).
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Histopathology
In the lung, all three macaques had multiple or coalescing foci of inflammation and necrosis that 
centered on the bronchioles (Figure 2). In these foci, the alveolar and bronchiolar lumina were filled 
with macrophages, lymphocytes, neutrophils, and rare eosinophils, mixed with edema fluid, fibrin, 
erythrocytes, and cellular debris. Alveolar and bronchiolar epithelia had evidence of both necrosis 
(denuded basement membranes, attenuated bronchiolar epithelial cells) and regeneration (type 
II pneumocyte hypertrophy and hyperplasia). The alveolar and bronchiolar walls were moderately 
thickened by the presence of mononuclear cells, neutrophils, and edema fluid. Some alveolar walls 
were lined by hyaline membranes. The bronchi were only mildly affected. There was moderate 
accumulation of lymphocytes around branches of both pulmonary arteries and pulmonary veins, and 
mild infiltration of mononuclear cells and neutrophils in pulmonary vein walls. The pleura overlying the 
inflammatory foci was infiltrated with mononuclear cells, neutrophils, and eosinophils.
 
Figure 2. Pulmonary histopathology and immunohistochemistry of experimental PPMV-1 inoculation in cynomolgus 
macaques. A: Pulmonary section of macaque #1. Diffuse alveolar damage. There is edema fluid and inflammatory cells in 
the alveolar lumina (H&E. Original magnification X2). B: Pulmonary section of macaque #1. Diffuse alveolar damage. There 
are macrophages, lymphocytes, neutrophils, and rare eosinophils, mixed with fibrin strands, in the alveolar lumen (H&E. 
Original magnification X40). C: Pulmonary section of macaque #1. Diffuse alveolar damage. In addition to inflammatory 
cells, there is abundant edema fluid in in the alveolar lumen (H&E. Original magnification X40). D: Pulmonary section 
of macaque #1. Diffuse alveolar damage. Hyaline membranes lining the alveolar walls (H&E. Original magnification 
X20). E: Pulmonary section of macaque #1. Diffuse alveolar damage. There is loss of epithelial cells from the bronchiolar 
wall (H&E. Original magnification X40). F: Pulmonary section of macaque #2. Diffuse alveolar damage. Hypertrophy of 
type II pneumocytes lining the alveolar wall (H&E. Original magnification X40). G: Pulmonary section of macaque #2. 
Diffuse alveolar damage. Expression of NDV in epithelial cells of the alveoli (Immunoperoxidase stain for PPMV-1. 
Original magnification X40). H: Pulmonary section of macaque #1. Diffuse alveolar damage. Expression of NDV in type I 
pneumocytes and type II pneumocytes (Immunoperoxidase stain for PPMV-1. Original magnification X100).
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The lymph nodes and spleen had benign lymphoid hyperplasia, characterized by increased number of 
lymphocytes and expansion of germinal centers. In addition, the medullary sinuses in the pancreatic 
and mesenteric lymph nodes of macaque #1 contained many erythrocytes; furthermore, the colon of 
this macaque had multiple small hemorrhages in the lamina propria. Macaques #1 and #2 had a mild 
superficial tonsillitis, characterized by the presence of neutrophils and bacterial colonies in the lumen 
and epithelium of the tonsillar crypt. Macaque #3 had a mild superficial conjunctivitis, characterized 
by the presence of neutrophils, lymphocytes, plasma cells, and expansile lymphoid follicles in the 
subconjunctival connective tissue, and migration of neutrophils through the conjunctiva into the 
lumen (Figure 3).
Figure 3. Conjunctival histopathology of experimental PPMV-1 inoculation in cynomolgus macaques. A: Conjunctival 
section of macaque #3. Conjunctivitis. There are neutrophils in the subconjunctival connective tissue and conjunctiva 
(H&E. Original magnification X20). B: Conjunctival section of macaque #3. Conjunctivitis. Enlarged lymphoid follical in the 
subconjunctival connective tissue (H&E. Original magnification X2).
Immunohistochemistry
Expression of NDV was visible as red-brown granular cytoplasmic staining in alveolar and bronchiolar 
epithelial cells in affected areas of the lung in all three macaques (Figure 2). Neither unaffected areas of 
the respiratory tract nor extra-respiratory organs showed NDV expression. NDV expression was present 
in the positive control tissue and absent in the isotype control and negative control tissues.
qRT-PCR and virus isolation
By qRT-PCR, the highest levels of PPMV-1 RNA were detected in eye, nose, and throat swabs of all 
three macaques at 1 dpi (Figure 4). The amount of RNA declined on subsequent days, but RNA was 
still detectable at 3 dpi in one (nose swab) or two out of three macaques (eye and throat swabs). Virus 
isolation conducted with PPMV RNA-positive swabs, demonstrated the presence of infectious virus 
only at 1 dpi in the throat swabs of macaques #2 (titer: 1.0 x 101 TCID
50
/ml) and #3 (2.3 x 102 TCID
50
/ml) 
and the eye swab of macaque #3 (7.4 x 102 TCID
50
/ml).
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Figure 4. Detection of PPMV-1 by qRT-PCR in experimentally 
inoculated cynomolgus macaques. Circle: macaque #1, square: 
macaque #2, triangle: macaque #3.
At autopsy, PPMV-1 was detected by qRT-PCR and virus isolation in the lung of all three macaques 
(Table 2). PPMV-1 also was detected by qRT-PCR but not by virus isolation in other respiratory tract 
tissues: nasal turbinate, trachea, or bronchus. Except for the tracheo-bronchial lymph node, which was 
positive by qRT-PCR but not by virus isolation, all extra-respiratory organs were negative for PPMV-1 
by qRT-PCR.
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Discussion
This experimental inoculation shows that PPMV-1 can cause severe pneumonia in a non-human 
primate model. Histological lesions in PPMV-1-infected macaques consisted of diffuse alveolar 
damage, affecting up to 30% of the lungs. The co-localization of these lesions with specific expression 
of PPMV-1 antigen, together with the re-isolation of PPMV-1 from lung samples at autopsy, support our 
conclusion that PPMV-1 was the cause of pneumonia.
These findings largely correspond with the presentation of PPMV-1 infection in two human fatal cases 
from New York [168] and The Netherlands (unpublished data). Both human patients also developed 
pneumonia. The pathological characterization of the pneumonia in our macaques was nearly identical 
to that in the New York patient: “a subacute, severe, diffuse interstitial pneumonia with flooding of 
alveoli by fibrin, protein-rich fluid, red blood cells, sloughed pneumocytes, and a few neutrophils” 
[168]. The lower number of neutrophils in the New York patient is likely due to the later stage of disease 
and treatment with a nonmyeloablative regimen for peripheral blood stem cell transplantation. The 
cell tropism also appeared to be the same in our macaques (pneumocytes and bronchioloar epithelial 
cells) and the New York patient, where NDV antigen expressing cells “appeared to be mostly sloughed 
pneumocytes” [168]. This sloughing may have been due to a prolonged interval between death and 
autopsy; it also would preclude definite differentiation between alveoli and adjacent bronchioles as 
the source of the sloughed epithelial cells. While it was suggested that the New York patient had 
systemic infection based on PPMV-1-positive urine and stool samples, we did not detect PPMV-1 in 
any extra-respiratory tissues—including kidney, small and large intestine, pancreas and liver—of our 
macaques, either by qRT-PCR or immunohistochemistry. However, it cannot be excluded that under 
conditions of immunosuppression, the virus would be able to spread systemically in macaques.
It remains to be determined whether PPMV-1, and particularly these isolates from fatal human cases, 
are more virulent for people than other NDV strains. NDV is able to selectively replicate in cancer cells 
and therefore is a potential therapeutic agent in cancer therapy. The virulence of PPMV-1—a pigeon-
specific lineage of NDV—for humans and macaques suggests that the strain used for cancer therapy 
should be carefully selected. However, during application of different NDV strains by different routes—
locally, subcutaneously, intravenously, by inhalation—in thousands of people, severe adverse effects 
have never been recorded [234]. Also, preclinical studies employing NDV as a vaccine vector using 
subcutaneous, intranasal and/or intratracheal administration, or even employing NDV as a high dose 
intravenous oncolytic agent, all demonstrated that oncolytic NDV is highly attenuated in non-human 
primates [127-132,233].
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In this thesis, experiments are presented that were undertaken to develop oncolytic NDV for the 
treatment of pancreatic adenocarcinoma. Oncolytic viruses (OVs), reported first halfway the previous 
century, have undergone a tremendous evolution from anecdotal experimental and clinical efficacy 
to state-of-the-art clinical trials employing recombinant viruses in the last decade. With the advent 
of reverse engineering techniques, modifications attributing to efficacy and safety have marked the 
introduction of new generations of recombinant OVs.
In the following, an overview is given of the current state of affairs concerning oncolytic virotherapy, 
including different OV platforms that are being developed towards clinical trials or that are used in 
clinical trials. An overview of discussed OVs is given in table 1. 
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Current status of (pre)clinical research on oncolytic virus platforms 
Herpes simplex virus 1 (HSV)
HSV-1 was one of the first viruses to be developed into a recombinant oncolytic virotherapeutic vector. 
The large HSV genome is easy to manipulate and allows insertions of multiple additional transgenes. 
Furthermore, HSV infects and replicates in most tumor cell types and spreads throughout the tumor. 
If needed, viral replication can be hampered with anti-HSV medication (Acyclovir). Because HSV is 
neurotropic and causes a latent infection, most genetic modifications of oncolytic HSV (oHSV) have 
first focused on this potential safety issue. To generate tumor-specific oHSVs, three main strategies 
have been used [235]. These strategies include first attenuation by conditional replication in tumor 
cells by means of deletion of viral genes that are essential for viral replication in non-dividing cells 
(UL39) [236], counteract the protein kinase R (PKR) response (γ
1
-34.5) [237-242], or contribute to immune 
evasion (α47) [243,244]. Secondly, to increase the oncolytic efficacy, oHSVs have been armed with 
immune stimulatory genes to boost local cytotoxic immune responses or other therapy enhancing 
transgenes [235]. Thirdly, targeting by tropism or transcription specificity has been applied.
First generation oHSVs harboring the aforementioned genetic deletions have shown to be safe based 
on their attenuation in normal cells. However, they are also attenuated in tumor cells and thus less 
cytotoxic. Recent strategies have focused on improving the targeting of less attenuated oHSVs by 
changing tropism or transcription specificity. Glycoprotein D is the receptor binding protein of HSV-1, 
and fusion of this glycoprotein with a heterologous ligand can retarget the virus to the tumor-specific 
receptor of choice. This tumor specific targeting is enhanced by detargeting the normal receptor 
[245,246]. Examples include IL-13Rα2, human epidermal growth factor receptor 2 (HER2), and epidermal 
growth factor receptor (EGF-R) [247-249]. Using transcriptional targeting, tumor specificity has been 
enhanced by placing viral genes under the control of tumor-specific promoters. A promising example 
is rQNestin34.5, which has the expression of the γ
1
-34.5 gene under the control of the glioma-specific 
nestin promoter, which restores viral replication and cytotoxicity only in glioma tumors [250].
Several early generation oHSVs (talimogene laherparepvec, HSV1716, NV1020, G207, M032, rRp450 and 
others) have already been evaluated in clinical trials [235]. Most of these trials have demonstrated a good 
safety profile of HSV and treatment benefits were also observed. Talimogene laherparepvec (oHSV with 
deletions in γ
1
-34.5 and α47, armed with granulocyte-macrophage colony-stimulating factor (GM-CSF) 
has recently undergone evaluation in a phase III clinical trial in patients with advanced or metastatic 
melanoma. Probably this will be the first oncolytic virus to obtain Food and Drug Administration (FDA) 
approval, while a marketing authorization application for the European Union has just been submitted 
to the European Medicines Agency (EMA) [86].
Human mastadenovirus (HAdV)
Because of its association with mild disease and a relatively easy to manipulate genome, most work 
on HAdV as vector for (cancer) gene therapy has been done with serotype 5 of species C. HAdVs have 
distinct advantages as a gene transfer vector, including high transfection efficiency of cells irrespective 
of their growth status. The genome of HAdVs is easy to manipulate for retargeting and insertion of 
transgenes, and efficient production of high titer virus stocks is possible. Disadvantages include high 
immunogenicity of prevalent serotypes with pre-existing immunity, and transient expression of the 
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transgene due to dilution of HAdV episomes upon cellular division [251].
Replication of oncolytic HAdV vectors is thought to be advantageous because of direct cancer cell 
killing induced by viral replication, and due to which the number of administrations needed for 
effective treatment can be reduced. Efforts have been made to develop conditionally replicating HAdVs 
(crHAdVs), with specific and higher replication in cancer cells. Early examples are ONYX-015 (dl1520) 
and H101, which have a deletion of E1B-55kDa (and a deletion in E3 for H101), normally responsible 
for p53 binding and inactivation [252]. The tumor specific replication of ONYX-015 was later shown 
to be due to loss of E1B-55kDa-mediated late viral RNA export, rather than p53-inactivation [253]. In 
a similar approach, newer crHAdVs have been created exploiting the defects in retinoblastoma (Rb) 
pathways in cancer cells by deleting the Rb-binding E1A-CR2 region, creating dl922-947, also known as 
Delta24 [254,255]. Additional modifications in Delta24 have been created and successfully evaluated 
for oncolytic efficacy [256-259], as well as oncolytic crHAdVs which target cells with an (hyper)active 
Kirsten rat sarcoma viral oncogene homolog (KRAS) pathway [260], or cells with YB-1 overexpression 
[261-264]. A different approach for creating crHAdVs is using cancer- or tissue-specific promoters to 
limit expression of essential early HAdV genes to specific cell types and/or tissues [265,266].
Like other oncolytic viruses that have undergone extensive development, crHAdVs have also been 
armed with transgenes, often under the control of a tissue/cancer-specific promoter. Examples include 
i.e. immunomodulatory, pro-apoptotic or pro-drug converting enzyme genes [267-270].
Despite their capacity to achieve tumor infection in animal models, the therapeutic efficacy of crHAdVs 
in clinical trials has thus far been disappointing [271,272]. The discrepancy between preclinical and 
clinical studies using crHAdV-5 could be explained by the differences in expression of the Coxsackie 
Adenovirus receptor (CAR) in primary tumors compared to established laboratory cell lines [273]. In 
addition, off-target toxicity by sequestration in mainly the liver is a serious concern, even when crHAdVs 
are blinded for CAR [274-277]. Hexon mutations or even complete exchange of hexons have been 
shown to reduce liver sequestration and transduction dramatically [278-280]. Other strategies used 
to circumvent liver sequestration include polyethylene glycol (PEG)-ylation or polymer/dendrimer 
coating of crHAdV virions, and cell-based or magnetic/liposomal nanoparticle delivery [281-323].
To circumvent the limitation of low CAR expression in (tumor) cells, retargeting has also been applied 
to crHAdVs, permitting CAR-independent infection [324]. The retargeting strategy can also circumvent 
existing humoral immunity for HAdV-5 in the general population, and contributes to the prevention of 
liver sequestration as described above. Examples include conjugation with anti-knob or anti-penton/
hexon antibodies or adapters with retargeting ligands, pseudotyping or xenotyping with (chimeric) 
fiber knobs or capsids, peptide presentation (arginylglycylaspartic acid (Arg-Gly-Asp / RGD) or other), 
Affibody targeting, knob-less HAdVs and genetically modified capsids and/or fiber knobs [251]. More 
recently, efforts have also been made to develop crHAdVs fully based on other serotypes, most notably 
HAdV-3, or even non-human AdVs [315,325-339]. Using ‘directed evolution’ or ‘accelerated evolution’ 
strategies, ColoAd1 and other crHAdVs have been generated which appear to be more potent than 
their parental HAdV-5 based vectors [340-343].
A total of 458 clinical trials employing HAdV-mediated gene therapy have been reported to date. 
ONYX-015, H101 (Oncorine) and other first-generation oncolytic crHAdVs have gone through several 
phase I/II trials without relevant signs of toxicity but also without significant therapeutic effects, 
resulting in discontinuation of further trails [344]. More recent clinical trials employing new generations 
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of crHAdVs like RGD retargeted oncolytic crHAdVs [251,345,346], crHAdV-5/3 chimeric vectors [269,347-
350], ColoAd1 [351], human telomerase reverse transcriptase (hTERT)-promoter driven crHAdV-5 vector 
Telomelysin [352], E2F-1-promoter driven CG0070 [270], Rb-targeted crHAdV expressing hyaluronidase 
(VCN-01) [353], and crHAdV vectors expressing immunomodulating genes [269,270,349,354-357] have 
shown safety with some promising preliminary results.
Measles virus (MeV)
Most (pre) clinical research with oncolytic MeVs have used the attenuated vaccine Edmonston strain 
[358,359]. The cancer selectivity of MeV stems from overexpression of the MeV receptor CD46 on 
malignant cells [360]. Recombinant MeV can accommodate and maintain large sizes of foreign genetic 
material with good genetic stability in vitro and in vivo [361-364], and MeVs expressing transgene(s) 
have shown good genetic stability upon passaging. Both arming and targeting strategies have been 
used to improve efficacy of MeV in a wide array of malignancies [358].
Completed and ongoing clinical trials in patients with T cell lymphoma, ovarian cancer or glioblastoma 
multiforme have first used wild type MeV and later recombinant MeV expressing marker genes 
carcinoembryonic antigen (CEA) and sodium/iodide symporter (NIS) [359,365,366].
Vesicular stomatitis virus (VSV)
Compared with other oncolytic viruses, VSV has some distinct advantages: first of all a well-studied 
biology with relative replication independency of cell cycle and a specific receptor. Secondly, VSV 
produces high virus yields in a wide range of cell types, it replicates intracytoplasmatic without risk 
of genomic integration, it harbors a small and easy to manipulate genome, and there is no pre-
existing immunity in humans [367]. VSV infection in humans is generally asymptomatic and limited to 
people having direct contact with VSV [367]. A single case of VSV strain Indiana related encephalitis in 
humans has been reported [368]. VSV oncoselectivity is based largely on defective or reduced type 
I interferon (IFN) responses in tumor cells [369-372], although abnormal translation machinery and 
other cellular proteins have also been shown to play a role [373-376]. All three strategies previously 
described (conditional replication, arming, and targeting) have been employed to increase efficacy 
of VSV [367]. Furthermore, combination therapy has been described with different other therapies. 
Finally, optimizing delivery and distribution of oncolytic VSVs has been evaluated using cell-based 
carriers and aptamer or PEGylation of virions [377-380].
Coxsackievirus (CVA)
Similarly to rhinoviruses, CVA-21 binds to intercellular adhesion molecule 1 (ICAM-1) and additionally 
needs decay accelerating factor (DAF)-attachment for productive viral infection [381]. Given that ICAM-
1 and DAF are overexpressed in melanoma cells, efforts to evaluate the oncolytic potential of wildtype 
CVA-21 (and other coxsackieviruses) have mainly focused on this disease [382]. 
Currently ongoing phase I/II clinical trials employing intratumoral injection of wildtype CVA-21 
(CAVATAK) in Australian patients with advanced melanoma are showing promising preliminary results 
[383]. All (pre) clinical work so far has been conducted with wildtype CVA, while no progress has been 
made regarding conditional replication, arming or targeting.
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Poliovirus (PV)
Overexpression of CD155, one of the natural receptors for PV, has been shown in (neuro) ectodermal 
tumors, and transcriptional upregulation has been linked to signaling pathways commonly affected in 
malignancy, including Raf-Erk-Mnk signaling [384,385]. The neuropathogenicity of PV is dependent on 
the neuronal cell-type-specific function of its internal ribosome entry site (IRES) element, which assures 
initiation of translation in a 5’ end- and cap-independent manner. Mutations in the IRES genomic 
region or exchange with other viral IRES counterparts result in markedly neuro-attenuation in CD155-
transgenic mice and non-human primates, without reducing the cytopathogenicity in malignant cell 
types that express CD155 [386].
Most preclinical research has been performed with PVS-RIPO, a recombinant PV type 1 (Sabin vaccine) 
strain with the IRES element of human rhinovirus type 2. PVS-RIPO has shown oncolytic efficacy in 
immune-deficient xenograft rat and mouse models of malignant glioma [387]. Currently a phase I 
clinical trial is ongoing with intratumoral infusion of PVS-RIPO in patients with recurrent glioblastoma 
multiforme showing durable responses [388].
Seneca Valley virus (SVV) 
SVV does not infect humans but does propagate in tumor cells with neuroendocrine features [389,390]. 
Since its introduction as an oncolytic virus in 2007, SVV has shown preclinical efficacy in nude mouse 
xenograft models for several malignancies [389-394].
In a phase I clinical trial employing an intravenous dose escalation in patients with neuroendocrine 
tumors, SVV had (marginal) treatment benefits without causing serious adverse events when 
administered even in high dose (1011 viral particles/kg) [395]. A phase II randomized clinical trial in 
patients with extensive stage non-small cell lung carcinoma and a phase I dose escalation trial in 
pediatric patients with neuroblastoma, rhabdomyosarcoma or rare tumors with neuroendocrine 
features are currently underway [396].
Vaccinia virus (VV)
VV infection induces a strong cytotoxic T lymphocyte response and neutralizing antibodies without 
causing significant disease in humans [397,398]. As an oncolytic virus, VV has the advantage of fast 
replication and cell lysis with a broad cell/tumor tropism [399,400]. Furthermore, it lacks genomic 
integration, and shields extracellular enveloped virus VV virions from host immunity resulting in 
capability of (systemic) spreading between tumors [400-404]. Lastly, it also harbors a large genome 
packaging accommodation [404].
Several strategies have been described to target oncolytic VV to tumor cells. The VV protein Vaccinia 
growth factor (VGF) is homologous to cellular growth factor EGF and transforming growth factor alpha 
(TGFα) and can stimulate the cell for enhanced viral replication through EGF-R [405-407]. Deletion of 
the VGF gene will result in a VV that is targeted to cells with inherent EGF-R pathway activity, which is 
often observed in cancer cells [70,400,408]. J2R gene (encoding for viral thymidine kinase (tk) deletion 
similarly results in a VV that is dependent on overexpression of cellular tk, which is also often observed 
in cancer cells [409-412]. The combination of VGF and tk gene deletion is known as vvDD and results 
in an even more selective oncolytic VV [400,401]. VV gene B18R binds to the IFN receptor and can 
thereby inhibit the cellular antiviral innate immune response [413,414]. Deletion of B18R thus leads to 
90
selectivity for IFN-deficient cells [216]. A56R gene encodes for hemagglutinin and its deletion from the 
VV genome results in severe (neuro)-attenuation [415].
Arming of VV has also been described, e.g. with immune stimulators, apoptotic proteins, anti-
angiogenic antibodies/proteins, extracellular matrix proteases and prodrug-converting enzymes.
Early clinical trials employing non-recombinant vaccine strains of VV have shown safety when injected 
superficially into melanoma tumors, while local control of bladder cancer was also noted [416-418]. 
JX-594 (tk gene deleted, GM-CSF expressing VV Wyeth; Pexa-Vec)[419] has been evaluated in phase I-II 
clinical trials for patients with metastatic melanoma, (primary) liver tumors, lung, colorectal and various 
other solid cancer types [419-428]. GLV-1h68 (GL-ONC1) is currently being investigated in several phase 
I clinical trials [429,430].
Mammalian orthoreovirus type 3 Dearing (mORV-T3D)
mORV-T3D replicates in cells with dysfunctional cell signaling cascades, most importantly (but not 
exclusively) KRAS-overexpression and subsequent PKR inhibition, making it an inherent oncolytic 
virus [431-448]. A multitude of cancer types have been shown to respond to mORV-T3D treatment 
in (animal) models [435-437,443,449-483]. Cellular immunity has been found to be important for 
increasing anti-tumor efficacy [464,471,475,483-487]. The absence or inaccessibility of the JAM-A/1 
receptor is perceived as a possible limitation for mORV-T3D infection of tumor cells [454,456,488]. As 
such, bio-selection through passaging has been attempted to retarget mORV-T3D to other receptors, 
although this strategy is probably limited by the quasispecies presence in mORV-T3D isolates [489-
493]. Only one study using recombinant oncolytic mORV-T3D has been described thus far [494]. 
More studies with recombinant mORV-T3D can be expected in the near future, probably focusing on 
receptor retargeting and expression of therapeutic or imaging transgenes. 
At this time, 16 clinical trials employing intratumoral or intravenous injection of wildtype mORV-T3D 
(REOLYSIN®: pelareorep) have been conducted and more are currently underway or planned to start in 
the near future [484,495]. These trials have shown safety of mORV-T3D administration to patients with 
various solid tumors without dose limiting toxicities, while having some appreciable anti-tumor effects 
in phase II/III trials.
Murine leukemia virus (MuLV)
MuLV development for cancer therapy has been focusing on non-replicating, as well as more recently, 
replication competent retroviral (RCR) oncolytic vectors. The capacity of MuLV and other retroviruses to 
integrate into the host genome of dividing cells carries the risk of insertional mutagenesis/oncogenesis. 
Reducing this risk has been an important goal in designing retroviral vectors. The replication capacity 
of RCR-MuLV is considered to be beneficial for optimizing gene expression in tumors. Recent RCR-
MuLV vector genomes consist of an intact viral genome including an IRES-transgene immediately 
after the stop codon of the env gene, which results in more genetic stability, while retaining good 
replication capacity [496-498]. The fact that RCR-MuLVs can only infect and integrate in dividing cells 
results in an inherent onco-selectivity. In contrast to most other oncolytic viruses, the oncolytic activity 
of RCR-MuLVs depends solely on the transgene that is carried by the virus, since infection itself is not 
cytolytic. To date the transgene of choice has mostly been cytosine deaminase (CD), which converts 
the antifungal drug 5-fluorocytosine into active chemotherapeutic agent 5-fluorouracil. Oncolytic 
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activity of RCR-MuLV-CD (Toca 511) has been evaluated in preclinical (animal) models for breast cancer, 
glioblastoma multiforme and mesothelioma [499-504]. Toca 511 has a modified backbone and a 
codon-optimized and heat-stabilized CD gene and has been shown to be highly genomically stable 
while maintaining oncolytic efficacy upon passaging [500,505].
Newcastle disease virus (NDV)
NDV has been shown to be very safe in tumor models using mice or rats, even when used in high dose 
and injected intravenously, and NDV also appeared to be safe for high dose administration in humans, 
with no serious adverse events noted in early clinical trials [96]. Several wildtype NDV strains have 
shown (limited) antitumor activity without major side effects in phase I–II clinical trials for patients with 
various types of solid cancer [96].
Using recombinant NDVs, the oncolytic efficacy has been improved by increasing the virulence of the 
virus and the expression of immunomodulating or apoptotic transgenes. In addition, tumor cells are 
targeted with modified attachment proteins and combinations with other treatment modalities, most 
recently immune checkpoint blockade [114-117,119,120,125,506]. Clinical trials with these improved 
viruses have not yet been described, but pre-clinical data indicate efficacy in multiple tumor models 
for several solid malignancies, including pancreatic adenocarcinoma [114-117,119,120,125,204,506].
Work presented in this thesis regarding oncolytic NDV
Despite progress in several fields (e.g. surgery and peri-operative care, chemotherapy, radiotherapy, 
immunotherapy) in treatment of a multitude of different malignancies, the treatment of PDAC 
remains a very difficult one with little progress over the last decades. In our search for new therapies 
for pancreatic adenocarcinoma, we have focused our attention on the use of NDV as an oncolytic 
agent. For a rational design of a recombinant oncolytic NDV to treat patients with pancreatic tumors, 
the effect of wild-type NDV infection on human pancreatic adenocarcinoma cell lines (HPACs) in vitro 
was evaluated in chapter 2. Variations in NDV replication in the different HPACs generally coincided 
with differences in induced cytotoxic effects, with cell lines displaying more cytotoxic effects upon 
better NDV replication. This suggests that virus replication itself is a critical factor for NDV induced 
cytotoxicity, as was described in earlier studies in other cells [102-107,187,196-198]. This would argue 
for increasing the fusogenicity of an optimized recombinant NDV for treatment of pancreatic tumors.
It is thought that replication of oncolytic NDV is tumor specific based on defects in the innate immune 
responses, however, discrepancies for this theory have also been reported [107-109]. Most studies 
focusing on defective IFN production as a reason for tumor-specific NDV susceptibility, have only 
studied limited sets of tumor cell lines, which might have resulted in non-representative findings 
[105,106]. Using a more elaborate panel of HPACs we have demonstrated that IFN production upon NDV 
infection by these HPACs did not correlate with NDV susceptibility. Besides the lack of IFN production, 
defective IFN signaling through the JAK-STAT pathway has been indicated to be responsible for tumor 
specific replication of NDV [103-105]. Although our results with HPACs showed a highly variable and 
generally low anti-viral gene expression pattern after IFN stimulation, we also have shown that most 
HPACs still have an intact IFN signaling pathway, as IFN pretreatment protected the cells for NDV 
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replication and virus induced cytotoxicity. Few other groups have demonstrated that IFN production 
and signaling are not the only factors to consider. Cells over-expressing anti-apoptotic proteins like 
Rac1, Livin, and Bcl-xL have also shown markedly increased susceptibility to NDV replication and virus 
mediated killing, irrespective of IFN production and signaling [107-109].
Based on the results in chapter 2, we hypothesized that an oncolytic lentogenic rNDV would benefit 
from increased replication, or from the capacity to antagonize the innate immune pathways. In 
chapter 3, lentogenic rNDVs with immunomodulating potential (either stimulating innate immunity 
with human IFNβ (rNDV-hIFNβ-F
0
) or antagonizing with the influenza virus NS1 protein (rNDV-NS1-F
0) 
or increased virulence through increased cleavability of F protein (rNDV-F
3aa
) were evaluated in a 
panel of 6 representative HPACs to test these hypotheses. Immunomodulation with lentogenic rNDVs 
resulted in markedly changed early IFN responses of HPACs as compared to parental rNDV-F
0
 in vitro. 
Upon inoculation of HPACs with rNDV-hIFNβ-F
0
 exogenous hIFNβ was produced in high amounts. 
Conversely, inoculation with rNDV-NS1-F
0
 resulted in almost complete absence of IFNβ production in 
most HPACs, showing that immunomodulation using lentogenic rNDVs was successful. Interestingly, 
lower replication rates of rNDV-hIFNβ-F0 (compared to parental rNDV-F
0
) resulted in similar cytotoxicity 
in most HPACs, indicating that hIFNβ had a cytotoxic effect by itself. Blocking of the IFN production 
by exogenous expression of influenza NS1 protein from lentogenic rNDV-NS1-F
0
 lead to decreased 
cytotoxicity (compared to parental rNDV-F
0
) in most HPACs, indicating again that IFN has a cytotoxic 
effect on these cells. This is in contrast with results reported for a mesogenic rNDV expressing NS1 
(rNDV-NS1-F
3aa
), which induced enhanced tumor cell killing due to inhibition of apoptosis, leading to 
increased syncytia formation [120]. Hence, the expression of IFN-antagonists from either lentogenic or 
mesogenic rNDVs can have different outcomes for oncolytic efficacy. In our study, mesogenic rNDV-
F
3aa
 was capable of multicycle replication in all tested cells, in contrast to lentogenic rNDVs. Testing the 
cytotoxicity of rNDV-F
3aa
 revealed increased oncolytic efficacy in most HPACs as compared to rNDV-F
0
, 
indicating this to be the oncolytic rNDV with superior efficacy. This is in agreement with other studies 
that reported on the oncolytic efficacy of mesogenic rNDVs [114-119]. However, in 2 out of 6 HPACs 
(HPAF-II and Hs 700T) no significant differences were observed in cytotoxicity induced by rNDV-F
0
 or 
rNDV-F
3aa
. Specifically Hs 700T cells were very resistant to rNDV-F
3aa
-induced cytotoxicity and it remains 
to be determined why some cells are more resistant to oncolytic rNDV than others. In addition, in vivo 
experiments using a subcutaneous xenograft tumor model in immune-deficient mice demonstrated 
that intratumoral treatment with mesogenic rNDV-F3aa induced tumor regression or stabilization, 
whereas treatment with lentogenic (immunomodulating) rNDVs did not result in significant anti-tumor 
effects.
Safety of NDV for use in virotherapy
Early (pre)clinical trials employing wildtype oncolytic NDV have shown good safety with low toxicity 
in laboratory animals and human patients. However, information on environmental safety is relatively 
scarce. In the following, we discuss our findings on safety of oncolytic rNDV.
Virulent NDV strains pose an environmental risk, as birds (specifically poultry) are very susceptible to 
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infection with mesogenic or velogenic strains. Limited information is available on preclinical biosafety 
regarding administration of oncolytic NDV in a human-like animal model. Therefore, we carried out a 
safety study comparing the toxicity, biodistribution and shedding of NDV strains differing in virulence 
(commercially available clonal NDV vaccine strain Avipro ND C131, recombinant lentogenic rNDV-F
0 
and recombinant mesogenic rNDV-F
3aa
) in non-human primates, which is presented in chapter 4. 
Intravenous injection of a high dose of (a)virulent NDV was safe with regard to toxicity for the animals. 
No clinical signs of illness were observed in the vaccine or recombinant virus injected animals, except 
short-term fever in animals injected with the highest dose Avipro ND C131 and rNDV-F
3aa
. Hematologic 
and serum chemistry parameters were mostly within normal range. Analysis of the distribution of NDV 
showed that i.v. injection resulted in systemic spread, with most of the viral RNA ending up in the 
respiratory tract, spleen and liver. Histological examination however, did not reveal infected cells in 
any of the examined organs, indicating that substantial virus replication in these organs did not occur.
Shedding of virus from injected animals was observed, irrespective of the strain used and transmission 
of virus could not be excluded. However, productive infection of the contact animals did not occur, 
since no seroconversion was detected. Earlier studies of human infection with NDV reported mostly 
on workers in the poultry industry having contact with live virus either when handling infected or 
dead poultry or lyophilized or aerosolized vaccine strains [140-146]. The exposure of these human 
cases was probably to a higher dose than the contact animals in the present study, since the human 
cases developed symptoms within a couple of days and seroconverted 1-2 weeks after exposure. We 
therefore argue that contact animals in the present study were not exposed to high concentrations 
of shed NDV, since they did not develop any symptoms nor did they seroconvert after 3 weeks of 
observation. Nonetheless, appropriate biosafety measures preventing environmental spread have to 
be considered when administrating high dose oncolytic NDV.
Preclinical studies employing NDV as a vaccine vector using subcutaneous, intranasal and/or 
intratracheal administration showed that NDV as vaccine vector was highly attenuated in non-human 
primates [127-132]. However, it is difficult to compare the results of these studies with those described 
in chapter 4, as these animals were not i.v. inoculated and the viral doses administered in these vaccine 
studies were relatively low.
Several clinical phase I/II trials have been described in which high dose wild-type oncolytic NDV was 
injected i.v. into patients with advanced and/or metastatic solid cancer [91-93,97-101]. These trials 
employed naturally occurring, in vitro selected oncolytic strains of NDV. Viral doses used in these clinical 
studies were comparable to the dose administered in our primate study: up to 34-120 x 109 EID
50
 m-2 
(body surface) as compared to an equivalent dose of 4 x 109 TCID
50
 m-2 recombinant virus in our study. A 
study recruiting 14 patients suffering from glioblastoma multiforme showed that i.v. injection of a high 
dose of the lentogenic oncolytic strain NDV-HUJ was safe, with grade I-II fever as only adverse event 
[92]. Infectious virus was recovered from blood, saliva and urine samples up to 96 hours after injection. 
Two other phase I/II studies with a total of 95 patients showed that i.v. injection of a virulent NDV strain 
(PV701) was safe in patients with advanced or metastatic solid tumors [93,99]. Common side effects 
included fever, diarrhea and slight transient elevation of liver transaminases (but only in patients with 
hepatic metastases). Shedding of injected virus was also observed up to three weeks after injection. 
Measures to prevent environmental spread of this virulent NDV strain were not described [93,99].
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In chapter 4, we demonstrated that high dose i.v. oncolytic NDV is safe in a non-human primate 
model, and previous clinical studies have reported safety as well. However, Pigeon Paramyxovirus 
type 1 (PPMV-1), a pigeon-specific strain of NDV, has been shown to cause lethal disease with severe 
pneumonia in at least two human cases [168]. In chapter 5, we investigated whether PPMV-1 isolated 
from a fatal human case had zoonotic potential in a non-human primate model. We demonstrated 
that experimental infection resulted in severe pneumonia. These findings largely correspond with the 
presentation of PPMV-1 infection in two human fatal cases from New York [168] and The Netherlands 
(unpublished data). In contrast to what is reported for a PPMV-1 positive patient from New York, who 
had systemic infection based on PPMV-1-positive urine and stool samples, in our non-human primates 
no PPMV-1 was detected in any extra-respiratory tissues—including kidney, small and large intestine, 
pancreas and liver—of our macaques, either by qRT-PCR or immunohistochemistry. However, it 
cannot be excluded that under conditions of immunosuppression, the virus would be able to spread 
systemically.
The virulence of PPMV-1 for humans and macaques suggests that the safety of NDV as an oncolytic 
agent needs to be evaluated properly for different strains. The results presented in chapter 5, together 
with two fatal human cases of PPMV-1 infection, indicate that some variants of NDV can cause 
severe pneumonia in people under certain conditions, such as immunosuppression. It remains to be 
determined whether PPMV-1, and particularly these isolates from fatal human cases, is more virulent 
for people than other NDV strains.
Safety of other oncolytic virus platforms
As described earlier, several oncolytic viruses have made their way into clinical trials. Also, for these 
virus platforms, information regarding their safety, especially environmental, is limited. The following 
presents a discussion of findings from a literature study.
Herpes simplex virus 1 (HSV)
Preclinical evaluation employing intra-organ (brain or prostate) injection with oHSV in non-human 
primates demonstrated no shedding of virus, which points to limitation of oHSV replication to injection 
sites [507,508]. This was confirmed by early clinical trials in patients injected intratumorally (glioma) with 
oHSVs: sporadic shedding of HSV in saliva was noted, but this was shown to be wildtype virus as opposed 
to the injected oHSV [509,510]. Other studies have observed limited leakage of oHSV from injection 
sites up to 2 weeks post treatment, without other excreta containing viable oHSV [511-513]. Intra-arterial 
hepatic injection did not result in detectable environmental shedding either [514]. A possible concern 
is that an oHSV recombines with a wildtype endogenous virus. This however, is an unlikely event, given 
that the two viruses would have to infect the same cell in (near) equal genome copy numbers. If the 
oHSV carries heterologous genes, the recombinant would have to arise by illegitimate recombination 
– an extremely rare event that cannot be replicated in vitro [515]. Spontaneous reversion of oHSVs with 
deleted viral genes to wildtype virus is not possible. However, compensatory mutations can arise, but so 
far resulting HSV mutants have been highly attenuated [516]. These compensatory mutations can be of 
concern when evaluating the safety of newer generation oHSVs.
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Human mastadenovirus (HAdV)
In general, the use of early generation oncolytic crHAdVs appears to be reasonably safe when 
administered locally and at lower doses systemically. However, the development of newer generations of 
crHAdVs expressing transgenes, having altered capsids or different promoters can dramatically alter this 
perceived safety. Shedding of crHAdVs from injection sites and patient excretions, although not always 
reported, has been observed in several (pre) clinical trials, and increases with higher doses and systemic 
administration [345,517-523]. Homologous recombination between AdVs of the same subgroup occurs 
with high efficiency during growth in co-infected cultured cells, and there is evidence of recombination 
events in humans as well [524-526]. Theoretically, homologous recombination between wildtype AdVs 
and recombinant crHAdVs could lead to new wildtype AdVs that e.g. possess transgenes, or worse, have 
expanded tissue tropism due to retargeting strategies. However, to date such recombination has never 
been detected in any clinical trial.
Measles virus (MeV)
Intratumoral, intraperitoneal and intravenous administration has been reported using doses up to 109 
infectious viral particles without dose limiting toxicity or MeV induced immunosuppression [359,365,366]. 
Although wildtype MeV can cause potentially serious disease, attenuated MeV vaccine strains like 
Edmonston have an excellent safety record [527]. In clinical trials with rMeV-CEA, no evidence was seen 
of shedding in sputum and urine samples of patients who were intraperitoneally injected [365]. Spread of 
oncolytic MeV in the general population is highly unlikely since most individuals in industrialized countries 
are immunized, although herd immunity is currently waning with declining vaccination percentages.
Vesicular stomatitis virus (VSV)
A recent study in purpose-bred beagle dogs showed that a dose up to 1010 TCID
50
 of VSV-hIFNβ was 
well tolerated, with mild adverse events with the exception of one dog that received 1011 TCID
50
 which 
developed severe hepatotoxicity and shock leading to euthanasia [528]. A following study testing 
VSV-hIFNβ in rhesus macaques via intrahepatic injection did not result in neurological symptoms and 
is considered to be safe enough to proceed into phase I clinical trials, which are currently ongoing in 
humans and pet dogs [529,530]. No VSV RNA was detected in buccal swabs taken from non-human 
primates after intrahepatic injection with VSV-hIFNβ [529]. Theoretically, VSV mutants harboring 
mutations in their M or G gene (making them oncoselective and abolishing neurotropism) could revert 
to wildtype VSV upon passaging. Also, VSVs expressing attenuating transgenes like hIFNβ can acquire 
mutations in this transgene, which has been shown in several studies [531-533]. Furthermore, oncolytic 
VSVs have been shown to optimize targeting to glycoproteins upon passaging in tumor cells [534], and 
to mutate expressed transgenes to optimize replication [535]. These examples have strangely not been 
perceived as a safety problem.
Coxsackievirus (CVA)
Clinical trials thus far have not led to serious adverse events. No information is available regarding 
shedding. When considering non- or low-pathogenic coxsackieviruses for oncolytic virotherapy, 
environmental risks are considered to be low. However, when using viruses that do cause (severe) disease 
in humans, care should be taken to evaluate and/or attenuate these new vectors.
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Poliovirus (PV)
Extensive evaluation in non-human primates has shown PVS-RIPO to be safe for intraspinal and 
intrathalamic injection, without observations of extraneural replication or shedding [386,536]. No 
serious adverse events have been observed so far in an ongoing phase I clinical trial [388]. One of 
the biggest concerns with PV is the inherent genomic instability of picornaviruses and thus the 
possible reversion to wildtype pathogenicity. PVS-RIPO has been evaluated extensively for genomic 
instability by e.g. serial passaging in vitro and in vivo and it was shown that escape mutants reverting 
to neuropathogenic virulence in the CD155-transgenic mouse model do arise [537]. Similar mutants 
have not been observed in other animal models, which makes it unclear what the importance of this 
preclinical finding is in relation to currently ongoing clinical trials in humans.
Seneca Valley virus (SVV) 
Recent reports indicated that, although the natural host is still uncertain, this virus seems safe for use 
as oncolytic virotherapy in (pediatric) patients [395]. Analysis of samples obtained from researchers in 
close contact with phase I clinical trial patients revealed the absence of neutralizing antibody titers, 
which points to lack of viral shedding by the treated patients [395]. However, detailed evaluation of 
shedding was not performed, and should be determined in future clinical trials.
Vaccinia virus (VV)
Clinical trials with oncolytic VV have thus far reported good safety with minor side effects like transient 
low-grade fever and local pain [425,538,539]. Commonly, live vaccinia virus is shed from skin injection 
sites after vaccination [539]. Also, in clinical trials, live JX-594 was detected in throat swabs and skin 
pustules of patients up to one week after administration [428]. Theoretically, recombination between 
oncolytic recombinant VV and wildtype VV is possible, however, since VV vaccination is not practiced 
on a large scale anymore, this is highly unlikely. In addition, spontaneous mutation rates for VV have 
been shown to be very low [540].
Mammalian orthoreovirus type 3 Dearing (mORV-T3D)
High mORV titers injected intravenously have been shown to be reasonably safe, even in combination 
with standard therapies like chemo- or radiotherapy, as well as in combination with transient immune 
suppression [484,495]. Limited mORV shedding has been observed in clinical trials in patient samples 
of urine, saliva and feces, mostly with high intravenous administrations [484]. As an RNA virus with 
a viral RNA polymerase, mORV genome replication is prone to errors, which can lead to mutations 
in offspring. Furthermore, since wild-type isolates are in use, these probably represent several 
quasispecies [541]. Even so, since mORV-T3D does not seem to cause disease in human subjects, the 
relevance of this mutation rate is low.
Murine leukemia virus (MuLV)
Toca 511 is being investigated in clinical trials in the United States in subjects with recurrent high-
grade glioma. Up to now, over 70 patients have been treated without dose limiting toxicity and with 
evidence of clinical oncolytic efficacy [505]. Since RCR-MuLV vectors are capable of genomic integration, 
germline transmission is a theoretical risk of these vectors, and should be taken into consideration 
when designing clinical trials.
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Conclusions
Oncolytic virus platforms
The field of oncolytic virus research has seen a tremendous progression of several first and second 
generation vectors towards clinical trials. Most current strategies used in oncolytic virotherapy focus on 
the use of second and third generation of more virulent conditionally replicating viruses, armed with 
immune stimulating, anti-tumor or tracking transgenes. Also, immune evasion is still sought after to 
optimize vector delivery. There seems to be a general agreement that direct cell killing by an oncolytic 
virus might not be as important as once thought, and that indirect immunologic effects ultimately 
define the success of oncolytic virotherapy. With the first oncolytic virus (talimogene laherparepvec) 
now on the break of FDA and EMA approval, we can expect an even greater interest for this relatively 
young field of oncologic research in the near future.
Safety of oncolytic virus platforms
The newer generation of oncolytic viruses has been evaluated extensively for their efficacy in preclinical 
trials, and they have shown to be more effective than first generation vectors on many occasions. 
However, although some evidence has been gathered regarding their safety in terms of toxicity in 
laboratory animals, safety studies focusing on environmental shedding and possible recombination of 
these new oncolytic agents with wildtype viruses are scarce.
Future perspective
To further develop oncolytic recombinant NDV as treatment modality for pancreatic adenocarcinoma, 
there are a few key issues to address.
First and foremost, experiments in an immune-competent animal model of PDAC should be 
undertaken, since immune responses could dramatically alter the outcome (for better or worse) of 
oncolytic NDV treatment, especially with immunomodulating viruses or in combination with other 
(immuno)therapies [125]. Although transgenic animal models that mimic the natural development 
of PDAC have been created, these are also difficult to employ for evaluation of the efficacy of OVs. 
Mostly because the transgenic animal model for PDAC is a very difficult model to maintain with a lot of 
surplus animals needed for the breeding of specific genetic alterations. In addition, the tumors arising 
in this model have been shown to be very aggressive, which makes it difficult to evaluate therapies. 
Syngeneic models, either with orthotopic (in the pancreas or liver for local or metastatic disease 
respectively) or subcutaneous allografts, might be used to circumvent these disadvantages. These are 
less difficult to maintain in a breeding colony as the recipient animals do not need to have the same 
genetic alterations, only the same genetic background. Also, in these animals the PDAC tumors tend 
to develop more slowly, allowing a better evaluation of treatment over time. These syngeneic models 
could provide “naturally grown” mouse PDAC tumors in an immunocompetent animal, although 
it remains a model with artificially created tumors and an immune system that is not completely 
translatable to the human equivalent.
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Secondly, future experiments should elaborate more on the etiology of differences in susceptibility of 
HPACs for the oncolytic effect of NDV. These experiments should not only focus on innate immunity, 
but also on differences in apoptotic, necrotic, autophagy and/or immunogenic cell death pathways. 
Elucidating knowledge on the traits defining susceptibility to NDV induced oncolytic effects would 
allow improvement of oncolytic NDV to also attack relatively resistant tumor cells.
Thirdly, during the execution of our safety experiments with oncolytic NDVs in non-human primates, it 
was reported that NDV generated in embryonated chicken eggs was susceptible to neutralization by 
(human) serum through complement binding and activation [218]. We also confirmed that non-heat 
inactivated primate and human sera neutralized egg-generated NDV, in contrast to NDV generated 
in primate or human cells. All clinical trials thus far have been using egg-generated virus stocks and 
still reported positive effects for NDV virotherapy, as well as shedding of infectious virus, indicating 
that egg-generated NDV is still capable of replication [91-93,97-101]. The efficacy of NDV virotherapy 
might increase when using virus stocks generated in human or primate cells. However, neutralization 
by complement might also be important for safe administration of high doses of NDV, and abolishing 
this could result in more toxicity and a higher risk of shedding to the environment. More information 
should therefore be obtained on the safety and oncolytic efficacy of virotherapy with NDV stocks 
generated in human or primate cells.
Finally, the revival of oncolytic virus research has led to the investigation of new (recombinant) viruses 
without proper safety evaluations, especially environmental safety. A new OV should not only be tested 
for efficacy, but also for (environmental) safety, as this combination of efficacy and safety truly defines 
a promising new agent. Without a thorough environmental risk assessment, new agents will not be 
accepted by the regulatory agencies like EMA and FDA for marketing as new therapies. Especially with 
the latest oncolytic agents becoming more virulent, and with the possibility of expressing transgenes 
that alter the nature of the virus, any possibility of environmental shedding and recombination with 
wild type virus should be excluded. More studies evaluating the environmental safety of promising 
OVs (including NDV) should therefore be conducted and reported.
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Pancreascarcinoom is een zeer agressieve vorm van kanker met een slechte prognose en bijna iedere 
patiënt met pancreascarcinoom zal uiteindelijk aan zijn of haar ziekte overlijden. Dit wordt weerspiegeld 
in de incidentie (338.000 patiënten) en sterftecijfers (330.000 gevallen) wereldwijd per jaar, waarvan 
in Nederland in 2014 3000 patiënten. Er worden verschillende vormen van pancreascarcinoom 
onderscheiden, waarvan het ductaal type de meest voorkomende is. Pancreascarcinomen worden 
klinisch ingedeeld als zijnde operabel of inoperabel op basis van lokale (door)groei en uitzaaiingen. 
Helaas komt slechts 15 procent van de patiënten die wordt gediagnosticeerd met pancreascarcinoom 
in aanmerking voor een curatieve operatie middels pancreaticoduodenectomie (Whipple procedure) 
of pancreasstaartresectie. Voor de overige 85 procent van de patiënten rest slechts palliatieve 
chemotherapie. De prognose van een operabel pancreascarcinoom is ondanks verbeteringen in (peri-)
operatieve zorg en adjuvante therapieën nog steeds slecht: de vijfjaarsoverleving bedraagt 20 procent, 
met een mediane overleving van 24 maanden. Voor patiënten met een inoperabel pancreascarcinoom 
is het toekomstperspectief nog somberder, de mediane overleving bedraagt voor deze patiënten 
slechts 6 maanden.
Oncolytische virussen (OVs) zijn virussen die selectief kwaadaardige tumoren kunnen infecteren en 
beschadigen, zonder dat gezonde weefsels ernstige schade oplopen. Het gebruik van OVs voor de 
behandeling van kanker wordt oncolytische virotherapie genoemd. Veel kwaadaardige tumoren 
hebben in hun ontwikkeling eigenschappen verworven waardoor ze minder gevoelig zijn voor 
surveillance van het immuunsysteem, ze ongecontroleerd en ongeremd groeien en ze inductie 
van natuurlijke celdood tegengaan. Deze eigenschappen zorgen er tevens voor dat OVs deze cellen 
makkelijker kunnen infecteren. OVs maken gebruik van de cellulaire bronnen van kankercellen om 
zich te vermenigvuldigen en deze infectie leidt tot lysis van de cellen, waardoor deze kankercellen 
uiteindelijk te gronde gaan. De introductie van en de vooruitgang in genetische modificatie technieken 
heeft een enorme impuls gegeven aan het onderzoeksveld van de oncolytische virotherapie. Het is 
nu mogelijk om de eigenschappen van OVs zodanig aan te passen dat ze selectiever kankercellen 
infecteren en dus veiliger zijn. Bovendien kunnen OVs voorzien worden van additionele transgenen, 
waardoor de effectiviteit van de behandeling vergroot kan worden, de aflevering van OVs ter plaatse 
van tumoren kan worden verbeterd, en er bijvoorbeeld betere beeldvorming verricht kan worden.
Newcastle disease virus (NDV) is een van de veelbelovende OVs die verder ontwikkeld worden voor het 
gebruik in oncolytische virotherapie. De eerste klinische onderzoeken met wild type NDV stammen 
zijn verricht in de jaren ‘50-’60 van de vorige eeuw. Sindsdien zijn er meerdere klinische onderzoeken 
ondernomen in patiënten met diverse vormen van kanker, die in ieder geval hebben aangetoond dat 
het gebruik van wild type NDV in oncolytische virotherapie veilig is voor mensen. Het is niet geheel 
duidelijk waarom oncolytisch NDV selectief is voor kankercellen, hoewel verscheidene redenen zoals 
verschillen in aangeboren immuniteit of afwijkingen in de mechanismen voor groei en celdood van 
kankercellen zijn aangedragen. Sinds het mogelijk is om NDV genetisch te modificeren, is er meer 
aandacht gekomen voor het verder ontwikkelen van recombinant oncolytisch NDV voor het gebruik 
in oncolytische virotherapie. Dit heeft tot op heden nog niet geleid tot nieuwe klinische onderzoeken 
in patiënten. Een van de belangrijkste redenen hiervoor is dat hoog virulente stammen van NDV een 
gevaar kunnen vormen voor het milieu. Met name kippen en ander gevogelte zijn zeer gevoelig voor 
infectie en een uitbraak van NDV in een (commerciële) kippen populatie kan gepaard gaan met een 
hoge mortaliteit. Mensen kunnen ook geïnfecteerd worden met NDV, maar dit leidt slechts tot lichte 
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symptomen als conjunctivitis en laryngitis, welke spontaan weer voorbijgaan. Er zijn één tot twee 
casussen beschreven waarin immuun gecompromitteerde patiënten zijn overleden aan de gevolgen 
van een infectie met een speciale duivenstam van NDV, ook wel Pigeon Paramyxovirus type 1 (PPMV-1) 
genoemd.
In dit proefschrift worden studies gepresenteerd die zijn ondernomen om oncolytisch NDV verder te 
ontwikkelen als nieuwe behandeling van pancreascarcinoom.
In hoofdstuk 2 wordt een studie beschreven naar de effecten voor pancreascarcinoom cellen van 
inoculatie met wild type laag virulent NDV voor wat betreft immuun respons en celdood. Hoewel 
alle 11 verschillende cellijnen gevoelig waren voor infectie met NDV, was er wel verschil tussen de 
cellijnen in de mate van ondersteuning van replicatie van NDV en de geïnduceerde celdood. Over 
het algemeen leidde een betere replicatie van NDV tot meer celdood. Normale cellen reageren op 
een NDV infectie met het produceren van interferon (IFN) wat vervolgens virus replicatie remt, en 
er werd altijd verondersteld dat tumor cellen een defect in dit mechanisme hebben waardoor zij 
gevoeliger zijn voor NDV infectie. Wij hebben echter laten zien dat een aantal van de 11 onderzochte 
pancreascarcinoom cellijnen nog altijd IFN produceert, en dat deze IFN productie geen invloed heeft 
op de geïnduceerde celdood door het virus. Daarnaast hebben wij laten zien dat het voorbehandelen 
van pancreascarcinoom cellen met het aangeboren immuunsysteem stimulerend IFN bèta leidde tot 
een duidelijke bescherming tegen infectie en replicatie van oncolytisch NDV in de meeste cellen. Dit 
duidt er op dat er geen correlatie is tussen defecten in aangeboren immuniteit en gevoeligheid van 
cellen voor replicatie van NDV. 
Gebaseerd op de bevindingen van hoofdstuk 2, beschrijft hoofdstuk 3 het ontwikkelen van verbeterde 
recombinante NDVs om de oncolytische effectiviteit te vergroten. Hierbij is gekozen om laag virulente 
NDVs met ingebouwde immuun modulerende eigenschappen te vergelijken met een hoog virulent 
NDV zonder deze eigenschappen. Het bleek mogelijk om de immuunrespons van pancreascarcinoom 
cellen te beïnvloeden door middel van de virale expressie van IFN-stimulerende of IFN-remmende 
eiwitten. Dit leidde overigens niet tot een duidelijke verbetering van het oncolytisch effect in celkweken 
of in een immuun deficiënt muismodel voor pancreascarcinoom. Dit in tegenstelling tot hoog virulent 
recombinant NDV, dat een duidelijke verbetering van oncolytische effectiviteit liet zien in de meeste 
geteste modellen, zowel in vitro als in vivo.
Naast effectiviteit is veiligheid een belangrijke eigenschap van een oncolytisch virus. Hoofdstuk 4 
beschrijft een studie naar de veiligheid van oncolytisch NDV in non-humane primaten. Deze dieren 
werden intraveneus geïnjecteerd met een hoge doses van verschillende stammen van (recombinant) 
NDV en vervolgens onderzocht op toxische effecten en op eventuele uitscheiding van het virus, om 
een inschatting te kunnen maken wat betreft risico’s voor mens en milieu. Deze studie toonde aan dat 
intraveneuze injectie van de geteste stammen van (recombinant) NDV niet leidde tot toxiciteit in non-
humane primaten. De weinige uitscheiding van NDV die werd aangetoond, zorgde niet voor infectie 
van contactdieren. Deze studie heeft laten zien dat NDV veilig gebruikt kan worden in oncolytische 
virotherapie.
Hoewel NDV niet bekend staat als een veroorzaker van een ernstige zoönose in mensen, zijn er toch 
één à twee ernstige infecties in immuun-gecompromitteerde patiënten beschreven met een speciale 
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duiven stam van NDV, te weten PPMV-1. Een isolaat van één van deze casussen is gebruikt om in 
een non-humane primaten model te onderzoeken of dit virus inderdaad in staat is om zoogdieren 
te infecteren. De resultaten van deze studie staan beschreven in hoofdstuk 5. Hierbij werden non-
humane primaten geïnfecteerd via de natuurlijke route (intra-tracheaal, intra-nasaal en conjunctivaal) 
en enkele dagen later onderzocht op mogelijke PPMV-1 gerelateerde afwijkingen. Deze studie toonde 
dat non-humane primaten inderdaad gevoelig zijn voor virale pneumonie veroorzaakt door PPMV-1, 
wat in overeenstemming lijkt met de beschreven menselijke casussen.
De toekomst van oncolytische virotherapie, met in het bijzonder oncolytisch NDV, is veelbelovend, 
maar zit ook vol met uitdagingen. Zo bestaat nog steeds de vraag waarom NDV nu precies selectief 
is voor kankercellen. Een antwoord hierop zou de ontwikkeling naar de kliniek kunnen versnellen. 
Daarbij zal er ook onderzocht moeten worden welke van de recombinante stammen van NDV het 
meest geschikt is voor ontwikkeling richting klinische onderzoeken: laag virulente NDVs met immuun 
modulerende of andere versterkende eigenschappen of hoog virulente NDVs, waarbij middels 
genetische modificatie de replicatie wordt beperkt tot humane tumoren om schade aan het milieu 
te voorkomen. Onderzoeken in immuun competente muismodellen voor pancreascarcinoom zullen 
moeten worden ondernomen om een antwoord op deze vraag te krijgen. Hoe dan ook, het hier 
beschreven onderzoek heeft laten zien dat oncolytisch NDV de potentie heeft om uit te groeien tot 
een klinisch toepasbare modaliteit voor de behandeling van pancreascarcinoom en waarschijnlijk ook 
andere vormen van kanker.
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Dankwoord
Tot zover het wetenschappelijke deel. Nu is het tijd om iedereen te bedanken zonder wie dit proefschrift 
nooit tot stand was gekomen. Zoals vaker gezegd en geschreven: het meest gelezen onderdeel van 
een boekje. Mocht U ondanks aandachtig lezen Uw eigen naam missen, vergeef me, dat is dan mijn 
tekortkoming. Ook U ben ik uiteraard dankbaar!
Mijn heelkundige promotor, professor van Eijck. Ik had nooit gedacht dat een gemeenschappelijke kennis 
zou leiden tot het boekje wat hier voor U ligt. Vanaf het eerste kennismakings-/sollicitatiegesprek bent U 
altijd de stille motor geweest achter mijn promotietraject. Leidend met een losse hand, maar altijd op de 
hoogte en doortastend wanneer nodig. Dank voor Uw vertrouwen en stimulatie om dit project tot een 
goed einde te brengen. Ik hoop U in de toekomst als heelkundige collega nog vaak te kunnen spreken.
Mijn virologische promotor, professor Fouchier, beste Ron. Dank voor alle mogelijkheden die je me 
hebt gegeven op de afdeling Viroscience. Ondanks drukte met de zoveelste (vogel)griepepidemie of 
dodelijke coronavirussen was er altijd genoeg tijd en ruimte om mijn project aandacht te geven. Je hebt 
een fantastische groep mensen om je heen verzameld, wat mij betreft het kenmerk van een echte leider. 
Mijn copromotor, Dr. van den Hoogen, beste Bernadette. Vanaf begin tot eind: jij was er voor me als ik hulp 
nodig had. En of het nu ging om basale wetenschap, het schrijven van lappen tekst voor manuscripten 
en beursaanvragen, of het begeleiden van samenwerkingen, jij kunt het allemaal. Liefst in de kleine 
uurtjes van de dag of in het weekend, want ook thuis is genoeg te doen. Zonder jou was dit project nooit 
zover gekomen, en daarvoor ben ik je ontzettend dankbaar. Ik hoop dat het gaat lukken om verder te 
kunnen gaan met ‘ons kindje’ om er een volwassen onderzoekslijn van te maken. Wanneer is er weer een 
lab-diner bij jullie thuis…?
Leden van de leescommissie, prof.dr. C.M.F. Dirven, prof.dr. L.J. Hofland en prof.dr. R.C. Hoeben, dank voor 
het beoordelen van mijn proefschrift.
Beste (oud)collega’s van de afdeling Viroscience, bedankt voor jullie hulp en gezelligheid over de jaren. Wie 
denkt dat wetenschappers saai zijn, heeft nog nooit een SinterKerst feest of de bijna maandelijkse borrels 
meegemaakt op de 17e verdieping. Marina, Jonneke en Stefan v N., bedankt voor het begeleiden, helpen 
en onderwijzen van deze simpele jongen op het gebied van laboratoriumtechnieken. Kamergenoten 
Martin, Sander, Kim, Marine en Sasha: ik had geen betere buren kunnen wensen. Overige collega’s van de 
Flu-groep, bedankt voor jullie hulp door de jaren heen. Iedere vrijdagmiddag frituurlunch was altijd haute 
cuisine! Robert, jij bent waarschijnlijk de meest onderschatte collega van de afdeling, altijd (vroeg) paraat 
om alles in goede banen te leiden, dank voor je hulp en ondersteuning bij duizend en één dingen. Met 
name de Goody-Goody box en Surinaamse broodjes waren altijd goed voor de arbeidsproductiviteit. 
Geert, bedankt voor je hulp met de proeven in het EDC; je verhalen over vroege trektochten door de 
Duitse velden werkten altijd inspirerend.
Dames van het secretariaat, Simone, Loubna, Anouk, Maria, bedankt voor jullie ondersteuning door de 
jaren heen. Zonder jullie hulp en adviezen was ik waarschijnlijk niet ver gekomen.
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Lieve (oud)collega’s van de afdeling Heelkunde, bedankt voor de gezelligheid van de afgelopen jaren. Ik 
vond het altijd een leuk moment om op dinsdag even de week te breken met onze onderzoekerslunch. 
Stephanie, bedankt voor het ondersteunen van de 17e verdieping met jullie expertise van de celletjes. 
Mensen in de kelder, houd vol, er is licht aan het einde van de tunnel! Mensen in de Z-flat, geen idee 
wat jullie daar de hele dag doen, maar ga zo door! Ik zal altijd met trots refereren aan mijn periode in 
Rotterdam, met name de jaarlijkse ski-reis en maandelijkse regioborrel zijn uniek te noemen.
Dames van het secretariaat Heelkunde, bedankt voor jullie ondersteuning. Conny, bedankt voor je 
luisterende en ontnuchterende oor, de snoepjes gingen er altijd goed in. Carola, bedankt voor het 
begeleiden van de laatste loodjes richting het einde.
Timo en Gerben, en alle promovendi en medewerkers van LECO. Bedankt dat jullie mij op weg hebben 
geholpen in de chirurgische oncologie.
Heren en dames van het EDC, dank dat jullie mij hebben geholpen door alles altijd tot in de puntjes 
voorbereid te hebben. Vincent, er is geen betere prikkert dan jij. Dennis & Dennis, dank voor jullie hulp 
met het onderhouden van mijn proeven, met name in de weekenden.
People from UMD, professor Perez, dear Daniel. Thank you for enabling me to perform some cool 
experiments in your lab. Preparation was key (read hell), but we managed in the end anyway. Ade(bimpe), 
Troy and Matthew, thank you for teaching and escorting me around the lab and beyond. I am still on the 
lookout for a Chipotle and Sardi’s in Rotterdam.
People from Georgetown, professor Wellstein, thank you for enabling me to use your expertise regarding 
tumor models. Eveline en Marianne, bedankt voor jullie hulp bij het regelen van ons zeer speciale 
transport.
IJsvogels, ondanks dat ik inmiddels het nest verlaten heb, zal ik mijzelf altijd blijven beschouwen als een 
Capellenaar. Dr. Dawson, dank voor Uw begeleiding gedurende mijn tijd in het IJsselland, ik heb het 
gevoel dat ik U ook nog voor iets anders moet bedanken. Michiel, bedankt dat je voor mij een awesome 
kaft hebt ontworpen.
Nieuwe collega’s uit het Elisabeth-TweeSteden ziekenhuis, bedankt voor jullie warme Tilburgse welkom. 
Opleiders dr. Vriens en dr. Ibelings, bedankt voor het in mij gestelde vertrouwen. Ik verheug mij op de 
toekomst met jullie allemaal.
Roy en Manja met kids, Ward en Marloes met kid en Bastiaan en Anniek met kids. Alsof er niet genoeg 
clichés in het voorgaande stuk zitten: we zien elkaar te weinig. Ik hoop dan ook dat dat vanaf nu, ondanks 
de afstand tot sommige van jullie, gaat toenemen om alle ervaringen op het gebied van poepluiers en 
snottebellen te kunnen uitwisselen. Peek, ik hoop dat je in de toekomst nog veel bios-afspraken niet 
vergeet.
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Lieve schoonfamilie, Geert, Goof, Christianne, Gerard, Cockie en Kees. Jullie hebben de koude kant toch 
een warm gevoel gegeven. Bedankt voor de nimmer aflatende gastvrijheid en gezelligheid door de jaren 
heen.
Paranimf Stefan, nooit te beroerd om mee te gaan lunchen op elke dag behalve dinsdag. Leuk dat je 
vandaag naast me staat. Ik hoop dat we nog vaak kunnen ontspannen in de bios of op de tribune van 
ons cluppie.
Paranimf Manon, maar uiteraard ook lieve zus. Met bewondering heb ik vaak een voorbeeld aan jou 
proberen te nemen. Vanzelfsprekend sta jij vandaag ook naast mij, nadat eerder de rollen omgedraaid 
waren. Ik wil je bedanken voor de ontelbare dingen die je voor mij gedaan hebt, in binnen- en buitenland. 
Je bent de beste zus ever!
Lieve papa en mama, mijn Limburgse voorouders. Zonder jullie liefde en steun was ik nooit kunnen 
worden wie ik nu ben. Bedankt voor jullie zorg, vertrouwen, raad en daad. Ik hoop dat jullie trots op mij 
zijn.
Lieve Cox, project van mijn leven. Als geen ander begrijp jij mij. In vijf jaar tijd hebben we samen een 
fantastisch leven opgebouwd. Binnenkort begint ons grootste avontuur tot nu toe en ik weet zeker dat 
het heel leuk gaat worden. Ik hou van jou!
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Stellingen behorende bij het proefschrift
Oncolytisch Newcastle Disease Virus als Behandeling voor Pancreascarcinoom
1. Hoog virulent Newcastle disease virus heeft de meeste potentie als oncolytisch virus voor de 
behandeling van pancreascarcinoom. (dit proefschrift) 
2. Defecten in aangeboren immuniteit van pancreascarcinoom cellen bepalen niet alleen de 
gevoeligheid voor oncolytisch Newcastle disease virus. (dit proefschrift) 
3. Het intraveneus toedienen van hoge doses oncolytisch Newcastle disease virus is veilig voor 
niet-humane primaten voor wat betreft toxiciteit en uitscheiding. (dit proefschrift) 
4. Omdat een hoog virulent oncolytisch Newcastle disease virus een risico kan vormen voor 
het milieu, dient beperking van het gastheerbereik of immunomodulatie verder onderzocht 
te worden. (dit proefschrift) 
5. Het heterogene karakter van pancreastumoren vraagt om een ‘personalized medicine’  
aanpak, wat goed mogelijk is met verschillende oncolytische virussen. (dit proefschrift) 
6. De grootste uitdaging voor het onderzoeksveld van oncolytische virotherapie is niet het 
genereren van verbeterde virussen, maar de vraag welke te selecteren voor klinische  
onderzoeken. (Stephen Russell et al, Nat Biotechnol. 2012;30(7):658-70) 
7. De recente successen behaald in kanker immunotherapie zullen versterkt worden wanneer 
deze gecombineerd worden met oncolytische virotherapie. 
8. Oncolytische virotherapie zal in de nabije toekomst een plaats krijgen binnen de bestaande 
kanker behandelingen. 
9. Ondanks investeringen in nieuwe en betere behandelmethoden zijn er helaas maar weinig 
tot geen patiënten met ductaal type pancreascarcinoom die genezen kunnen worden. 
(Monika Carpelan-Holmström, Gut, 2005;54:385-387) 
10. Eet als je kan, slaap als je kan, en sol niet met het pancreas. 
(Miranda Bailey, Grey’s Anatomy - S07E08 - “Something’s Gotta Give”) 
11. Het is belangrijker om een arts te leren pipetteren, dan een giraf te leren touwtje springen.
Pascal Buijs, 30 september 2015
Propositions accompanying the doctoral thesis
Oncolytic Newcastle Disease Virus as Treatment for Pancreatic Cancer
1. High virulent Newcastle disease virus is the most potent oncolytic virus as treatment for 
pancreatic carcinoma. (this thesis) 
2. Defects in innate immunity of pancreatic carcinoma cell lines do not solely dictate the  
susceptibility for oncolytic Newcastle disease virus. (this thesis) 
3. The intravenous administration of high dose oncolytic Newcastle disease virus is safe for 
non-human primates with regards to toxicity and shedding. (this thesis) 
4. Because a high virulent oncolytic Newcastle disease virus can pose a risk for the  
environment, further research should focus on restriction of the host range or  
immunomodulation. (this thesis) 
5. The heterogeneity of pancreatic tumors demands a ‘personalized medicine’ approach, which 
can be acheived by using different oncolytic viruses. (this thesis) 
6. The biggest overall challenges facing the field [of oncolytic virotherapy] now have less to do 
with the development of technology solutions to enhance virus delivery and spread than 
with how to get new viruses clinically tested. 
(Stephen Russell et al, Nat Biotechnol. 2012;30(7):658-70) 
7. Recent successes in cancer immunotherapy will be enhanced when combined with  
oncolytic virotherapy. 
8. Oncolytic virotherapy will get its place among regular cancer treatments in the near future. 
9. Despite investments in new and better treatment methods there are few to no patients with 
ductal pancreatic carcinoma that can be cured. 
(Monika Carpelan-Holmström, Gut, 2005;54:385-387) 
10. Eat when you can, sleep when you can, and don’t screw with the pancreas. 
(Miranda Bailey, Grey’s Anatomy - S07E08 - “Something’s Gotta Give”) 
11. It is more important to teach a medical doctor how to pipet, than to teach a giraffe how to 
jump rope.
Pascal Buijs, 30 September 2015
